<SEC-DOCUMENT>0001193125-20-249151.txt : 20200918
<SEC-HEADER>0001193125-20-249151.hdr.sgml : 20200918
<ACCEPTANCE-DATETIME>20200918163056
ACCESSION NUMBER:		0001193125-20-249151
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20200915
ITEM INFORMATION:		Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200918
DATE AS OF CHANGE:		20200918

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adicet Bio, Inc.
		CENTRAL INDEX KEY:			0001720580
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				813305277
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38359
		FILM NUMBER:		201184314

	BUSINESS ADDRESS:	
		STREET 1:		500 BOYLSTON STREET
		STREET 2:		12TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		617-482-2333

	MAIL ADDRESS:	
		STREET 1:		500 BOYLSTON STREET
		STREET 2:		12TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	resTORbio, Inc.
		DATE OF NAME CHANGE:	20171024
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d91031d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:acet="http://www.adicetbio.com/20200915" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body>
 <div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2020-09-15_to_2020-09-15">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2020-09-15_to_2020-09-15">0001720580</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="acet-20200915.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2020-09-15_to_2020-09-15"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-09-15</xbrli:startDate> <xbrli:endDate>2020-09-15</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2020-09-15_to_2020-09-15">8-K</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2020-09-15_to_2020-09-15" format="ixt:datemonthdayyearen">September 15, 2020</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2020-09-15_to_2020-09-15">Adicet Bio, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2020-09-15_to_2020-09-15" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2020-09-15_to_2020-09-15">001-38359</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2020-09-15_to_2020-09-15">81-3305277</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2020-09-15_to_2020-09-15">500 Boylston Street</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2020-09-15_to_2020-09-15">13th Floor</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2020-09-15_to_2020-09-15">Boston</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2020-09-15_to_2020-09-15">MA</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2020-09-15_to_2020-09-15">02116</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2020-09-15_to_2020-09-15">(857)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2020-09-15_to_2020-09-15">315-5528</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2020-09-15_to_2020-09-15" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2020-09-15_to_2020-09-15" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2020-09-15_to_2020-09-15" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2020-09-15_to_2020-09-15" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2020-09-15_to_2020-09-15">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2020-09-15_to_2020-09-15">ACET</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2020-09-15_to_2020-09-15" format="ixt-sec:exchnameen">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2020-09-15_to_2020-09-15" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2020-09-15_to_2020-09-15" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;3.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Adicet Bio, Inc. (the &#8220;Company&#8221; or &#8220;Adicet&#8221;) common stock listed on The Nasdaq Global Select Market, previously trading through the close of business on September&#160;15, 2020 under the ticker symbol &#8220;TORC,&#8221; commenced trading on The Nasdaq Global Market, on a post-reverse stock split adjusted basis, under the ticker symbol &#8220;ACET,&#8221; on September&#160;16, 2020. The Company common stock is represented by a new CUSIP number, 007002108. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;5.02</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Employment Agreement with Chen Schor </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has entered into an employment agreement with Chen Schor, pursuant to which Mr.&#160;Schor will serve as President and Chief Executive Officer of the Company, effective as of September&#160;15, 2020 (the &#8220;Effective Date&#8221;). Mr.&#160;Schor&#8217;s employment agreement provides for &#8220;at will&#8221; employment. Pursuant to Mr.&#160;Schor&#8217;s employment agreement, Mr.&#160;Schor is entitled to an annual base salary of $520,000. Commencing in calendar year 2021, Mr.&#160;Schor is also eligible for annual incentive compensation targeted at 50% of his base salary, provided that any incentive compensation for calendar year 2020 will be prorated based on the Effective Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&#160;Schor is eligible to participate in the employee benefit plans generally available to full-time employees, subject to the terms of those plans. Pursuant to the terms of his employment agreement, if Mr.&#160;Schor&#8217;s employment is terminated by Adicet without cause or by Mr.&#160;Schor for good reason 3 months prior to or within the <span style="white-space:nowrap">12-month</span> period following a change in control (as such terms are defined in his employment agreement and subject to the terms and conditions therein), then Mr.&#160;Schor will be entitled to (1)&#160;a lump sum cash payment equal to <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">one-and-a-half</span></span></span> (1.5) times the sum of his then-current annual base salary (or his base salary in effect immediately prior to the change in control, if higher) and his target bonus for the then-current year (or his target bonus in effect immediately prior to the change in control, if higher), (2) any unpaid bonus earned for the year preceding the date of Mr.&#160;Schor&#8217;s employment termination, payable at the time it would otherwise have been paid had his employment not terminated, (3)&#160;full acceleration of all time-based stock options and other time-based stock awards held by Mr.&#160;Schor, and (4)&#160;monthly cash payments equal to the monthly employer contribution that Adicet would have made to provide health insurance for Mr.&#160;Schor and any covered dependents for up to 18&#160;months. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Employment Agreement with Carrie Krehlik </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has entered into an employment agreement with Carrie Krehlik, pursuant to which Ms.&#160;Krehlik will serve as Senior Vice President and Chief Human Resource Officer of the Company, effective as of the Effective Date. Ms.&#160;Krehlik&#8217;s employment agreement provides for &#8220;at will&#8221; employment. Pursuant to Ms.&#160;Krehlik&#8217;s employment agreement, Ms.&#160;Krehlik is entitled to an annual base salary of $300,000. Commencing in calendar year 2021, Ms.&#160;Krehlik is also eligible for annual incentive compensation targeted at 40% of her base salary, provided that any incentive compensation for calendar year 2020 will be prorated based on the Effective Date. Ms.&#160;Krehlik is eligible to participate in the employee benefit plans generally available to full-time employees, subject to the terms of those plans. Pursuant to Ms.&#160;Krehlik&#8217;s employment agreement, if Ms.&#160;Krehlik&#8217;s employment is terminated by Adicet without cause or by Ms.&#160;Krehlik for good reason within the <span style="white-space:nowrap">12-month</span> period following a change in control (as such terms are defined in her employment agreement and subject to the terms and conditions therein), then Ms.&#160;Krehlik will be entitled to (1)&#160;a lump sum cash payment equal to the sum of 12&#160;months of her then-current base salary (or her base salary in effect immediately prior to the change in control, if higher) and her target bonus for the then-current year (or her target bonus in effect immediately prior to the change in control, if higher), (2) any unpaid bonus earned for the year preceding the date of Ms.&#160;Krehlik&#8217;s employment termination, payable at the time it would otherwise have been paid had her employment not terminated, (3)&#160;full acceleration of all time-based stock options and other time-based stock awards held by Ms.&#160;Krehlik, and (4)&#160;monthly cash payments equal to the monthly employer contribution that Adicet would have made to provide health insurance for Ms.&#160;Krehlik and any covered dependents for up to 12&#160;months. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Employment Agreement with Francesco Galimi, M.D., Ph.D. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has entered into an employment agreement with Francesco Galimi, M.D., Ph.D., pursuant to which Dr.&#160;Galimi will serve as Senior Vice President and Chief Medical Officer of the Company, effective as of the Effective Date. Dr.&#160;Galimi&#8217;s employment agreement provides for &#8220;at will&#8221; employment. Pursuant to Dr.&#160;Galimi&#8217;s employment agreement, Dr.&#160;Galimi is entitled to an annual base salary of $400,000. Commencing in calendar year 2021, Dr.&#160;Galimi is also eligible for annual incentive compensation targeted at 40% of his base salary, provided that any incentive compensation for calendar year 2020 will be prorated based on the Effective Date. Dr.&#160;Galimi is eligible to participate in the employee benefit plans generally available to full-time employees, subject to the terms of those plans. Pursuant to Dr.&#160;Galimi&#8217;s employment agreement, if Dr.&#160;Galimi&#8217;s employment is terminated by Adicet without cause or by Dr.&#160;Galimi for good reason within the <span style="white-space:nowrap">12-month</span> period following a change in control (as such terms are defined in his employment agreement and subject to the terms and conditions therein), then Dr.&#160;Galimi will be entitled to (1)&#160;a lump sum cash payment equal to the sum of his then-current annual base salary (or his base salary in effect immediately prior to the change in control, if higher) and his target bonus for the then-current year (or his target bonus in effect immediately prior to the change in control, if higher), (2) any unpaid bonus earned for the year preceding the date of Dr.&#160;Galimi&#8217;s employment termination, payable at the time it would otherwise have been paid had his employment not terminated, (3)&#160;full acceleration of all time-based stock options and other time-based stock awards held by Dr.&#160;Galimi, and (4)&#160;monthly cash payments equal to the monthly employer contribution that Adicet would have made to provide health insurance for Dr.&#160;Galimi and any covered dependents for up to 12&#160;months. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Employment Agreement with Lloyd Klickstein, M.D., Ph.D. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has entered into an employment agreement with Lloyd Klickstein, M.D., Ph.D., pursuant to which Dr.&#160;Klickstein will serve as Chief Innovation Officer of the Company, effective as of the Effective Date. Dr.&#160;Klickstein&#8217;s employment agreement provides for &#8220;at will&#8221; employment. Pursuant to Dr.&#160;Klickstein&#8217;s employment agreement, Dr.&#160;Klickstein is entitled to an annual base salary of $403,700. Commencing in calendar year 2021, Dr.&#160;Klickstein is also eligible for annual incentive compensation targeted at 40% of his base salary, provided that any incentive compensation for calendar year 2020 will be prorated based on the Effective Date. Dr.&#160;Klickstein is eligible to participate in the employee benefit plans generally available to full-time employees, subject to the terms of those plans. Pursuant to Dr.&#160;Klickstein&#8217;s employment agreement, if Dr.&#160;Klickstein&#8217;s employment is terminated by Adicet without cause or by Dr.&#160;Klickstein for good reason within the <span style="white-space:nowrap">12-month</span> period following a change in control (as such terms are defined in his employment agreement and subject to the terms and conditions therein), then Dr.&#160;Klickstein will be entitled to (1)&#160;a lump sum cash payment equal to the sum of his then-current annual base </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
salary (or his base salary in effect immediately prior to the change in control, if higher) and his target bonus for the then-current year (or his target bonus in effect immediately prior to the change in control, if higher), (2) any unpaid bonus earned for the year preceding the date of Dr.&#160;Klickstein&#8217;s employment termination, payable at the time it would otherwise have been paid had his employment not terminated, (3)&#160;full acceleration of all time-based stock options and other time-based stock awards held by Dr.&#160;Klickstein, and (4)&#160;monthly cash payments equal to the monthly employer contribution that Adicet would have made to provide health insurance for Dr.&#160;Klickstein and any covered dependents for up to 18&#160;months. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Employment Agreement with Nick Harvey </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has entered into an employment agreement with Nick Harvey pursuant to which Mr.&#160;Harvey will serve as Chief Financial Officer of the Company, effective as of September&#160;16, 2020. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&#160;Harvey&#160;has over 20 years of experience in financial operations, capital markets, investor relations and M&amp;A transactions as well as managing corporate growth for life science companies.&#160;Mr.&#160;Harvey&#160;joins Adicet most recently from Centrexion Therapeutics, a privately held biotechnology company, where he served as Executive Vice President and Chief Financial Officer. Previously, he served as the Chief Financial Officer of Radius Health where he helped successfully complete its initial public offering and transition from a research and development stage company to a commercial organization. During his tenure at Radius, he oversaw financial operations, business development, legal, facilities, and information technology. Prior to that,&#160;Mr.&#160;Harvey&#160;served as a Managing Director at&#160;Shiprock Capital, a venture capital firm, where he managed investments and development of early and late-stage companies.&#160;Mr.&#160;Harvey&#160;received his MBA from&#160;Harvard Business School, and earned both a law degree and an undergraduate degree in Economics from the&#160;Australian National University. Mr.&#160;Harvey&#8217;s employment agreement provides for &#8220;at will&#8221; employment. Pursuant to Mr.&#160;Harvey&#8217;s employment agreement, Mr.&#160;Harvey is entitled to an annual base salary of $385,000. Mr.&#160;Harvey is also eligible for annual incentive compensation targeted at 40% of his base salary, provided that any incentive compensation for calendar year 2020 will be prorated based on the effective date of his hire. Mr.&#160;Harvey is eligible to participate in the employee benefit plans generally available to full-time employees, subject to the terms of those plans. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of his employment agreement, Mr.&#160;Harvey is entitled to an inducement <span style="white-space:nowrap">non-qualified</span> stock option to purchase up to 195,898 shares of the Company Common Stock. Twenty-five percent of the shares underlying such option shall vest on September&#160;15, 2021 and the remainder of such shares shall vest in <span style="white-space:nowrap">thirty-six</span> equal monthly installments thereafter. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Mr.&#160;Harvey&#8217;s employment agreement, if Mr.&#160;Harvey&#8217;s employment is terminated by Adicet without cause or by Mr.&#160;Harvey for good reason within the <span style="white-space:nowrap">12-month</span> period following a change in control (as such terms are defined in his employment agreement and subject to the terms and conditions therein), then Mr.&#160;Harvey will be entitled to (1)&#160;a lump sum cash payment equal to the sum of his then-current annual base salary (or his base salary in effect immediately prior to the change in control, if higher) and his target bonus for the then-current year (or his target bonus in effect immediately prior to the change in control, if higher), (2) any unpaid bonus earned for the year preceding the date of Mr.&#160;Harvey&#8217;s employment termination, payable at the time it would otherwise have been paid had his employment not terminated, (3)&#160;full acceleration of all time-based stock options and other time-based stock awards held by Mr.&#160;Harvey, and (4)&#160;monthly cash payments equal to the monthly employer contribution that Adicet would have made to provide health insurance for Mr.&#160;Harvey and any covered dependents for up to 12&#160;months. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the appointment of each of Chen Schor, Nick Harvey, Stewart Abbot, M.D., Francesco Galimi, Lloyd Klickstein, and Carrie Krehlik (collectively, the &#8220;Executive Officers&#8221;) as executive officers of Adicet, each has entered into the Company&#8217;s standard form of indemnification agreement, a copy of which was filed as Exhibit 10.3 to the Company&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-1,</span> as amended (File <span style="white-space:nowrap">No.&#160;333-222373)</span> filed with the Securities and Exchange Commission on January&#160;16, 2018. Pursuant to the terms of the indemnification agreement, the Company may be required, among other things, to indemnify each Executive Officer for some expenses, including attorneys&#8217; fees, judgments, fines and settlement amounts incurred by him or her in any action or proceeding arising out of his or her service as one of our Executive Officers. In addition, each Executive Officer entered into an Employee Confidentiality, Assignment and Nonsolicitation Agreement that contains, among other <span style="white-space:nowrap">things,&#160;non-solicitation&#160;provisions</span> that apply during the term of each Executive Officer&#8217;s employment and for one year thereafter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No Executive Officer has any family relationship with any of the executive officers or directors of the Company. There are no arrangements or understandings between an Executive Officer and any other person pursuant to which he or she was appointed as an officer of the Company. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;8.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information relating to Adicet Therapeutics, Inc.&#8217;s Management and Executive Compensation is filed herewith and attached hereto as Exhibit 99.1 and incorporated herein by reference. The information contained in Exhibit 99.1 is taken from the Company&#8217;s Proxy Statement (File No. 333-239372) filed with the Securities and Exchange Commission on August 21, 2020 and is further updated by the disclosure set forth in Item 5.02 herein. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Below is a list of exhibits included with this Current Report on Form <span style="white-space:nowrap">8-K.</span> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:93%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br />No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Document</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d91031dex101.htm">Employment Agreement, dated as of September&#160;15, 2020, by and between the Company and Chen Schor </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d91031dex102.htm">Employment Agreement, dated as of September&#160;15, 2020, by and between the Company and Carrie Krehlik </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d91031dex103.htm">Employment Agreement, dated as of September&#160;15, 2020, by and between the Company and Francisco Galimi </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d91031dex104.htm">Employment Agreement, dated as of September&#160;15, 2020, by and between the Company and Lloyd Klickstein </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.5</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d91031dex105.htm">Employment Agreement, dated as of September&#160;15, 2020, by and between the Company and Nick Harvey </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d91031dex991.htm">Adicet Therapeutics, Inc. Management and Executive Compensation </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:12%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:87%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">Adicet Bio, Inc.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Chen Schor</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-style:italic">Name:</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">Chen Schor</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-style:italic">Title:</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">President and Chief Executive Officer</span></td></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: September&#160;18, 2020 </p>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d91031dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Employment Agreement (&#147;Agreement&#148;) is made between Adicet Therapeutics, Inc., a Delaware corporation (the &#147;Company&#148;),
and Chen Schor (the &#147;Executive&#148;) and is contingent upon the closing (the &#147;Closing&#148;) of the transaction (the &#147;Merger&#148;) contemplated by that certain Agreement and Plan of Merger (the &#147;Merger Agreement&#148;) by and
among resTORbio, Inc. (&#147;Parent&#148;), Adicet Bio, Inc. (&#147;Adicet Bio&#148;) and the other parties thereto. Subject to Section&nbsp;11, except with respect to the Equity Documents (as defined below), this Agreement supersedes in all
respects all prior agreements between the Executive and Parent regarding the subject matter herein, including without limitation (i)&nbsp;the offer letter between the Executive and Parent dated March&nbsp;31, 2017, as amended by the Amendment to
Offer Letter dated January&nbsp;15, 2018 (together, the &#147;Prior Agreement&#148;) except as specifically preserved herein, and (ii)&nbsp;any offer letter, employment agreement or severance agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Adicet Bio, Inc. will change its name to Adicet Therapeutics, Inc. post- Closing and Parent will change its name to Adicet Bio, Inc.
post-Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company beginning on
the effective date of the Closing of the Merger (the &#147;Effective Date&#148;) on the terms contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in
consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Employment</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Term</U>. The term of this Agreement shall commence on the Effective Date and continue until terminated in
accordance with the provisions hereof (the &#147;Term&#148;). The Executive&#146;s employment with the Company shall be &#147;at will,&#148; meaning that the Executive&#146;s employment may be terminated by the Company or the Executive at any time
and for any reason subject to the terms of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Position and Duties</U>. The Executive shall
serve as the President and Chief Executive Officer of the Company and shall have such powers and duties as may from time to time be prescribed by the Board of Directors of Parent (the &#147;Board&#148;). The Executive shall devote his full working
time and efforts to the business and affairs of the Company. Notwithstanding the foregoing, the Executive may serve on other boards of directors, with the approval of the Governance Committee of the Board (the &#147;Governance Committee&#148;) or
engage in religious, charitable or other community activities as long as such services and activities do not interfere with the Executive&#146;s performance of his duties to the Parent and the Company as provided in this Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Compensation and Related Matters</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Base Salary</U>. The Executive&#146;s initial base salary shall be paid at the rate of $520,000 per year. The Executive&#146;s base
salary shall be subject to periodic review by the Compensation Committee of the Board (the &#147;Compensation Committee&#148;). The base salary in effect at any given time is referred to herein as &#147;Base Salary.&#148; The Base Salary shall be
payable in a manner that is consistent with the Company&#146;s usual payroll practices for executive officers. The Executive&#146;s salary and any other cash compensation may be provided through TriNet, Inc. or another professional employer
organization (a &#147;PEO&#148;). As a result of the Company&#146;s arrangement with the PEO, the PEO will be considered the Executive&#146;s employer of record for these purposes for so long as that arrangement exists. While the PEO will have
responsibility for the functions above, the Company retains responsibility for overseeing the Executive&#146;s work and reviewing the Executive&#146;s performance, among other functions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Incentive Compensation</U>. The Executive shall be eligible to receive cash incentive compensation as determined
by the Board or the Compensation Committee from time to time. Commencing in calendar year 2021, the Executive&#146;s initial target annual incentive compensation shall be fifty (50)&nbsp;percent of the Executive&#146;s Base Salary; provided that any
incentive compensation for calendar year 2020 will be prorated based on the Effective Date. The target annual incentive compensation in effect at any given time is referred to herein as &#147;Target Bonus.&#148; The actual amount of the
Executive&#146;s annual incentive compensation, if any, shall be determined in the sole discretion of the Board or the Compensation Committee, subject to the terms of any applicable incentive compensation plan that may be in effect from time to
time. Except as otherwise provided herein, as may be provided by the Board or the Compensation Committee or as may otherwise be set forth in the applicable incentive compensation plan the Executive must be employed by the Company on the day such
incentive compensation is paid in order to earn or receive any incentive compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Expenses</U>. The
Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by the Executive during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the
Company for its executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Other Benefits</U>. The Executive shall be eligible to participate in
or receive benefits under the Company&#146;s employee benefit plans in effect from time to time, subject to the terms of such plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Paid Time Off</U>. The Company&#146;s current paid time off policy for executives is flexible and paid time off
may be taken at such times and intervals as the Executive may determine, subject to the business needs of the Company and the terms and conditions of any policies as may be in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Equity</U>. The equity awards held by the Executive shall be treated as described in the Merger Agreement and,
subject to the terms and conditions of the Merger Agreement, shall continue to be governed by the terms and conditions of the applicable equity incentive plan(s) and the applicable award agreement(s) governing the terms of such equity awards
(collectively, the &#147;Equity Documents&#148;); provided, however, and notwithstanding anything to the contrary in the Equity Documents, Section&nbsp;6(a)(ii) of this Agreement shall apply in the event of a termination by the Company without Cause
or by the Executive for Good Reason in either event within the Change in Control Period (as such terms are defined below). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification</U>. The Company shall indemnify the Executive
to the extent that its officers, directors and employees are entitled to indemnification pursuant to the Company&#146;s Certificate of Incorporation and Bylaws for any acts or omissions by reason of being an officer or employee of the Company as of
the Effective Date. At all times during the Employment Term, the Company shall maintain in effect a director and officers liability insurance policy with the Executive as a covered officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>. The Executive&#146;s employment hereunder may be terminated without any breach of this Agreement
under the following circumstances: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Death</U>. The Executive&#146;s employment hereunder shall terminate upon death. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Disability</U>. The Company may terminate the Executive&#146;s employment if the Executive is disabled and unable to perform or
expected to be unable to perform the essential functions of the Executive&#146;s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in any <FONT
STYLE="white-space:nowrap">12-month</FONT> period. If any question shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executive&#146;s then existing position or
positions with or without reasonable accommodation, the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the Executive or the
Executive&#146;s guardian has no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and such certification shall for the purposes of this Agreement be conclusive of the issue. The
Executive shall cooperate with any reasonable request of the physician in connection with such certification. If such question shall arise and the Executive shall fail to submit such certification, the Company&#146;s determination of such issue
shall be binding on the Executive. Nothing in this Section&nbsp;3(b) shall be construed to waive the Executive&#146;s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. &#167;2601
<I>et seq</I>. and the Americans with Disabilities Act, 42 U.S.C. &#167;12101 <I>et seq.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination by
the Company for Cause</U>. The Company may terminate the Executive&#146;s employment hereunder for Cause. For purposes of this Agreement, &#147;Cause&#148; shall mean: (i)&nbsp;conduct by the Executive constituting a material act of misconduct in
connection with the performance of his duties, including, without limitation, misappropriation of funds or property of the Company, Parent or any of its or their subsidiaries or affiliates other than the occasional, customary and de minimis use of
Company or Parent property for personal purposes; (ii) the commission by the Executive of acts satisfying the elements of (A)&nbsp;any felony or (B)&nbsp;a misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii)&nbsp;any misconduct
by the Executive, regardless of whether or not in the course of the Executive&#146;s employment, that would reasonably be expected to result in material injury or reputational harm to the Company, Parent or any of its or their subsidiaries or
affiliates if the Executive were to continue to be employed in the same position; (iv)&nbsp;continued willful nonperformance by the Executive of his material duties hereunder (other than by reason of the Executive&#146;s physical or mental illness,
incapacity or disability) which, to the extent it is curable by the Executive, is not cured within thirty (30)&nbsp;after written notice thereof is given to the Executive by the Board; (v)&nbsp;a breach by the Executive of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Restrictive Covenants Agreement or any of the provisions contained in Section&nbsp;8 of this Agreement;
(vi)&nbsp;a material violation by the Executive of the Company&#146;s or Parent&#146;s written employment policies; or (vii)&nbsp;failure to cooperate with a bona fide internal investigation or an investigation by regulatory or law enforcement
authorities, after being instructed by the Company or Parent to cooperate, or the willful destruction or failure to preserve documents or other materials known to be relevant to such investigation or the inducement of others to fail to cooperate or
to produce documents or other materials in connection with such investigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Termination by the Company without Cause</U>. The
Company may terminate the Executive&#146;s employment hereunder at any time without Cause. Any termination by the Company of the Executive&#146;s employment under this Agreement which does not constitute a termination for Cause under
Section&nbsp;3(c) and does not result from the death or disability of the Executive under Section&nbsp;3(a) or (b)&nbsp;shall be deemed a termination without Cause. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination by the Executive</U>. The Executive may terminate his employment hereunder at any time for any
reason, including for Good Reason. For purposes of this Agreement, &#147;Good Reason&#148; shall mean that the Executive has complied with the &#147;Good Reason Process&#148; (hereinafter defined) following the occurrence of any of the following
events: (i) a material diminution in the Executive&#146;s responsibilities, authority or duties <I>provided </I>changes to the Executive&#146;s responsibilities, authority or duties prior to a Change in Control that are made in the good faith
discretion of the Board as part of the Company&#146;s evolving business needs and strategy shall not be a Good Reason occurrence; (ii)&nbsp;a material diminution in the Executive&#146;s Base Salary except for <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">across-the-board</FONT></FONT> salary reductions based on the Company&#146;s or Parent&#146;s financial performance similarly affecting all or substantially all senior management employees of the Company or Parent;
(iii)&nbsp;a material change in the geographic location at which the Executive provides services to the Company such that there is an increase of at least thirty (30)&nbsp;miles of driving distance to such location from the Executive&#146;s
principal residence as of such change; or (iv) the material breach of this Agreement by the Company. &#147;Good Reason Process&#148; shall mean that (i)&nbsp;the Executive reasonably determines in good faith that a &#147;Good Reason&#148; condition
has occurred; (ii)&nbsp;the Executive notifies the Company in writing of the first occurrence of the Good Reason condition within 60 days of the first occurrence of such condition; (iii)&nbsp;the Executive cooperates in good faith with the
Company&#146;s efforts, for a period not less than 30 days following such notice (the &#147;Cure Period&#148;), to remedy the condition; (iv)&nbsp;notwithstanding such efforts, the Good Reason condition continues to exist; and (v)&nbsp;the Executive
terminates his employment within 180 days after the end of the Cure Period. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Matters Related to</U><U> </U><U>Termination</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice of Termination</U>. Except for termination as specified in Section&nbsp;3(a), any termination of the
Executive&#146;s employment by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto. For purposes of this Agreement, a &#147;Notice of Termination&#148; shall mean a
notice which shall indicate the specific termination provision in this Agreement relied upon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Date of
Termination</U>. &#147;Date of Termination&#148; shall mean: (i)&nbsp;if the Executive&#146;s employment is terminated by death, the date of death; (ii)&nbsp;if the Executive&#146;s employment is terminated on account of disability under
Section&nbsp;3(b) or by the Company for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cause under Section&nbsp;3(c), the date on which Notice of Termination is given; (iii)&nbsp;if the
Executive&#146;s employment is terminated by the Company without Cause under Section&nbsp;3(d), the date on which a Notice of Termination is given or the date otherwise specified by the Company in the Notice of Termination; (iv)&nbsp;if the
Executive&#146;s employment is terminated by the Executive under Section&nbsp;3(e) other than for Good Reason, 30 days after the date on which a Notice of Termination is given, and (v)&nbsp;if the Executive&#146;s employment is terminated by the
Executive under Section&nbsp;3(e) for Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period. Notwithstanding the foregoing, in the event that the Executive gives a Notice of Termination to the Company, the
Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Accrued Obligations</U>. If the Executive&#146;s employment with the Company is terminated for any reason, the
Company shall pay or provide to the Executive (or to the Executive&#146;s authorized representative or estate)&nbsp;(i) any Base Salary earned through the Date of Termination; (ii)&nbsp;unpaid expense reimbursements (subject to, and in accordance
with, Section&nbsp;2(c) of this Agreement); and (iii)&nbsp;any vested benefits the Executive may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance
with the terms of such employee benefit plans (collectively, the &#147;Accrued Obligations&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Resignation of All Other Positions</U>. To the extent applicable, the Executive shall be deemed to have resigned
from all officer and board member positions that the Executive holds with the Company or any of its respective subsidiaries and affiliates upon the termination of the Executive&#146;s employment for any reason. The Executive shall execute any
documents in reasonable form as may be requested to confirm or effectuate any such resignations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Severance
Pay and Benefits Upon Termination by the Company without Cause or by the Executive for Good Reason Outside the Change in Control Period</U>. If the Executive&#146;s employment is terminated by the Company without Cause as provided in
Section&nbsp;3(d) or the Executive terminates employment for Good Reason as provided in Section&nbsp;3(e), in each case outside of the Change in Control Period (as defined below), then, in addition to the Accrued Obligations, subject to the
Executive signing a separation agreement containing, among other provisions, a general release of claims in favor of the Company and related persons and entities, including the PEO, a reaffirmation of the Executive&#146;s Continuing Obligations (as
defined below), confidentiality, return of property and <FONT STYLE="white-space:nowrap">non-disparagement,</FONT> in a form and manner satisfactory to the Company (the &#147;Separation Agreement and Release&#148;) and the Separation Agreement and
Release becoming irrevocable and fully effective, all within 60 days after the Date of Termination (or such shorter time period provided in the Separation Agreement and Release): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall pay the Executive an amount equal to twelve (12)&nbsp;months of the Executive&#146;s Base Salary
(the &#147;Severance Amount&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall pay any unpaid bonus earned for the year preceding
the date of Executive&#146;s employment termination, payable at the time it otherwise would have been paid had the Executive&#146;s employment with the Company not terminated; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;subject to the Executive&#146;s copayment of premium amounts at
the applicable active employees&#146; rate and the Executive&#146;s proper election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#147;<U>COBRA</U>&#148;), the Company shall pay to the Executive a
monthly cash payment (including a gross up payment to account for applicable taxes and withholdings) equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive and covered dependents if
the Executive had remained employed by the Company until the earliest of (A)&nbsp;the twelve (12)&nbsp;month anniversary of the Date of Termination; (B)&nbsp;the date that the Executive becomes eligible for group medical plan benefits under any
other employer&#146;s group medical plan; or (C)&nbsp;the cessation of the Executive&#146;s health continuation rights under COBRA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts payable
under Section&nbsp;5(a) and (c), to the extent taxable, shall be paid out in substantially equal installments in accordance with the Company&#146;s payroll practice over twelve (12) months commencing within 60 days after the Date of Termination;
provided, however, that if the <FONT STYLE="white-space:nowrap">60-day</FONT> period begins in one calendar year and ends in a second calendar year, such payments, to the extent they qualify as
<FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; within the meaning of Section&nbsp;409A of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), shall begin to be paid in the second calendar
year by the last day of such <FONT STYLE="white-space:nowrap">60-day</FONT> period; provided, further, that the initial payment shall include a <FONT STYLE="white-space:nowrap">catch-up</FONT> payment to cover amounts retroactive to the day
immediately following the Date of Termination. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Severance Pay and Benefits Upon Termination by the Company without Cause or by the Executive for Good Reason
within the Change in Control Period</U>. The provisions of this Section&nbsp;6 shall apply in lieu of, and expressly supersede, the provisions of Section&nbsp;5 if (i)&nbsp;the Executive&#146;s employment is terminated either (a)&nbsp;by the Company
without Cause as provided in Section&nbsp;3(d), or (b)&nbsp;by the Executive for Good Reason as provided in Section&nbsp;3(e), and (ii)&nbsp;the Date of Termination 3 months prior to or within 12 months after the occurrence of the first event
constituting a Change in Control (such period, the &#147;Change in Control Period&#148;) following the Effective Date. These provisions shall terminate and be of no further force or effect after the Change in Control Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;If the Executive&#146;s employment is terminated by the Company without Cause as provided in Section&nbsp;3(d) or
the Executive terminates employment for Good Reason as provided in Section&nbsp;3(e) and in each case the Date of Termination occurs during the Change in Control Period, then, in addition to the Accrued Obligations, and subject to the signing of the
Separation Agreement and Release by the Executive and the Separation Agreement and Release becoming fully effective, all within the time frame set forth in the Separation Agreement and Release but in no event more than 60 days after the Date of
Termination: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall pay the Executive a lump sum in cash in an amount equal to one
and a half (1.5) times the sum of (A)&nbsp;the Executive&#146;s then-current Base Salary (or the Executive&#146;s Base Salary in effect immediately prior to the Change in Control, if higher) plus (B)&nbsp;the Executive&#146;s Target Bonus for the
then-current year (or the Executive&#146;s Target Bonus in effect immediately prior to the Change in Control, if higher) and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall pay any unpaid bonus earned
for the year preceding the date of Executive&#146;s employment termination, payable at the time it otherwise would have been paid had the Executive&#146;s employment with the Company not terminated, and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;notwithstanding anything to the contrary in any applicable option agreement or other stock-based
award agreement, all stock options and other stock-based awards held by the Executive that are subject solely to time-based vesting (the &#147;Time- Based Equity Awards&#148;) shall immediately accelerate and become fully vested and exercisable or
nonforfeitable as of the later of (i)&nbsp;the Date of Termination or (ii)&nbsp;the effective date of the Separation Agreement and Release (the &#147;Accelerated Vesting Date&#148;), provided in order to effectuate the accelerated vesting
contemplated by this subsection, the unvested portion of the Executive&#146;s options that would otherwise be forfeited on the Date of Termination will be delayed until the earlier of (A)&nbsp;the effective date of the Separation Agreement Release
(at which time acceleration will occur), or (B)&nbsp;the date that the Separation Agreement and Release can no longer become fully effective (at which time the unvested Time-Based Equity Awards will be terminated or forfeited). Notwithstanding the
foregoing, no additional time-based vesting of the Time-Based Equity Awards shall occur during the period between the Date of Termination and the Accelerated Vesting Date; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;subject to the Executive&#146;s copayment of premium amounts at the applicable active
employees&#146; rate and the Executive&#146;s proper election to receive benefits under COBRA, the Company shall pay to the Executive a monthly cash payment (including a gross up payment to account for applicable taxes and withholdings) equal to the
monthly employer contribution that the Company would have made to provide health insurance to the Executive and covered dependents if the Executive had remained employed by the Company until the earliest of (A)&nbsp;the eighteen (18)&nbsp;month
anniversary of the Date of Termination; (B)&nbsp;the date that the Executive becomes eligible for group medical plan benefits under any other employer&#146;s group medical plan; or (C)&nbsp;the cessation of the Executive&#146;s health continuation
rights under COBRA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts payable under this Section&nbsp;6(a), to the extent taxable, shall be paid or commence to be paid within 60 days after
the Date of Termination; provided, however, that if the <FONT STYLE="white-space:nowrap">60-day</FONT> period begins in one calendar year and ends in a second calendar year, such payments to the extent they qualify as
<FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; within the meaning of Section&nbsp;409A of the Code, shall be paid or commence to be paid in the second calendar year by the last day of such <FONT
STYLE="white-space:nowrap">60-day</FONT> period. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Additional</U><U> </U><U>Limitation</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any
compensation, payment or distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with
Section&nbsp;280G of the Code, and the applicable regulations thereunder (the &#147;Aggregate Payments&#148;), would be subject to the excise tax imposed by Section&nbsp;4999 of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Code, then the Aggregate Payments shall be reduced (but not below zero) so that the sum of all of the
Aggregate Payments shall be $1.00 less than the amount at which the Executive becomes subject to the excise tax imposed by Section&nbsp;4999 of the Code; provided that such reduction shall only occur if it would result in the Executive receiving a
higher After Tax Amount (as defined below) than the Executive would receive if the Aggregate Payments were not subject to such reduction. In such event, the Aggregate Payments shall be reduced in the following order, in each case, in reverse
chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section&nbsp;280G of the Code: (1)&nbsp;cash payments not subject to Section&nbsp;409A of the
Code; (2)&nbsp;cash payments subject to Section&nbsp;409A of the Code; (3)&nbsp;equity-based payments and acceleration; and <FONT STYLE="white-space:nowrap">(4)&nbsp;non-cash</FONT> forms of benefits; provided that in the case of all the foregoing
Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. <FONT STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT STYLE="white-space:nowrap">Q&amp;A-24(b)</FONT> or (c) shall be reduced before any amounts
that are subject to calculation under Treas. Reg. <FONT STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT STYLE="white-space:nowrap">Q&amp;A-24(b)</FONT> or (c). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;For purposes of this Section&nbsp;6(b), the &#147;After Tax Amount&#148; means the amount of the
Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on the Executive as a result of the Executive&#146;s receipt of the Aggregate Payments. For purposes of determining the After Tax Amount, the Executive
shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal
rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to
Section&nbsp;6(b)(i) shall be made by a nationally recognized accounting firm selected by the Company (the &#147;Accounting Firm&#148;), which shall provide detailed supporting calculations both to the Company and the Executive within 15 business
days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Executive. Any determination by the Accounting Firm shall be binding upon the Company and the Executive. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For purposes of this Section&nbsp;6, the following terms shall have the following meanings:
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Change in Control&#148; shall mean any of the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;any &#147;person,&#148; as such term is used in Sections 13(d) and 14(d) of the Securities Exchange
Act of 1934, as amended (the &#147;Act&#148;), any of its subsidiaries, or any trustee, fiduciary or other person or entity holding securities under any employee benefit plan or trust of Parent or any of its subsidiaries), together with all
&#147;affiliates&#148; and &#147;associates&#148; (as such terms are defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Act) of such person, shall become the &#147;beneficial owner&#148; (as such term is defined in Rule <FONT
STYLE="white-space:nowrap">13d-3</FONT> under the Act), directly or indirectly, of securities of Parent representing 50&nbsp;percent or more of the combined voting power of Parent&#146;s then outstanding securities having the right to vote in an
election of the Board (&#147;Voting Securities&#148;) (in such case other than as a result of an acquisition of securities directly from Parent); or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the date a majority of the members of the Board
is replaced during any <FONT STYLE="white-space:nowrap">12-month</FONT> period by directors whose appointment or election is not endorsed by a majority of the members of the Board before the date of the appointment or election; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;the consummation of (A)&nbsp;any consolidation or merger of Parent where the stockholders of
Parent, immediately prior to the consolidation or merger, would not, immediately after the consolidation or merger, beneficially own (as such term is defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Act), directly or
indirectly, shares representing in the aggregate more than 50&nbsp;percent of the voting shares of Parent issuing cash or securities in the consolidation or merger (or of its ultimate parent corporation, if any), or (B)&nbsp;any sale or other
transfer (in one transaction or a series of transactions contemplated or arranged by any party as a single plan) of all or substantially all of the assets of Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, a &#147;Change in Control&#148; shall not be deemed to have occurred for purposes of the foregoing clause
(i)&nbsp;solely as the result of an acquisition of securities by Parent which, by reducing the number of shares of Voting Securities outstanding, increases the proportionate number of Voting Securities beneficially owned by any person to
50&nbsp;percent or more of the combined voting power of all of the then outstanding Voting Securities; provided, however, that if any person referred to in this sentence shall thereafter become the beneficial owner of any additional shares of Voting
Securities (other than pursuant to a stock split, stock dividend, or similar transaction or as a result of an acquisition of securities directly from Parent) and immediately thereafter beneficially owns 50&nbsp;percent or more of the combined voting
power of all of the then outstanding Voting Securities, then a &#147;Change in Control&#148; shall be deemed to have occurred for purposes of the foregoing clause (i). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Section</U><U></U><U>&nbsp;409A</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive&#146;s separation from
service within the meaning of Section&nbsp;409A of the Code, the Company determines that the Executive is a &#147;specified employee&#148; within the meaning of Section&nbsp;409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit
that the Executive becomes entitled to under this Agreement or otherwise on account of the Executive&#146;s separation from service would be considered deferred compensation otherwise subject to the 20&nbsp;percent additional tax imposed pursuant to
Section&nbsp;409A(a) of the Code as a result of the application of Section&nbsp;409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A)&nbsp;six months and one
day after the Executive&#146;s separation from service, or (B)&nbsp;the Executive&#146;s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a
<FONT STYLE="white-space:nowrap">catch-up</FONT> payment covering amounts that would otherwise have been paid during the <FONT STYLE="white-space:nowrap">six-month</FONT> period but for the application of this provision, and the balance of the
installments shall be payable in accordance with their original schedule. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;All <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits
provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively
practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits provided or
reimbursable expenses incurred in one taxable year shall not affect the <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other
aggregate limitation applicable to medical expenses). Such right to reimbursement or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits is not subject to liquidation or exchange for another benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;To the extent that any payment or benefit described in this Agreement constitutes
<FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; under Section&nbsp;409A of the Code, and to the extent that such payment or benefit is payable upon the Executive&#146;s termination of employment, then such
payments or benefits shall be payable only upon the Executive&#146;s &#147;separation from service.&#148; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in
Treasury Regulation Section <FONT STYLE="white-space:nowrap">1.409A-1(h).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;The parties intend that this
Agreement will be administered in accordance with Section&nbsp;409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section&nbsp;409A of the Code, the provision shall be read in such a manner so
that all payments hereunder comply with Section&nbsp;409A of the Code. Each payment pursuant to this Agreement or the Restrictive Covenants Agreement is intended to constitute a separate payment for purposes of Treasury Regulation <FONT
STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2).</FONT> The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section&nbsp;409A of the Code and all related
rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;The Company makes no representation or warranty and shall have no liability to the Executive or any other person
if any provisions of this Agreement are determined to constitute deferred compensation subject to Section&nbsp;409A of the Code but do not satisfy an exemption from, or the conditions of, such Section. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Continuing</U><U> </U><U>Obligations</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Restrictive Covenants Agreement</U>. As a condition of employment, the Executive is required to enter into the
Employee Confidentiality, Assignment and Nonsolicitation Agreement, attached hereto as <U>Exhibit A</U> (the &#147;Restrictive Covenants Agreement&#148;). For the avoidance of doubt, the Restrictive Covenants Agreement is supplemental to
Section&nbsp;4 of the Prior Agreement (the &#147;Preserved Provision&#148;); <I>provided </I>that Section&nbsp;4(c) <FONT STYLE="white-space:nowrap">(&#147;Non-Competition</FONT> Restrictions&#148;) shall only apply to the products and services of
resTORbio, Inc. developed prior to the Effective Date which remains in full force and effect. For purposes of this Agreement, the obligations in this Section&nbsp;8 and those that arise in the Restrictive Covenants Agreement, the Preserved Provision
and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the &#147;Continuing Obligations.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Third-Party Agreements and Rights</U>. The Executive hereby
confirms that the Executive is not bound by the terms of any agreement with any previous employer or other party which restricts in any way the Executive&#146;s use or disclosure of information, other than confidentiality restrictions (if any), or
the Executive&#146;s engagement in any business. The Executive represents to the Company that the Executive&#146;s execution of this Agreement, the Executive&#146;s employment with the Company and the performance of the Executive&#146;s proposed
duties for the Company will not violate any obligations the Executive may have to any such previous employer or other party. In the Executive&#146;s work for the Company, the Executive will not disclose or make use of any information in violation of
any agreements with or rights of any such previous employer or other party, and the Executive will not bring to the premises of the Company any copies or other tangible embodiments of <FONT STYLE="white-space:nowrap">non-public</FONT> information
belonging to or obtained from any such previous employment or other party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Litigation and Regulatory
Cooperation</U>. During and after the Executive&#146;s employment, the Executive shall cooperate fully with the Company in (i)&nbsp;the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or
on behalf of the Company which relate to events or occurrences that transpired while the Executive was employed by the Company, and (ii)&nbsp;the investigation, whether internal or external, of any matters about which the Company believes the
Executive may have knowledge or information. The Executive&#146;s full cooperation in connection with such claims, actions or investigations shall include, but not be limited to, being available to meet with counsel to answer questions or to prepare
for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During and after the Executive&#146;s employment, the Executive also shall cooperate fully with the Company in connection with any investigation or
review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Executive was employed by the Company. The Company shall reimburse the Executive for any
reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with the Executive&#146;s performance of obligations pursuant to this Section&nbsp;8(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Relief</U>. The Executive agrees that it would be difficult to measure any damages caused to the Company which
might result from any breach by the Executive of the Continuing Obligations, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly<B>, </B>the Executive agrees that if the Executive breaches, or proposes
to breach, any portion of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other appropriate equitable relief to restrain any such breach without showing or proving
any actual damage to the Company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Arbitration of</U><U> </U><U>Disputes</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Arbitration Generally</U>. Any controversy or claim arising out of or relating to this Agreement or the breach
thereof or otherwise arising out of the Executive&#146;s employment or the termination of that employment (including, without limitation, any claims of unlawful employment discrimination or retaliation, whether based on race, religion, national
origin, sex, gender, age, disability, sexual orientation, or any other protected class under applicable law) shall, to the fullest extent permitted by law, be settled by arbitration in any forum and form agreed upon by the parties or, in the absence
of such an agreement, under the auspices of JAMS </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in Boston, Massachusetts in accordance with the JAMS Employment Arbitration Rules, including, but not
limited to, the rules and procedures applicable to the selection of arbitrators. The Executive understands that the Executive may only bring such claims in the Executive&#146;s individual capacity, and not as a plaintiff or class member in any
purported class proceeding or any purported representative proceeding.&nbsp;&nbsp;&nbsp;&nbsp;The Executive further understands that, by signing this Agreement, the Company and the Executive are giving up any right they may have to a jury trial on
all claims they may have against each other. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. This Section&nbsp;9 shall be specifically enforceable. Notwithstanding the foregoing, this
Section&nbsp;9 shall not preclude either party from pursuing a court action for the sole purpose of obtaining a temporary restraining order or a preliminary injunction in circumstances in which such relief is appropriate, including without
limitation relief sought under the Restrictive Covenants Agreement; provided that any other relief shall be pursued through an arbitration proceeding pursuant to this Section&nbsp;9. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Arbitration Fees and Costs</U>. The Executive shall be required to pay an arbitration fee to initiate any
arbitration equal to what the Executive would be charged as a first appearance fee in court. The Company shall advance the remaining fees and costs of the arbitrator. However, to the extent permissible under the law, and following the
arbitrator&#146;s ruling on the matter, the arbitrator may rule that the arbitrator&#146;s fees and costs be distributed in an alternative manner. Each party shall pay its own costs and attorneys&#146; fees, if any. If, however, any party prevails
on a statutory or contractual claim that affords the prevailing party attorneys&#146; fees (including pursuant to this Agreement), the arbitrator may award attorneys&#146; fees to the prevailing party to the extent permitted by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Consent to Jurisdiction</U>. The parties hereby consent to the jurisdiction of the state and federal courts of
the Commonwealth of Massachusetts. Accordingly, with respect to any such court action, the Executive (a)&nbsp;submits to the exclusive personal jurisdiction of such courts; (b) consents to service of process; and (c)&nbsp;waives any other
requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&nbsp;&nbsp;&nbsp;&nbsp;<U>Integration</U>. This Agreement constitutes the entire agreement between the parties with respect to the subject
matter hereof and supersedes all prior agreements between the parties concerning such subject matter including the Prior Agreement provided that the Preserved Provision, the Restrictive Covenants Agreement and the Equity Documents remain in full
force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&nbsp;&nbsp;&nbsp;&nbsp;<U>Withholding; Tax Effect</U>. All payments made by the Company to the Executive under this
Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law. Nothing in this Agreement shall be construed to require the Company to make any payments to compensate the Executive for any adverse tax
effect associated with any payments or benefits or for any deduction or withholding from any payment or benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors and Assigns</U>. Neither the Executive nor the Company may make any assignment of this Agreement or
any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement (including the Restrictive Covenants Agreement)
without the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive&#146;s consent to any affiliate or to any person or entity with whom the Company shall hereafter
effect a reorganization or consolidation, into which the Company merges or to whom it transfers all or substantially all of its properties or assets; provided further that if the Executive remains employed or becomes employed by the Company, the
purchaser or any of their affiliates in connection with any such transaction, then the Executive shall not be entitled to any payments, benefits or vesting pursuant to Section&nbsp;5 or pursuant to Section&nbsp;6 of this Agreement solely as a result
of such transaction. This Agreement shall inure to the benefit of and be binding upon the Executive and the Company, and each of the Executive&#146;s and the Company&#146;s respective successors, executors, administrators, heirs and permitted
assigns. In the event of the Executive&#146;s death after the Executive&#146;s termination of employment but prior to the completion by the Company of all payments due to the Executive under this Agreement, the Company shall continue such payments
to the Executive&#146;s beneficiary designated in writing to the Company prior to the Executive&#146;s death (or to the Executive&#146;s estate, if the Executive fails to make such designation). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.&nbsp;&nbsp;&nbsp;&nbsp;<U>Enforceability</U>. If any portion or provision of this Agreement (including, without limitation, any portion or
provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other
than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U>. The provisions of this Agreement shall survive the termination of this Agreement and/or the
termination of the Executive&#146;s employment to the extent necessary to effectuate the terms contained herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver</U>. No waiver of any provision hereof shall be effective unless made in writing and signed by the
waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be
deemed a waiver of any subsequent breach. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>. Any notices, requests, demands and other
communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to
the Executive at the last address the Executive has filed in writing with the Company or, in the case of the Company, at its main offices, attention of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18.&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment</U>. This Agreement may be amended or modified only by a written instrument signed by the Executive
and by a duly authorized representative of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.&nbsp;&nbsp;&nbsp;&nbsp;<U>Effect on Other Plans and Agreements</U>. An
election by the Executive to resign for Good Reason under the provisions of this Agreement shall not be deemed a voluntary termination of employment by the Executive for the purpose of interpreting the provisions of any of the Company&#146;s benefit
plans, programs or policies. Nothing in this Agreement shall be construed to limit the rights of the Executive under the Company&#146;s benefit plans, programs or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">policies except as otherwise provided in Section&nbsp;8 hereof, and except that the Executive shall have no
rights to any severance benefits under any Company severance pay plan, offer letter or otherwise. In the event that the Executive is party to an agreement with the Company providing for payments or benefits under such plan or agreement and under
this Agreement, the terms of this Agreement shall govern and the Executive may receive payment under this Agreement only and not both. Further, Section&nbsp;5 and Section&nbsp;6 of this Agreement are mutually exclusive and in no event shall the
Executive be entitled to payments or benefits pursuant to both Section&nbsp;5 and Section&nbsp;6 of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20.&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing Law</U>. This is a Massachusetts contract and shall be construed under and be governed in all respects
by the laws of the Commonwealth of Massachusetts, without giving effect to the conflict of laws principles thereof. With respect to any disputes concerning federal law, such disputes shall be determined in accordance with the law as it would be
interpreted and applied by the United States Court of Appeals for the 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> Circuit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>. This Agreement may be executed in any number of counterparts, each of which when so executed
and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS
WHEREOF, the parties have executed this Agreement effective on the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ADICET THERAPEUTICS,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>INC./RESTORBIO, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ ILLEGIBLE</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Partner</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CHEN SCHOR</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Chen schor</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chen schor</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>[Exhibit A</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Restrictive Covenants Agreement] </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>d91031dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Employment Agreement (&#147;Agreement&#148;) is made between Adicet Therapeutics, Inc., a Delaware corporation (the &#147;Company&#148;),
and Carrie Krehlik (the &#147;Executive&#148;) and is contingent upon the closing (the &#147;Closing&#148;) of the transaction (the &#147;Merger&#148;) contemplated by that certain Agreement and Plan of Merger (the &#147;Merger Agreement&#148;) by
and among resTORbio, Inc. (&#147;Parent&#148;), Adicet Bio, Inc. (&#147;Adicet Bio&#148;) and the other parties thereto. Subject to Section&nbsp;11, except with respect to the Employee Proprietary Information and Invention Assignment Agreement
between the Executive and Adicet Bio, dated November&nbsp;3, 2017 (the &#147;Prior Restrictive Covenants Agreement&#148;) and the Equity Documents (as defined below), this Agreement supersedes in all respects all prior agreements between the
Executive and Adicet Bio regarding the subject matter herein, including without limitation (i)&nbsp;the offer letter between the Executive and Adicet Bio dated November&nbsp;1, 2017, as amended (the &#147;Prior Agreement&#148;), and (ii) any offer
letter, employment agreement or severance agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Adicet Bio, Inc. will change its name to Adicet Therapeutics, Inc. post-
Closing and Parent will change its name to Adicet Bio, Inc. post-Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company desires to employ the Executive and the
Executive desires to be employed by the Company beginning on the effective date of the Closing of the Merger (the &#147;Effective Date&#148;) on the terms contained herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, the parties agree as follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Employment</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Term</U>. The term of this Agreement shall commence on the Effective Date and continue until terminated in
accordance with the provisions hereof (the &#147;Term&#148;). The Executive&#146;s employment with the Company shall be &#147;at will,&#148; meaning that the Executive&#146;s employment may be terminated by the Company or the Executive at any time
and for any reason subject to the terms of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Position and Duties</U>. The Executive shall
serve as the Senior Vice President, Chief Human Resource Officer of the Company and shall have such powers and duties as may from time to time be prescribed by the Chief Executive Officer of the Company (the &#147;CEO&#148;). The Executive shall
devote her full working time and efforts to the business and affairs of the Company. Notwithstanding the foregoing, the Executive may serve on other boards of directors, with the approval of the Governance Committee of the Board of Directors of the
Parent (the &#147;Governance Committee&#148; of the &#147;Board&#148;), or engage in religious, charitable or other community activities as long as such services and activities do not interfere with the Executive&#146;s performance of her duties to
the Parent and the Company as provided in this Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Compensation and Related</U><U> </U><U>Matters</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Base Salary</U>. The Executive&#146;s initial base salary shall be paid at the rate of $300,000 per year. The Executive&#146;s base
salary shall be subject to periodic review by the Compensation Committee of the Board (the &#147;Compensation Committee&#148;). The base salary in effect at any given time is referred to herein as &#147;Base Salary.&#148; The Base Salary shall be
payable in a manner that is consistent with the Company&#146;s usual payroll practices for executive officers. The Executive&#146;s salary and any other cash compensation may be provided through TriNet, Inc. or another professional employer
organization (a &#147;<U>PEO</U>&#148;). As a result of the Company&#146;s arrangement with the PEO, the PEO will be considered the Executive&#146;s employer of record for these purposes for so long as that arrangement exists. While the PEO will
have responsibility for the functions above, the Company retains responsibility for overseeing the Executive&#146;s work and reviewing the Executive&#146;s performance, among other functions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Incentive Compensation</U>. The Executive shall be eligible to receive cash incentive compensation as determined
by the Board or the Compensation Committee from time to time. Commencing in calendar year 2021, the Executive&#146;s initial target annual incentive compensation shall be forty (40)&nbsp;percent of the Executive&#146;s Base Salary; provided that any
incentive compensation for calendar year 2020 will be prorated based on the Effective Date. The target annual incentive compensation in effect at any given time is referred to herein as &#147;Target Bonus.&#148; The actual amount of the
Executive&#146;s annual incentive compensation, if any, shall be determined in the sole discretion of the Board or the Compensation Committee, subject to the terms of any applicable incentive compensation plan that may be in effect from time to
time. Except as otherwise provided herein, as may be provided by the Board or the Compensation Committee or as may otherwise be set forth in the applicable incentive compensation plan the Executive must be employed by the Company on the day such
incentive compensation is paid in order to earn or receive any incentive compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Expenses</U>. The
Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by the Executive during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the
Company for its executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Other Benefits</U>. The Executive shall be eligible to participate in
or receive benefits under the Company&#146;s employee benefit plans in effect from time to time, subject to the terms of such plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Paid Time Off</U>. The Company&#146;s current paid time off policy for executives is flexible and paid time off
may be taken at such times and intervals as the Executive may determine, subject to the business needs of the Company and the terms and conditions of any policies as may be in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Equity</U>. The equity awards held by the Executive shall be treated as described in the Merger Agreement and,
subject to the terms and conditions of the Merger Agreement, shall continue to be governed by the terms and conditions of the applicable equity incentive plan(s) and the applicable award agreement(s) governing the terms of such equity awards
(collectively, the &#147;Equity Documents&#148;); provided, however, and notwithstanding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
anything to the contrary in the Equity Documents, Section&nbsp;6(a)(ii) of this Agreement shall apply in the event of a termination by the Company without Cause or by the Executive for Good
Reason in either event within the Change in Control Period (as such terms are defined below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification</U>. The Company shall indemnify the Executive to the extent that its officers, directors and
employees are entitled to indemnification pursuant to the Company&#146;s Certificate of Incorporation and Bylaws for any acts or omissions by reason of being an officer or employee of the Company as of the Effective Date. At all times during the
Employment Term, the Company shall maintain in effect a director and officers liability insurance policy with the Executive as a covered officer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>. The Executive&#146;s employment hereunder may be terminated without any breach of this Agreement
under the following circumstances: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Death</U>. The Executive&#146;s employment hereunder shall terminate upon death. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Disability</U>. The Company may terminate the Executive&#146;s employment if the Executive is disabled and unable to perform or
expected to be unable to perform the essential functions of the Executive&#146;s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in any <FONT
STYLE="white-space:nowrap">12-month</FONT> period. If any question shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executive&#146;s then existing position or
positions with or without reasonable accommodation, the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the Executive or the
Executive&#146;s guardian has no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and such certification shall for the purposes of this Agreement be conclusive of the issue. The
Executive shall cooperate with any reasonable request of the physician in connection with such certification. If such question shall arise and the Executive shall fail to submit such certification, the Company&#146;s determination of such issue
shall be binding on the Executive. Nothing in this Section&nbsp;3(b) shall be construed to waive the Executive&#146;s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. &#167;2601
<I>et seq</I>. and the Americans with Disabilities Act, 42 U.S.C. &#167;12101 <I>et seq.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination by
the Company for Cause</U>. The Company may terminate the Executive&#146;s employment hereunder for Cause. For purposes of this Agreement, &#147;Cause&#148; shall mean: (i)&nbsp;conduct by the Executive constituting a material act of misconduct in
connection with the performance of her duties, including, without limitation, misappropriation of funds or property of the Company, Parent or any of its or their subsidiaries or affiliates other than the occasional, customary and de minimis use of
Company or Parent property for personal purposes; (ii) the commission by the Executive of acts satisfying the elements of (A)&nbsp;any felony or (B)&nbsp;a misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii)&nbsp;any misconduct
by the Executive, regardless of whether or not in the course of the Executive&#146;s employment, that would reasonably be expected to result in material injury or reputational harm to the Company, Parent or any of its or their subsidiaries or
affiliates if the Executive were to continue to be employed in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the same position; (iv)&nbsp;continued willful nonperformance by the Executive of her material duties hereunder (other than by reason of the Executive&#146;s physical or mental illness,
incapacity or disability) which, to the extent it is curable by the Executive, is not cured within thirty (30)&nbsp;after written notice thereof is given to the Executive by the CEO; (v)&nbsp;a breach by the Executive of the Restrictive Covenants
Agreement or any of the provisions contained in Section&nbsp;8 of this Agreement; (vi)&nbsp;a material violation by the Executive of the Company&#146;s or Parent&#146;s written employment policies; or (vii)&nbsp;failure to cooperate with a bona fide
internal investigation or an investigation by regulatory or law enforcement authorities, after being instructed by the Company or Parent to cooperate, or the willful destruction or failure to preserve documents or other materials known to be
relevant to such investigation or the inducement of others to fail to cooperate or to produce documents or other materials in connection with such investigation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Termination by the Company without Cause</U>. The Company may terminate the Executive&#146;s employment hereunder at any time without
Cause. Any termination by the Company of the Executive&#146;s employment under this Agreement which does not constitute a termination for Cause under Section&nbsp;3(c) and does not result from the death or disability of the Executive under
Section&nbsp;3(a) or (b)&nbsp;shall be deemed a termination without Cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination by the
Executive</U>. The Executive may terminate her employment hereunder at any time for any reason, including for Good Reason. For purposes of this Agreement, &#147;Good Reason&#148; shall mean that the Executive has complied with the &#147;Good Reason
Process&#148; (hereinafter defined) following the occurrence of any of the following events: (i)&nbsp;&nbsp;&nbsp;&nbsp;a material diminution in the Executive&#146;s responsibilities, authority or duties <I>provided </I>changes to the
Executive&#146;s responsibilities, authority or duties prior to a Change in Control that are made in the good faith discretion of the Company&#146;s CEO as part of the Company&#146;s evolving business needs and strategy shall not be a Good Reason
occurrence; (ii)&nbsp;a material diminution in the Executive&#146;s Base Salary except for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">across-the-board</FONT></FONT> salary reductions based on the Company&#146;s or
Parent&#146;s financial performance similarly affecting all or substantially all senior management employees of the Company or Parent; (iii)&nbsp;a material change in the geographic location at which the Executive provides services to the Company
such that there is an increase of at least thirty (30) miles of driving distance to such location from the Executive&#146;s principal residence as of such change; or (iv)&nbsp;the material breach of this Agreement by the Company. &#147;Good Reason
Process&#148; shall mean that (i)&nbsp;the Executive reasonably determines in good faith that a &#147;Good Reason&#148; condition has occurred; (ii)&nbsp;the Executive notifies the Company in writing of the first occurrence of the Good Reason
condition within 60 days of the first occurrence of such condition; (iii)&nbsp;the Executive cooperates in good faith with the Company&#146;s efforts, for a period not less than 30 days following such notice (the &#147;Cure Period&#148;), to remedy
the condition; (iv)&nbsp;notwithstanding such efforts, the Good Reason condition continues to exist; and (v)&nbsp;the Executive terminates her employment within 180 days after the end of the Cure Period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Matters Related to</U><U> </U><U>Termination</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice of Termination</U>. Except for termination as specified in Section&nbsp;3(a), any termination of the
Executive&#146;s employment by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto. For purposes of this Agreement, a &#147;Notice of Termination&#148; shall mean a
notice which shall indicate the specific termination provision in this Agreement relied upon. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Date of Termination</U>. &#147;Date of Termination&#148; shall
mean: (i)&nbsp;if the Executive&#146;s employment is terminated by death, the date of death; (ii)&nbsp;if the Executive&#146;s employment is terminated on account of disability under Section&nbsp;3(b) or by the Company for Cause under
Section&nbsp;3(c), the date on which Notice of Termination is given; (iii)&nbsp;if the Executive&#146;s employment is terminated by the Company without Cause under Section&nbsp;3(d), the date on which a Notice of Termination is given or the date
otherwise specified by the Company in the Notice of Termination; (iv)&nbsp;if the Executive&#146;s employment is terminated by the Executive under Section&nbsp;3(e) other than for Good Reason, 30 days after the date on which a Notice of Termination
is given, and (v)&nbsp;if the Executive&#146;s employment is terminated by the Executive under Section&nbsp;3(e) for Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period. Notwithstanding the foregoing, in
the event that the Executive gives a Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Accrued Obligations</U>. If the Executive&#146;s employment with the Company is terminated for any reason, the
Company shall pay or provide to the Executive (or to the Executive&#146;s authorized representative or estate)&nbsp;(i) any Base Salary earned through the Date of Termination; (ii)&nbsp;unpaid expense reimbursements (subject to, and in accordance
with, Section&nbsp;2(c) of this Agreement); and (iii)&nbsp;any vested benefits the Executive may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance
with the terms of such employee benefit plans (collectively, the &#147;Accrued Obligations&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Resignation of All Other Positions</U>. To the extent applicable, the Executive shall be deemed to have resigned
from all officer and board member positions that the Executive holds with the Company or any of its respective subsidiaries and affiliates upon the termination of the Executive&#146;s employment for any reason. The Executive shall execute any
documents in reasonable form as may be requested to confirm or effectuate any such resignations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Severance
Pay and Benefits Upon Termination by the Company without Cause or by the Executive for Good Reason Outside the Change in Control Period</U>. If the Executive&#146;s employment is terminated by the Company without Cause as provided in
Section&nbsp;3(d) or the Executive terminates employment for Good Reason as provided in Section&nbsp;3(e), in each case outside of the Change in Control Period (as defined below), then, in addition to the Accrued Obligations, subject to the
Executive signing a separation agreement containing, among other provisions, a general release of claims in favor of the Company and related persons and entities, including the PEO, a reaffirmation of the Executive&#146;s Continuing Obligations (as
defined below), confidentiality, return of property and <FONT STYLE="white-space:nowrap">non-disparagement,</FONT> in a form and manner satisfactory to the Company (the &#147;Separation Agreement and Release&#148;) and the Separation Agreement and
Release becoming irrevocable and fully effective, all within 60 days after the Date of Termination (or such shorter time period provided in the Separation Agreement and Release): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall pay the Executive an amount equal to nine (9)&nbsp;months of the Executive&#146;s Base Salary
(the &#147;Severance Amount&#148;); and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall pay any unpaid bonus earned for the year
preceding the date of Executive&#146;s employment termination, payable at the time it otherwise would have been paid had the Executive&#146;s employment with the Company not terminated; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;subject to the Executive&#146;s copayment of premium amounts at the applicable active employees&#146; rate and the
Executive&#146;s proper election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#147;<U>COBRA</U>&#148;), the Company shall pay to the Executive a monthly cash payment (including a gross up payment
to account for applicable taxes and withholdings) equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive and covered dependents if the Executive had remained employed by the Company
until the earliest of (A)&nbsp;the nine (9)&nbsp;month anniversary of the Date of Termination; (B)&nbsp;the date that the Executive becomes eligible for group medical plan benefits under any other employer&#146;s group medical plan; or (C)&nbsp;the
cessation of the Executive&#146;s health continuation rights under COBRA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts payable under Section&nbsp;5 (a) and (c), to the extent taxable,
shall be paid out in substantially equal installments in accordance with the Company&#146;s payroll practice over nine (9)&nbsp;months commencing within 60 days after the Date of Termination; provided, however, that if the <FONT
STYLE="white-space:nowrap">60-day</FONT> period begins in one calendar year and ends in a second calendar year, such payments, to the extent they qualify as <FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148;
within the meaning of Section&nbsp;409A of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), shall begin to be paid in the second calendar year by the last day of such <FONT STYLE="white-space:nowrap">60-day</FONT> period;
provided, further, that the initial payment shall include a <FONT STYLE="white-space:nowrap">catch-up</FONT> payment to cover amounts retroactive to the day immediately following the Date of Termination. Each payment pursuant to this Agreement is
intended to constitute a separate payment for purposes of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Severance Pay and Benefits Upon Termination by the Company without Cause or by the Executive for Good Reason
within the Change in Control Period</U>. The provisions of this Section&nbsp;6 shall apply in lieu of, and expressly supersede, the provisions of Section&nbsp;5 if (i)&nbsp;the Executive&#146;s employment is terminated either (a)&nbsp;by the Company
without Cause as provided in Section&nbsp;3(d), or (b)&nbsp;by the Executive for Good Reason as provided in Section&nbsp;3(e), and (ii)&nbsp;the Date of Termination occurs on or within 12 months after the occurrence of the first event constituting a
Change in Control (such period, the &#147;Change in Control Period&#148;) following the Effective Date. These provisions shall terminate and be of no further force or effect after the Change in Control Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;If the Executive&#146;s employment is terminated by the Company without Cause as provided in Section&nbsp;3(d) or
the Executive terminates employment for Good Reason as provided in Section&nbsp;3(e) and in each case the Date of Termination occurs during the Change in Control Period, then, in addition to the Accrued Obligations, and subject to the signing of the
Separation Agreement and Release by the Executive and the Separation Agreement and Release becoming fully effective, all within the time frame set forth in the Separation Agreement and Release but in no event more than 60 days after the Date of
Termination: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall pay the Executive a lump sum in cash in an amount equal to one
(1)&nbsp;times the sum of (A)&nbsp;the Executive&#146;s then-current Base Salary (or the Executive&#146;s Base Salary in effect immediately prior to the Change in Control, if higher) plus (B)&nbsp;the Executive&#146;s Target Bonus for the
then-current year (or the Executive&#146;s Target Bonus in effect immediately prior to the Change in Control, if higher) and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall pay any unpaid bonus earned
for the year preceding the date of Executive&#146;s employment termination, payable at the time it otherwise would have been paid had the Executive&#146;s employment with the Company not terminated, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;notwithstanding anything to the contrary in any applicable option agreement or other stock-based
award agreement, all stock options and other stock-based awards held by the Executive that are subject solely to time-based vesting (the &#147;Time- Based Equity Awards&#148;) shall immediately accelerate and become fully vested and exercisable or
nonforfeitable as of the later of (i)&nbsp;the Date of Termination or (ii)&nbsp;the effective date of the Separation Agreement and Release (the &#147;Accelerated Vesting Date&#148;), provided in order to effectuate the accelerated vesting
contemplated by this subsection, the unvested portion of the Executive&#146;s options that would otherwise be forfeited on the Date of Termination will be delayed until the earlier of (A)&nbsp;the effective date of the Separation Agreement Release
(at which time acceleration will occur), or (B)&nbsp;the date that the Separation Agreement and Release can no longer become fully effective (at which time the unvested Time-Based Equity Awards will be terminated or forfeited). Notwithstanding the
foregoing, no additional time-based vesting of the Time-Based Equity Awards shall occur during the period between the Date of Termination and the Accelerated Vesting Date; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;subject to the Executive&#146;s copayment of premium amounts at the applicable active
employees&#146; rate and the Executive&#146;s proper election to receive benefits under COBRA, the Company shall pay to the Executive a monthly cash payment (including a gross up payment to account for applicable taxes and withholdings) equal to the
monthly employer contribution that the Company would have made to provide health insurance to the Executive and covered dependents if the Executive had remained employed by the Company until the earliest of (A)&nbsp;the twelve (12)&nbsp;month
anniversary of the Date of Termination; (B)&nbsp;the date that the Executive becomes eligible for group medical plan benefits under any other employer&#146;s group medical plan; or (C)&nbsp;the cessation of the Executive&#146;s health continuation
rights under COBRA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts payable under this Section&nbsp;6(a), to the extent taxable, shall be paid or commence to be paid within 60 days after
the Date of Termination; provided, however, that if the <FONT STYLE="white-space:nowrap">60-day</FONT> period begins in one calendar year and ends in a second calendar year, such payments to the extent they qualify as
<FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; within the meaning of Section&nbsp;409A of the Code, shall be paid or commence to be paid in the second calendar year by the last day of such <FONT
STYLE="white-space:nowrap">60-day</FONT> period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Additional</U><U> </U><U>Limitation</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any
compensation, payment or distribution by the Company to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with
Section&nbsp;280G of the Code, and the applicable regulations thereunder (the &#147;Aggregate Payments&#148;), would be subject to the excise tax imposed by Section&nbsp;4999 of the Code, then the Aggregate Payments shall be reduced (but not below
zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which the Executive becomes subject to the excise tax imposed by Section&nbsp;4999 of the Code; provided that such reduction shall only occur if it would
result in the Executive receiving a higher After Tax Amount (as defined below) than the Executive would receive if the Aggregate Payments were not subject to such reduction. In such event, the Aggregate Payments shall be reduced in the following
order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section&nbsp;280G of the Code: (1)&nbsp;cash payments not
subject to Section&nbsp;409A of the Code; (2)&nbsp;cash payments subject to Section&nbsp;409A of the Code; (3)&nbsp;equity-based payments and acceleration; and <FONT STYLE="white-space:nowrap">(4)&nbsp;non-cash</FONT> forms of benefits; provided
that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. <FONT STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT STYLE="white-space:nowrap">Q&amp;A-24(b)</FONT> or
(c) shall be reduced before any amounts that are subject to calculation under Treas. Reg. <FONT STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT STYLE="white-space:nowrap">Q&amp;A-24(b)</FONT> or (c). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;For purposes of this Section&nbsp;6(b), the &#147;After Tax Amount&#148; means the amount of the
Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on the Executive as a result of the Executive&#146;s receipt of the Aggregate Payments. For purposes of determining the After Tax Amount, the Executive
shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal
rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to
Section&nbsp;6(b)(i) shall be made by a nationally recognized accounting firm selected by the Company (the &#147;Accounting Firm&#148;), which shall provide detailed supporting calculations both to the Company and the Executive within 15 business
days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Executive. Any determination by the Accounting Firm shall be binding upon the Company and the Executive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>. For purposes of this Section&nbsp;6, the following terms shall have the following meanings:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Change in Control&#148; shall mean any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;any &#147;person,&#148; as such term is used in Sections 13(d) and 14(d) of the Securities Exchange
Act of 1934, as amended (the &#147;Act&#148;), any of its subsidiaries, or any trustee, fiduciary or other person or entity holding securities under any employee benefit plan or trust of Parent or any of its subsidiaries), together with all
&#147;affiliates&#148; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
&#147;associates&#148; (as such terms are defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Act) of such person, shall become the &#147;beneficial owner&#148; (as such term
is defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Act), directly or indirectly, of securities of Parent representing 50&nbsp;percent or more of the combined voting power of Parent&#146;s then outstanding securities having
the right to vote in an election of the Board (&#147;Voting Securities&#148;) (in such case other than as a result of an acquisition of securities directly from Parent); or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the date a majority of the members of the Board is replaced during any <FONT
STYLE="white-space:nowrap">12-month</FONT> period by directors whose appointment or election is not endorsed by a majority of the members of the Board before the date of the appointment or election; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;the consummation of (A)&nbsp;any consolidation or merger of Parent where the stockholders of
Parent, immediately prior to the consolidation or merger, would not, immediately after the consolidation or merger, beneficially own (as such term is defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Act), directly or
indirectly, shares representing in the aggregate more than 50&nbsp;percent of the voting shares of Parent issuing cash or securities in the consolidation or merger (or of its ultimate parent corporation, if any), or (B)&nbsp;any sale or other
transfer (in one transaction or a series of transactions contemplated or arranged by any party as a single plan) of all or substantially all of the assets of Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, a &#147;Change in Control&#148; shall not be deemed to have occurred for purposes of the foregoing clause
(i)&nbsp;solely as the result of an acquisition of securities by Parent which, by reducing the number of shares of Voting Securities outstanding, increases the proportionate number of Voting Securities beneficially owned by any person to
50&nbsp;percent or more of the combined voting power of all of the then outstanding Voting Securities; provided, however, that if any person referred to in this sentence shall thereafter become the beneficial owner of any additional shares of Voting
Securities (other than pursuant to a stock split, stock dividend, or similar transaction or as a result of an acquisition of securities directly from Parent) and immediately thereafter beneficially owns 50&nbsp;percent or more of the combined voting
power of all of the then outstanding Voting Securities, then a &#147;Change in Control&#148; shall be deemed to have occurred for purposes of the foregoing clause (i). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Section</U><U></U><U>&nbsp;409A</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive&#146;s separation from
service within the meaning of Section&nbsp;409A of the Code, the Company determines that the Executive is a &#147;specified employee&#148; within the meaning of Section&nbsp;409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit
that the Executive becomes entitled to under this Agreement or otherwise on account of the Executive&#146;s separation from service would be considered deferred compensation otherwise subject to the 20&nbsp;percent additional tax imposed pursuant to
Section&nbsp;409A(a) of the Code as a result of the application of Section&nbsp;409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A)&nbsp;six months and one
day after the Executive&#146;s separation from service, or (B)&nbsp;the Executive&#146;s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a
<FONT STYLE="white-space:nowrap">catch-up</FONT> payment covering amounts that would otherwise have been paid during the <FONT STYLE="white-space:nowrap">six-month</FONT> period but for the application of this provision, and the balance of the
installments shall be payable in accordance with their original schedule. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;All <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits
provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively
practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits provided or
reimbursable expenses incurred in one taxable year shall not affect the <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other
aggregate limitation applicable to medical expenses). Such right to reimbursement or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits is not subject to liquidation or exchange for another benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;To the extent that any payment or benefit described in this Agreement constitutes
<FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; under Section&nbsp;409A of the Code, and to the extent that such payment or benefit is payable upon the Executive&#146;s termination of employment, then such
payments or benefits shall be payable only upon the Executive&#146;s &#147;separation from service.&#148; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in
Treasury Regulation Section <FONT STYLE="white-space:nowrap">1.409A-1(h).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;The parties intend that this
Agreement will be administered in accordance with Section&nbsp;409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section&nbsp;409A of the Code, the provision shall be read in such a manner so
that all payments hereunder comply with Section&nbsp;409A of the Code. Each payment pursuant to this Agreement or the Restrictive Covenants Agreement is intended to constitute a separate payment for purposes of Treasury Regulation <FONT
STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2).</FONT> The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section&nbsp;409A of the Code and all related
rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;The Company makes no representation or warranty and shall have no liability to the Executive or any other person if
any provisions of this Agreement are determined to constitute deferred compensation subject to Section&nbsp;409A of the Code but do not satisfy an exemption from, or the conditions of, such Section. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Continuing</U><U> </U><U>Obligations</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Restrictive Covenants Agreement</U>. As a condition of employment, the Executive is required to enter into the
Employee Confidentiality, Assignment and Nonsolicitation Agreement, attached hereto as <U>Exhibit A</U> (the &#147;Restrictive Covenants Agreement&#148;). For the avoidance of doubt, the Restrictive Covenants Agreement is supplemental to the Prior
Restrictive Covenants Agreement, which remains in full force and effect. For purposes of this Agreement, the obligations in this Section&nbsp;8 and those that arise in the Restrictive Covenants Agreement, the Prior Restrictive Covenants Agreement
and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the &#147;Continuing Obligations.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Third-Party Agreements and Rights</U>. The
Executive hereby confirms that the Executive is not bound by the terms of any agreement with any previous employer or other party which restricts in any way the Executive&#146;s use or disclosure of information, other than confidentiality
restrictions (if any), or the Executive&#146;s engagement in any business. The Executive represents to the Company that the Executive&#146;s execution of this Agreement, the Executive&#146;s employment with the Company and the performance of the
Executive&#146;s proposed duties for the Company will not violate any obligations the Executive may have to any such previous employer or other party. In the Executive&#146;s work for the Company, the Executive will not disclose or make use of any
information in violation of any agreements with or rights of any such previous employer or other party, and the Executive will not bring to the premises of the Company any copies or other tangible embodiments of
<FONT STYLE="white-space:nowrap">non-public</FONT> information belonging to or obtained from any such previous employment or other party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Litigation and Regulatory Cooperation</U>. During and after the Executive&#146;s employment, the
Executive shall cooperate fully with the Company in (i)&nbsp;the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that
transpired while the Executive was employed by the Company, and (ii)&nbsp;the investigation, whether internal or external, of any matters about which the Company believes the Executive may have knowledge or information. The Executive&#146;s full
cooperation in connection with such claims, actions or investigations shall include, but not be limited to, being available to meet with counsel to answer questions or to prepare for discovery or trial and to act as a witness on behalf of the
Company at mutually convenient times. During and after the Executive&#146;s employment, the Executive also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority as
any such investigation or review relates to events or occurrences that transpired while the Executive was employed by the Company. The Company shall reimburse the Executive for any reasonable <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with the Executive&#146;s performance of obligations pursuant to this Section&nbsp;8(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Relief</U>. The Executive agrees that it would be difficult to measure any damages caused to the
Company which might result from any breach by the Executive of the Continuing Obligations, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly<B>, </B>the Executive agrees that if the Executive
breaches, or proposes to breach, any portion of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other appropriate equitable relief to restrain any such breach without
showing or proving any actual damage to the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Arbitration of</U><U> </U><U>Disputes</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Arbitration Generally</U>. Any controversy or claim arising out of or relating to this Agreement or the breach
thereof or otherwise arising out of the Executive&#146;s employment or the termination of that employment (including, without limitation, any claims of unlawful employment discrimination or retaliation, whether based on race, religion, national
origin, sex, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
gender, age, disability, sexual orientation, or any other protected class under applicable law) shall, to the fullest extent permitted by law, be settled by arbitration in any forum and form
agreed upon by the parties or, in the absence of such an agreement, under the auspices of JAMS in San Francisco, California in accordance with the JAMS Employment Arbitration Rules, including, but not limited to, the rules and procedures applicable
to the selection of arbitrators. The Executive understands that the Executive may only bring such claims in the Executive&#146;s individual capacity, and not as a plaintiff or class member in any purported class proceeding or any purported
representative proceeding.&nbsp;&nbsp;&nbsp;&nbsp;The Executive further understands that, by signing this Agreement, the Company and the Executive are giving up any right they may have to a jury trial on all claims they may have against each other.
Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. This Section&nbsp;9 shall be specifically enforceable. Notwithstanding the foregoing, this Section&nbsp;9 shall not preclude either party
from pursuing a court action for the sole purpose of obtaining a temporary restraining order or a preliminary injunction in circumstances in which such relief is appropriate, including without limitation relief sought under the Restrictive Covenants
Agreement; provided that any other relief shall be pursued through an arbitration proceeding pursuant to this Section&nbsp;9. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Arbitration Fees and Costs</U>. The Executive shall be required to pay an arbitration fee to initiate any
arbitration equal to what the Executive would be charged as a first appearance fee in court. The Company shall advance the remaining fees and costs of the arbitrator. However, to the extent permissible under the law, and following the
arbitrator&#146;s ruling on the matter, the arbitrator may rule that the arbitrator&#146;s fees and costs be distributed in an alternative manner. Each party shall pay its own costs and attorneys&#146; fees, if any. If, however, any party prevails
on a statutory or contractual claim that affords the prevailing party attorneys&#146; fees (including pursuant to this Agreement), the arbitrator may award attorneys&#146; fees to the prevailing party to the extent permitted by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Consent to Jurisdiction</U>. The parties hereby consent to the jurisdiction of the state and federal courts of
the State of California. Accordingly, with respect to any such court action, the Executive (a)&nbsp;submits to the exclusive personal jurisdiction of such courts; (b)&nbsp;consents to service of process; and (c)&nbsp;waives any other requirement
(whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&nbsp;&nbsp;&nbsp;&nbsp;<U>Integration</U>. This Agreement constitutes the entire agreement between the parties with respect to the subject
matter hereof and supersedes all prior agreements between the parties concerning such subject matter including the Prior Agreement, provided that the Prior Restrictive Covenants Agreement, the Restrictive Covenants Agreement and the Equity Documents
remain in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&nbsp;&nbsp;&nbsp;&nbsp;<U>Withholding; Tax Effect</U>. All payments made by the Company to the
Executive under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law. Nothing in this Agreement shall be construed to require the Company to make any payments to compensate the Executive
for any adverse tax effect associated with any payments or benefits or for any deduction or withholding from any payment or benefit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors and Assigns</U>. Neither the Executive nor the
Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement
(including the Restrictive Covenants Agreement) without the Executive&#146;s consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization or consolidation, into which the Company merges or to whom
it transfers all or substantially all of its properties or assets; provided further that if the Executive remains employed or becomes employed by the Company, the purchaser or any of their affiliates in connection with any such transaction, then the
Executive shall not be entitled to any payments, benefits or vesting pursuant to Section&nbsp;5 or pursuant to Section&nbsp;6 of this Agreement solely as a result of such transaction. This Agreement shall inure to the benefit of and be binding upon
the Executive and the Company, and each of the Executive&#146;s and the Company&#146;s respective successors, executors, administrators, heirs and permitted assigns. In the event of the Executive&#146;s death after the Executive&#146;s termination
of employment but prior to the completion by the Company of all payments due to the Executive under this Agreement, the Company shall continue such payments to the Executive&#146;s beneficiary designated in writing to the Company prior to the
Executive&#146;s death (or to the Executive&#146;s estate, if the Executive fails to make such designation). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.&nbsp;&nbsp;&nbsp;&nbsp;<U>Enforceability</U>. If any portion or provision of this Agreement (including, without limitation, any portion or
provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other
than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U>. The provisions of this Agreement shall survive the termination of this Agreement and/or the
termination of the Executive&#146;s employment to the extent necessary to effectuate the terms contained herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver</U>. No waiver of any provision hereof shall be effective unless made in writing and signed by the
waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be
deemed a waiver of any subsequent breach. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>. Any notices, requests, demands and other
communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to
the Executive at the last address the Executive has filed in writing with the Company or, in the case of the Company, at its main offices, attention of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18.&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment</U>. This Agreement may be amended or modified only by a written instrument signed by the Executive
and by a duly authorized representative of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.&nbsp;&nbsp;&nbsp;&nbsp;<U>Effect on Other Plans and Agreements</U>. An election by the
Executive to resign for Good Reason under the provisions of this Agreement shall not be deemed a voluntary termination of employment by the Executive for the purpose of interpreting the provisions of any of the Company&#146;s benefit plans, programs
or policies. Nothing in this Agreement shall be construed to limit the rights of the Executive under the Company&#146;s benefit plans, programs or policies except as otherwise provided in Section&nbsp;8 hereof, and except that the Executive shall
have no rights to any severance benefits under any Company severance pay plan, offer letter or otherwise. In the event that the Executive is party to an agreement with the Company providing for payments or benefits under such plan or agreement and
under this Agreement, the terms of this Agreement shall govern and the Executive may receive payment under this Agreement only and not both. Further, Section&nbsp;5 and Section&nbsp;6 of this Agreement are mutually exclusive and in no event shall
the Executive be entitled to payments or benefits pursuant to both Section&nbsp;5 and Section&nbsp;6 of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20.&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing Law</U>. This is a California contract and shall be construed under and be governed in all respects by
the laws of the State of California, without giving effect to the conflict of laws principles thereof. With respect to any disputes concerning federal law, such disputes shall be determined in accordance with the law as it would be interpreted and
applied by the United States Court of Appeals for the 9<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Circuit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>. This Agreement may be executed in any number of counterparts, each of which when so executed
and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS
WHEREOF, the parties have executed this Agreement effective on the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ADICET THERAPEUTICS,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>INC./RESTORBIO, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Chen Schor</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chen Schor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>CARRIE KREHLIK</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Carrie Krehlik</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Carrie Krehlik</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>[Exhibit A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Restrictive Covenants Agreement] </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>d91031dex103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Employment Agreement (&#147;Agreement&#148;) is made between Adicet Therapeutics, Inc., a Delaware corporation (the &#147;Company&#148;),
and Francesco Galimi (the &#147;Executive&#148;) and is contingent upon the closing (the &#147;Closing&#148;) of the transaction (the &#147;Merger&#148;) contemplated by that certain Agreement and Plan of Merger (the &#147;Merger Agreement&#148;) by
and among resTORbio, Inc. (&#147;Parent&#148;), Adicet Bio, Inc. (&#147;Adicet Bio&#148;) and the other parties thereto. Subject to Section&nbsp;11, except with respect to the Employee Proprietary Information and Invention Assignment Agreement
between the Executive and Adicet Bio, dated September&nbsp;5, 2019 (the &#147;Prior Restrictive Covenants Agreement&#148;) and the Equity Documents (as defined below), this Agreement supersedes in all respects all prior agreements between the
Executive and Adicet Bio regarding the subject matter herein, including without limitation (i)&nbsp;the offer letter between the Executive and Adicet Bio dated September&nbsp;4, 2019, as amended by the Amendment to Offer Letter, dated April&nbsp;25,
2020 (together, the &#147;Prior Agreement&#148;) except as expressly preserved herein, and (ii)&nbsp;any offer letter, employment agreement or severance agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Adicet Bio, Inc. will change its name to Adicet Therapeutics, Inc. post- Closing and Parent will change its name to Adicet Bio, Inc.
post-Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company beginning on
the effective date of the Closing of the Merger (the &#147;Effective Date&#148;) on the terms contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in
consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Employment</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Term</U>. The term of this Agreement shall commence on the Effective Date and continue until terminated in
accordance with the provisions hereof (the &#147;Term&#148;). The Executive&#146;s employment with the Company shall be &#147;at will,&#148; meaning that the Executive&#146;s employment may be terminated by the Company or the Executive at any time
and for any reason subject to the terms of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Position and Duties</U>. The Executive shall
serve as the Senior Vice President, Chief Medical Officer of the Company and shall have such powers and duties as may from time to time be prescribed by the Chief Executive Officer of the Company (the &#147;CEO&#148;). The Executive shall devote his
full working time and efforts to the business and affairs of the Company. Notwithstanding the foregoing, the Executive may serve on other boards of directors, with the approval of the Governance Committee of the Board of Directors of the Parent (the
&#147;Governance Committee&#148; of the &#147;Board&#148;), or engage in religious, charitable or other community activities as long as such services and activities do not interfere with the Executive&#146;s performance of his duties to the Parent
and the Company as provided in this Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Compensation and Related</U><U> </U><U>Matters</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Base Salary</U>. The Executive&#146;s initial base salary shall be paid at the rate of $400,000 per year. The Executive&#146;s base
salary shall be subject to periodic review by the Compensation Committee of the Board (the &#147;Compensation Committee&#148;). The base salary in effect at any given time is referred to herein as &#147;Base Salary.&#148; The Base Salary shall be
payable in a manner that is consistent with the Company&#146;s usual payroll practices for executive officers. The Executive&#146;s salary and any other cash compensation may be provided through TriNet, Inc. or another professional employer
organization (a &#147;<U>PEO</U>&#148;). As a result of the Company&#146;s arrangement with the PEO, the PEO will be considered the Executive&#146;s employer of record for these purposes for so long as that arrangement exists. While the PEO will
have responsibility for the functions above, the Company retains responsibility for overseeing the Executive&#146;s work and reviewing the Executive&#146;s performance, among other functions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Incentive Compensation</U>. The Executive shall be eligible to receive cash incentive compensation as determined
by the Board or the Compensation Committee from time to time. Commencing in calendar year 2021, the Executive&#146;s initial target annual incentive compensation shall be forty (40)&nbsp;percent of the Executive&#146;s Base Salary; provided that any
incentive compensation for calendar year 2020 will be prorated based on the Effective Date. The target annual incentive compensation in effect at any given time is referred to herein as &#147;Target Bonus.&#148; The actual amount of the
Executive&#146;s annual incentive compensation, if any, shall be determined in the sole discretion of the Board or the Compensation Committee, subject to the terms of any applicable incentive compensation plan that may be in effect from time to
time. Except as otherwise provided herein, as may be provided by the Board or the Compensation Committee or as may otherwise be set forth in the applicable incentive compensation plan the Executive must be employed by the Company on the day such
incentive compensation is paid in order to earn or receive any incentive compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Expenses</U>. The
Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by the Executive during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the
Company for its executive officers; provided that the Executive&#146;s commuting expenses shall continue to be governed by Section&nbsp;2.f of the Prior Agreement (the &#147;Preserved Provision&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Other Benefits</U>. The Executive shall be eligible to participate in or receive benefits under the
Company&#146;s employee benefit plans in effect from time to time, subject to the terms of such plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Paid
Time Off</U>. The Company&#146;s current paid time off policy for executives is flexible and paid time off may be taken at such times and intervals as the Executive may determine, subject to the business needs of the Company and the terms and
conditions of any policies as may be in effect from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Equity</U>. The equity awards held by the
Executive shall be treated as described in the Merger Agreement and, subject to the terms and conditions of the Merger Agreement, shall continue to be governed by the terms and conditions of the applicable equity
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
incentive plan(s) and the applicable award agreement(s) governing the terms of such equity awards (collectively, the &#147;Equity Documents&#148;); provided, however, and notwithstanding anything
to the contrary in the Equity Documents, Section&nbsp;6(a)(ii) of this Agreement shall apply in the event of a termination by the Company without Cause or by the Executive for Good Reason in either event within the Change in Control Period (as such
terms are defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification</U>. The Company shall indemnify the Executive to the extent that
its officers, directors and employees are entitled to indemnification pursuant to the Company&#146;s Certificate of Incorporation and Bylaws for any acts or omissions by reason of being an officer or employee of the Company as of the Effective Date.
At all times during the Employment Term, the Company shall maintain in effect a director and officers liability insurance policy with the Executive as a covered officer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>. The Executive&#146;s employment hereunder may be terminated without any breach of this Agreement
under the following circumstances: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Death</U>. The Executive&#146;s employment hereunder shall terminate upon death. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Disability</U>. The Company may terminate the Executive&#146;s employment if the Executive is disabled and unable to perform or
expected to be unable to perform the essential functions of the Executive&#146;s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in any <FONT
STYLE="white-space:nowrap">12-month</FONT> period. If any question shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executive&#146;s then existing position or
positions with or without reasonable accommodation, the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the Executive or the
Executive&#146;s guardian has no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and such certification shall for the purposes of this Agreement be conclusive of the issue. The
Executive shall cooperate with any reasonable request of the physician in connection with such certification. If such question shall arise and the Executive shall fail to submit such certification, the Company&#146;s determination of such issue
shall be binding on the Executive. Nothing in this Section&nbsp;3(b) shall be construed to waive the Executive&#146;s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. &#167;2601
<I>et seq</I>. and the Americans with Disabilities Act, 42 U.S.C. &#167;12101 <I>et seq.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination by
the Company for Cause</U>. The Company may terminate the Executive&#146;s employment hereunder for Cause. For purposes of this Agreement, &#147;Cause&#148; shall mean: (i)&nbsp;conduct by the Executive constituting a material act of misconduct in
connection with the performance of his duties, including, without limitation, misappropriation of funds or property of the Company, Parent or any of its or their subsidiaries or affiliates other than the occasional, customary and de minimis use of
Company or Parent property for personal purposes; (ii) the commission by the Executive of acts satisfying the elements of (A)&nbsp;any felony or (B)&nbsp;a misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii)&nbsp;any misconduct
by the Executive, regardless of whether or not in the course of the Executive&#146;s employment, that would </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reasonably be expected to result in material injury or reputational harm to the Company, Parent or any of its or their subsidiaries or affiliates if the Executive were to continue to be employed
in the same position; (iv)&nbsp;continued willful nonperformance by the Executive of his material duties hereunder (other than by reason of the Executive&#146;s physical or mental illness, incapacity or disability) which, to the extent it is curable
by the Executive, is not cured within thirty (30)&nbsp;after written notice thereof is given to the Executive by the CEO; (v)&nbsp;a breach by the Executive of the Restrictive Covenants Agreement or any of the provisions contained in Section&nbsp;8
of this Agreement; (vi)&nbsp;a material violation by the Executive of the Company&#146;s or Parent&#146;s written employment policies; or (vii)&nbsp;failure to cooperate with a bona fide internal investigation or an investigation by regulatory or
law enforcement authorities, after being instructed by the Company or Parent to cooperate, or the willful destruction or failure to preserve documents or other materials known to be relevant to such investigation or the inducement of others to fail
to cooperate or to produce documents or other materials in connection with such investigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Termination by the Company without
Cause</U>. The Company may terminate the Executive&#146;s employment hereunder at any time without Cause. Any termination by the Company of the Executive&#146;s employment under this Agreement which does not constitute a termination for Cause under
Section&nbsp;3(c) and does not result from the death or disability of the Executive under Section&nbsp;3(a) or (b)&nbsp;shall be deemed a termination without Cause. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination by the Executive</U>. The Executive may terminate his employment hereunder at any time for any
reason, including for Good Reason. For purposes of this Agreement, &#147;Good Reason&#148; shall mean that the Executive has complied with the &#147;Good Reason Process&#148; (hereinafter defined) following the occurrence of any of the following
events: (i)&nbsp;&nbsp;&nbsp;&nbsp;a material diminution in the Executive&#146;s responsibilities, authority or duties <I>provided </I>changes to the Executive&#146;s responsibilities, authority or duties prior to a Change in Control that are made
in the good faith discretion of the Company&#146;s CEO as part of the Company&#146;s evolving business needs and strategy shall not be a Good Reason occurrence; (ii)&nbsp;a material diminution in the Executive&#146;s Base Salary except for <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">across-the-board</FONT></FONT> salary reductions based on the Company&#146;s or Parent&#146;s financial performance similarly affecting all or substantially all senior management employees
of the Company or Parent; (iii)&nbsp;a material change in the geographic location at which the Executive provides services to the Company such that there is an increase of at least thirty (30) miles of driving distance to such location from the
Executive&#146;s principal residence as of such change; or (iv)&nbsp;the material breach of this Agreement by the Company. &#147;Good Reason Process&#148; shall mean that (i)&nbsp;the Executive reasonably determines in good faith that a &#147;Good
Reason&#148; condition has occurred; (ii)&nbsp;the Executive notifies the Company in writing of the first occurrence of the Good Reason condition within 60 days of the first occurrence of such condition; (iii)&nbsp;the Executive cooperates in good
faith with the Company&#146;s efforts, for a period not less than 30 days following such notice (the &#147;Cure Period&#148;), to remedy the condition; (iv)&nbsp;notwithstanding such efforts, the Good Reason condition continues to exist; and
(v)&nbsp;the Executive terminates his employment within 180 days after the end of the Cure Period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Matters Related to</U><U>
</U><U>Termination</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice of Termination</U>. Except for termination as specified in Section&nbsp;3(a),
any termination of the Executive&#146;s employment by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto. For purposes of this Agreement, a &#147;Notice of
Termination&#148; shall mean a notice which shall indicate the specific termination provision in this Agreement relied upon. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Date of Termination</U>. &#147;Date of Termination&#148; shall
mean: (i)&nbsp;if the Executive&#146;s employment is terminated by death, the date of death; (ii)&nbsp;if the Executive&#146;s employment is terminated on account of disability under Section&nbsp;3(b) or by the Company for Cause under
Section&nbsp;3(c), the date on which Notice of Termination is given; (iii)&nbsp;if the Executive&#146;s employment is terminated by the Company without Cause under Section&nbsp;3(d), the date on which a Notice of Termination is given or the date
otherwise specified by the Company in the Notice of Termination; (iv)&nbsp;if the Executive&#146;s employment is terminated by the Executive under Section&nbsp;3(e) other than for Good Reason, 30 days after the date on which a Notice of Termination
is given, and (v)&nbsp;if the Executive&#146;s employment is terminated by the Executive under Section&nbsp;3(e) for Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period. Notwithstanding the foregoing, in
the event that the Executive gives a Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Accrued Obligations</U>. If the Executive&#146;s employment with the Company is terminated for any reason, the
Company shall pay or provide to the Executive (or to the Executive&#146;s authorized representative or estate)&nbsp;(i) any Base Salary earned through the Date of Termination; (ii)&nbsp;unpaid expense reimbursements (subject to, and in accordance
with, Section&nbsp;2(c) of this Agreement); and (iii)&nbsp;any vested benefits the Executive may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance
with the terms of such employee benefit plans (collectively, the &#147;Accrued Obligations&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Resignation of All Other Positions</U>. To the extent applicable, the Executive shall be deemed to have resigned
from all officer and board member positions that the Executive holds with the Company or any of its respective subsidiaries and affiliates upon the termination of the Executive&#146;s employment for any reason. The Executive shall execute any
documents in reasonable form as may be requested to confirm or effectuate any such resignations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Severance
Pay and Benefits Upon Termination by the Company without Cause or by the Executive for Good Reason Outside the Change in Control Period</U>. If the Executive&#146;s employment is terminated by the Company without Cause as provided in
Section&nbsp;3(d) or the Executive terminates employment for Good Reason as provided in Section&nbsp;3(e), in each case outside of the Change in Control Period (as defined below), then, in addition to the Accrued Obligations, subject to the
Executive signing a separation agreement containing, among other provisions, a general release of claims in favor of the Company and related persons and entities, including the PEO, a reaffirmation of the Executive&#146;s Continuing Obligations (as
defined below), confidentiality, return of property and <FONT STYLE="white-space:nowrap">non-disparagement,</FONT> in a form and manner satisfactory to the Company (the &#147;Separation Agreement and Release&#148;) and the Separation Agreement and
Release becoming irrevocable and fully effective, all within 60 days after the Date of Termination (or such shorter time period provided in the Separation Agreement and Release): </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall pay the Executive an amount equal to nine
(9)&nbsp;months of the Executive&#146;s Base Salary (the &#147;Severance Amount&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall
pay any unpaid bonus earned for the year preceding the date of Executive&#146;s employment termination, payable at the time it otherwise would have been paid had the Executive&#146;s employment with the Company not terminated; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;subject to the Executive&#146;s copayment of premium amounts at the applicable active employees&#146; rate and the
Executive&#146;s proper election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#147;<U>COBRA</U>&#148;), the Company shall pay to the Executive a monthly cash payment (including a gross up payment
to account for applicable taxes and withholdings) equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive and covered dependents if the Executive had remained employed by the Company
until the earliest of (A)&nbsp;the nine (9)&nbsp;month anniversary of the Date of Termination; (B)&nbsp;the date that the Executive becomes eligible for group medical plan benefits under any other employer&#146;s group medical plan; or (C) the
cessation of the Executive&#146;s health continuation rights under COBRA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts payable under Section&nbsp;5 (a) and (c), to the extent taxable,
shall be paid out in substantially equal installments in accordance with the Company&#146;s payroll practice over nine (9)&nbsp;months commencing within 60 days after the Date of Termination; provided, however, that if the <FONT
STYLE="white-space:nowrap">60-day</FONT> period begins in one calendar year and ends in a second calendar year, such payments, to the extent they qualify as <FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148;
within the meaning of Section&nbsp;409A of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), shall begin to be paid in the second calendar year by the last day of such <FONT STYLE="white-space:nowrap">60-day</FONT> period;
provided, further, that the initial payment shall include a <FONT STYLE="white-space:nowrap">catch-up</FONT> payment to cover amounts retroactive to the day immediately following the Date of Termination. Each payment pursuant to this Agreement is
intended to constitute a separate payment for purposes of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Severance Pay and Benefits Upon Termination by the Company without Cause or by the Executive for Good Reason
within the Change in Control Period</U>. The provisions of this Section&nbsp;6 shall apply in lieu of, and expressly supersede, the provisions of Section&nbsp;5 if (i)&nbsp;the Executive&#146;s employment is terminated either (a)&nbsp;by the Company
without Cause as provided in Section&nbsp;3(d), or (b)&nbsp;by the Executive for Good Reason as provided in Section&nbsp;3(e), and (ii)&nbsp;the Date of Termination occurs on or within 12 months after the occurrence of the first event constituting a
Change in Control (such period, the &#147;Change in Control Period&#148;) following the Effective Date. These provisions shall terminate and be of no further force or effect after the Change in Control Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;If the Executive&#146;s employment is terminated by the Company without Cause as provided in Section&nbsp;3(d) or
the Executive terminates employment for Good Reason as provided in Section&nbsp;3(e) and in each case the Date of Termination occurs during the Change in Control Period, then, in addition to the Accrued Obligations, and subject to the signing of the
Separation Agreement and Release by the Executive and the Separation Agreement and Release becoming fully effective, all within the time frame set forth in the Separation Agreement and Release but in no event more than 60 days after the Date of
Termination: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall pay the Executive a lump sum in
cash in an amount equal to one (1)&nbsp;times the sum of (A)&nbsp;the Executive&#146;s then-current Base Salary (or the Executive&#146;s Base Salary in effect immediately prior to the Change in Control, if higher) plus (B)&nbsp;the Executive&#146;s
Target Bonus for the then-current year (or the Executive&#146;s Target Bonus in effect immediately prior to the Change in Control, if higher) and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall pay any unpaid bonus earned for the year preceding the date of Executive&#146;s
employment termination, payable at the time it otherwise would have been paid had the Executive&#146;s employment with the Company not terminated, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;notwithstanding anything to the contrary in any applicable option agreement or other stock-based
award agreement, all stock options and other stock-based awards held by the Executive that are subject solely to time-based vesting (the &#147;Time- Based Equity Awards&#148;) shall immediately accelerate and become fully vested and exercisable or
nonforfeitable as of the later of (i)&nbsp;the Date of Termination or (ii)&nbsp;the effective date of the Separation Agreement and Release (the &#147;Accelerated Vesting Date&#148;), provided in order to effectuate the accelerated vesting
contemplated by this subsection, the unvested portion of the Executive&#146;s options that would otherwise be forfeited on the Date of Termination will be delayed until the earlier of (A)&nbsp;the effective date of the Separation Agreement Release
(at which time acceleration will occur), or (B)&nbsp;the date that the Separation Agreement and Release can no longer become fully effective (at which time the unvested Time-Based Equity Awards will be terminated or forfeited). Notwithstanding the
foregoing, no additional time-based vesting of the Time-Based Equity Awards shall occur during the period between the Date of Termination and the Accelerated Vesting Date; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;subject to the Executive&#146;s copayment of premium amounts at the applicable active
employees&#146; rate and the Executive&#146;s proper election to receive benefits under COBRA, the Company shall pay to the Executive a monthly cash payment (including a gross up payment to account for applicable taxes and withholdings) equal to the
monthly employer contribution that the Company would have made to provide health insurance to the Executive and covered dependents if the Executive had remained employed by the Company until the earliest of (A)&nbsp;the twelve (12)&nbsp;month
anniversary of the Date of Termination; (B)&nbsp;the date that the Executive becomes eligible for group medical plan benefits under any other employer&#146;s group medical plan; or (C)&nbsp;the cessation of the Executive&#146;s health continuation
rights under COBRA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts payable under this Section&nbsp;6(a), to the extent taxable, shall be paid or commence to be paid within 60 days after
the Date of Termination; provided, however, that if the <FONT STYLE="white-space:nowrap">60-day</FONT> period begins in one calendar year and ends in a second calendar year, such payments to the extent they qualify as
<FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; within the meaning of Section&nbsp;409A of the Code, shall be paid or commence to be paid in the second calendar year by the last day of such <FONT
STYLE="white-space:nowrap">60-day</FONT> period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Additional</U><U> </U><U>Limitation</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any
compensation, payment or distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with
Section&nbsp;280G of the Code, and the applicable regulations thereunder (the &#147;Aggregate Payments&#148;), would be subject to the excise tax imposed by Section&nbsp;4999 of the Code, then the Aggregate Payments shall be reduced (but not below
zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which the Executive becomes subject to the excise tax imposed by Section&nbsp;4999 of the Code; provided that such reduction shall only occur if it would
result in the Executive receiving a higher After Tax Amount (as defined below) than the Executive would receive if the Aggregate Payments were not subject to such reduction. In such event, the Aggregate Payments shall be reduced in the following
order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section&nbsp;280G of the Code: (1)&nbsp;cash payments not
subject to Section&nbsp;409A of the Code; (2)&nbsp;cash payments subject to Section&nbsp;409A of the Code; (3)&nbsp;equity-based payments and acceleration; and <FONT STYLE="white-space:nowrap">(4)&nbsp;non-cash</FONT> forms of benefits; provided
that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. <FONT STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT STYLE="white-space:nowrap">Q&amp;A-24(b)</FONT> or
(c) shall be reduced before any amounts that are subject to calculation under Treas. Reg. <FONT STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT STYLE="white-space:nowrap">Q&amp;A-24(b)</FONT> or (c). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;For purposes of this Section&nbsp;6(b), the &#147;After Tax Amount&#148; means the amount of the
Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on the Executive as a result of the Executive&#146;s receipt of the Aggregate Payments. For purposes of determining the After Tax Amount, the Executive
shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal
rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to
Section&nbsp;6(b)(i) shall be made by a nationally recognized accounting firm selected by the Company (the &#147;Accounting Firm&#148;), which shall provide detailed supporting calculations both to the Company and the Executive within 15 business
days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Executive. Any determination by the Accounting Firm shall be binding upon the Company and the Executive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>. For purposes of this Section&nbsp;6, the following terms shall have the following meanings:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Change in Control&#148; shall mean any of the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;any &#147;person,&#148; as such term is used in Sections 13(d) and 14(d) of the Securities Exchange
Act of 1934, as amended (the &#147;Act&#148;), any of its subsidiaries, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
any trustee, fiduciary or other person or entity holding securities under any employee benefit plan or trust of Parent or any of its subsidiaries), together with all &#147;affiliates&#148; and
&#147;associates&#148; (as such terms are defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Act) of such person, shall become the &#147;beneficial owner&#148; (as such term is defined in Rule
<FONT STYLE="white-space:nowrap">13d-3</FONT> under the Act), directly or indirectly, of securities of Parent representing 50&nbsp;percent or more of the combined voting power of Parent&#146;s then outstanding securities having the right to vote in
an election of the Board (&#147;Voting Securities&#148;) (in such case other than as a result of an acquisition of securities directly from Parent); or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the date a majority of the members of the Board is replaced during any <FONT
STYLE="white-space:nowrap">12-month</FONT> period by directors whose appointment or election is not endorsed by a majority of the members of the Board before the date of the appointment or election; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;the consummation of (A)&nbsp;any consolidation or merger of Parent where the stockholders of
Parent, immediately prior to the consolidation or merger, would not, immediately after the consolidation or merger, beneficially own (as such term is defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Act), directly or
indirectly, shares representing in the aggregate more than 50&nbsp;percent of the voting shares of Parent issuing cash or securities in the consolidation or merger (or of its ultimate parent corporation, if any), or (B)&nbsp;any sale or other
transfer (in one transaction or a series of transactions contemplated or arranged by any party as a single plan) of all or substantially all of the assets of Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, a &#147;Change in Control&#148; shall not be deemed to have occurred for purposes of the foregoing clause
(i)&nbsp;solely as the result of an acquisition of securities by Parent which, by reducing the number of shares of Voting Securities outstanding, increases the proportionate number of Voting Securities beneficially owned by any person to
50&nbsp;percent or more of the combined voting power of all of the then outstanding Voting Securities; provided, however, that if any person referred to in this sentence shall thereafter become the beneficial owner of any additional shares of Voting
Securities (other than pursuant to a stock split, stock dividend, or similar transaction or as a result of an acquisition of securities directly from Parent) and immediately thereafter beneficially owns 50&nbsp;percent or more of the combined voting
power of all of the then outstanding Voting Securities, then a &#147;Change in Control&#148; shall be deemed to have occurred for purposes of the foregoing clause (i). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Section</U><U></U><U>&nbsp;409A</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive&#146;s separation from
service within the meaning of Section&nbsp;409A of the Code, the Company determines that the Executive is a &#147;specified employee&#148; within the meaning of Section&nbsp;409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit
that the Executive becomes entitled to under this Agreement or otherwise on account of the Executive&#146;s separation from service would be considered deferred compensation otherwise subject to the 20&nbsp;percent additional tax imposed pursuant to
Section&nbsp;409A(a) of the Code as a result of the application of Section&nbsp;409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A)&nbsp;six months and one
day after the Executive&#146;s separation from service, or (B)&nbsp;the Executive&#146;s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a
<FONT STYLE="white-space:nowrap">catch-up</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payment covering amounts that would otherwise have been paid during the <FONT STYLE="white-space:nowrap">six-month</FONT> period but for the application of this provision, and the balance of the
installments shall be payable in accordance with their original schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;All
<FONT STYLE="white-space:nowrap">in-kind</FONT> benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement. All
reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of <FONT
STYLE="white-space:nowrap">in-kind</FONT> benefits provided or reimbursable expenses incurred in one taxable year shall not affect the <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits to be provided or the expenses eligible for reimbursement
in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits is not subject to liquidation or exchange for
another benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;To the extent that any payment or benefit described in this Agreement constitutes <FONT
STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; under Section&nbsp;409A of the Code, and to the extent that such payment or benefit is payable upon the Executive&#146;s termination of employment, then such payments
or benefits shall be payable only upon the Executive&#146;s &#147;separation from service.&#148; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury
Regulation Section <FONT STYLE="white-space:nowrap">1.409A-1(h).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;The parties intend that this Agreement
will be administered in accordance with Section&nbsp;409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section&nbsp;409A of the Code, the provision shall be read in such a manner so that all
payments hereunder comply with Section&nbsp;409A of the Code. Each payment pursuant to this Agreement or the Restrictive Covenants Agreement is intended to constitute a separate payment for purposes of Treasury Regulation <FONT
STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2).</FONT> The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section&nbsp;409A of the Code and all related
rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;The Company makes no representation or warranty and shall have no liability to the Executive or any other person if
any provisions of this Agreement are determined to constitute deferred compensation subject to Section&nbsp;409A of the Code but do not satisfy an exemption from, or the conditions of, such Section. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Continuing</U><U> </U><U>Obligations</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Restrictive Covenants Agreement</U>. As a condition of employment, the Executive is required to enter into the
Employee Confidentiality, Assignment and Nonsolicitation Agreement, attached hereto as <U>Exhibit A</U> (the &#147;Restrictive Covenants Agreement&#148;). For the avoidance of doubt, the Restrictive Covenants Agreement is supplemental to the Prior
Restrictive Covenants Agreement, which remains in full force and effect. For purposes of this Agreement, the obligations in this Section&nbsp;8 and those that arise in the Restrictive Covenants Agreement, the Prior Restrictive Covenants Agreement
and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the &#147;Continuing Obligations.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Third-Party Agreements and Rights</U>. The Executive hereby
confirms that the Executive is not bound by the terms of any agreement with any previous employer or other party which restricts in any way the Executive&#146;s use or disclosure of information, other than confidentiality restrictions (if any), or
the Executive&#146;s engagement in any business. The Executive represents to the Company that the Executive&#146;s execution of this Agreement, the Executive&#146;s employment with the Company and the performance of the Executive&#146;s proposed
duties for the Company will not violate any obligations the Executive may have to any such previous employer or other party. In the Executive&#146;s work for the Company, the Executive will not disclose or make use of any information in violation of
any agreements with or rights of any such previous employer or other party, and the Executive will not bring to the premises of the Company any copies or other tangible embodiments of <FONT STYLE="white-space:nowrap">non-public</FONT> information
belonging to or obtained from any such previous employment or other party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Litigation and Regulatory
Cooperation</U>. During and after the Executive&#146;s employment, the Executive shall cooperate fully with the Company in (i)&nbsp;the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or
on behalf of the Company which relate to events or occurrences that transpired while the Executive was employed by the Company, and (ii)&nbsp;the investigation, whether internal or external, of any matters about which the Company believes the
Executive may have knowledge or information. The Executive&#146;s full cooperation in connection with such claims, actions or investigations shall include, but not be limited to, being available to meet with counsel to answer questions or to prepare
for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During and after the Executive&#146;s employment, the Executive also shall cooperate fully with the Company in connection with any investigation or
review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Executive was employed by the Company. The Company shall reimburse the Executive for any
reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with the Executive&#146;s performance of obligations pursuant to this Section&nbsp;8(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Relief</U>. The Executive agrees that it would be difficult to measure any damages caused to the Company which
might result from any breach by the Executive of the Continuing Obligations, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly<B>, </B>the Executive agrees that if the Executive breaches, or proposes
to breach, any portion of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other appropriate equitable relief to restrain any such breach without showing or proving
any actual damage to the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Arbitration of</U><U> </U><U>Disputes</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Arbitration Generally</U>. Any controversy or claim arising out of or relating to this Agreement or the breach
thereof or otherwise arising out of the Executive&#146;s employment or the termination of that employment (including, without limitation, any claims of unlawful employment discrimination or retaliation, whether based on race, religion, national
origin, sex, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
gender, age, disability, sexual orientation, or any other protected class under applicable law) shall, to the fullest extent permitted by law, be settled by arbitration in any forum and form
agreed upon by the parties or, in the absence of such an agreement, under the auspices of JAMS in San Francisco, California in accordance with the JAMS Employment Arbitration Rules, including, but not limited to, the rules and procedures applicable
to the selection of arbitrators. The Executive understands that the Executive may only bring such claims in the Executive&#146;s individual capacity, and not as a plaintiff or class member in any purported class proceeding or any purported
representative proceeding.&nbsp;&nbsp;&nbsp;&nbsp;The Executive further understands that, by signing this Agreement, the Company and the Executive are giving up any right they may have to a jury trial on all claims they may have against each other.
Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. This Section&nbsp;9 shall be specifically enforceable. Notwithstanding the foregoing, this Section&nbsp;9 shall not preclude either party
from pursuing a court action for the sole purpose of obtaining a temporary restraining order or a preliminary injunction in circumstances in which such relief is appropriate, including without limitation relief sought under the Restrictive Covenants
Agreement; provided that any other relief shall be pursued through an arbitration proceeding pursuant to this Section&nbsp;9. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Arbitration Fees and Costs</U>. The Executive shall be required to pay an arbitration fee to initiate any
arbitration equal to what the Executive would be charged as a first appearance fee in court. The Company shall advance the remaining fees and costs of the arbitrator. However, to the extent permissible under the law, and following the
arbitrator&#146;s ruling on the matter, the arbitrator may rule that the arbitrator&#146;s fees and costs be distributed in an alternative manner. Each party shall pay its own costs and attorneys&#146; fees, if any. If, however, any party prevails
on a statutory or contractual claim that affords the prevailing party attorneys&#146; fees (including pursuant to this Agreement), the arbitrator may award attorneys&#146; fees to the prevailing party to the extent permitted by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Consent to Jurisdiction</U>. The parties hereby consent to the jurisdiction of the state and federal courts of
the State of California. Accordingly, with respect to any such court action, the Executive (a)&nbsp;submits to the exclusive personal jurisdiction of such courts; (b)&nbsp;consents to service of process; and (c)&nbsp;waives any other requirement
(whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&nbsp;&nbsp;&nbsp;&nbsp;<U>Integration</U>. This Agreement constitutes the entire agreement between the parties with respect to the subject
matter hereof and supersedes all prior agreements between the parties concerning such subject matter including the Prior Agreement, provided that the Prior Restrictive Covenants Agreement, the Preserved Provision, the Restrictive Covenants Agreement
and the Equity Documents remain in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&nbsp;&nbsp;&nbsp;&nbsp;<U>Withholding; Tax Effect</U>. All payments made by
the Company to the Executive under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law. Nothing in this Agreement shall be construed to require the Company to make any payments to
compensate the Executive for any adverse tax effect associated with any payments or benefits or for any deduction or withholding from any payment or benefit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors and Assigns</U>. Neither the Executive nor the
Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement
(including the Restrictive Covenants Agreement) without the Executive&#146;s consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization or consolidation, into which the Company merges or to whom
it transfers all or substantially all of its properties or assets; provided further that if the Executive remains employed or becomes employed by the Company, the purchaser or any of their affiliates in connection with any such transaction, then the
Executive shall not be entitled to any payments, benefits or vesting pursuant to Section&nbsp;5 or pursuant to Section&nbsp;6 of this Agreement solely as a result of such transaction. This Agreement shall inure to the benefit of and be binding upon
the Executive and the Company, and each of the Executive&#146;s and the Company&#146;s respective successors, executors, administrators, heirs and permitted assigns. In the event of the Executive&#146;s death after the Executive&#146;s termination
of employment but prior to the completion by the Company of all payments due to the Executive under this Agreement, the Company shall continue such payments to the Executive&#146;s beneficiary designated in writing to the Company prior to the
Executive&#146;s death (or to the Executive&#146;s estate, if the Executive fails to make such designation). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.&nbsp;&nbsp;&nbsp;&nbsp;<U>Enforceability</U>. If any portion or provision of this Agreement (including, without limitation, any portion or
provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other
than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U>. The provisions of this Agreement shall survive the termination of this Agreement and/or the
termination of the Executive&#146;s employment to the extent necessary to effectuate the terms contained herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver</U>. No waiver of any provision hereof shall be effective unless made in writing and signed by the
waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be
deemed a waiver of any subsequent breach. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>. Any notices, requests, demands and other
communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to
the Executive at the last address the Executive has filed in writing with the Company or, in the case of the Company, at its main offices, attention of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18.&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment</U>. This Agreement may be amended or modified only by a written instrument signed by the Executive
and by a duly authorized representative of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.&nbsp;&nbsp;&nbsp;&nbsp;<U>Effect on Other Plans and Agreements</U>. An election by the
Executive to resign for Good Reason under the provisions of this Agreement shall not be deemed a voluntary termination of employment by the Executive for the purpose of interpreting the provisions of any of the Company&#146;s benefit plans, programs
or policies. Nothing in this Agreement shall be construed to limit the rights of the Executive under the Company&#146;s benefit plans, programs or policies except as otherwise provided in Section&nbsp;8 hereof, and except that the Executive shall
have no rights to any severance benefits under any Company severance pay plan, offer letter or otherwise. In the event that the Executive is party to an agreement with the Company providing for payments or benefits under such plan or agreement and
under this Agreement, the terms of this Agreement shall govern and the Executive may receive payment under this Agreement only and not both. Further, Section&nbsp;5 and Section&nbsp;6 of this Agreement are mutually exclusive and in no event shall
the Executive be entitled to payments or benefits pursuant to both Section&nbsp;5 and Section&nbsp;6 of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20.&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing Law</U>. This is a California contract and shall be construed under and be governed in all respects by
the laws of the State of California, without giving effect to the conflict of laws principles thereof. With respect to any disputes concerning federal law, such disputes shall be determined in accordance with the law as it would be interpreted and
applied by the United States Court of Appeals for the 9<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Circuit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>. This Agreement may be executed in any number of counterparts, each of which when so executed
and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS
WHEREOF, the parties have executed this Agreement effective on the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ADICET THERAPEUTICS,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>INC./RESTORBIO, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Chen Schor</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chen Schor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>FRANCESCO GALIMI</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Francesco Galimi</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Francesco Galimi</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>[Exhibit A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Restrictive Covenants Agreement] </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>d91031dex104.htm
<DESCRIPTION>EX-10.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.4 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
Employment Agreement (&#147;Agreement&#148;) is made between Adicet Therapeutics, Inc., a Delaware corporation (the &#147;Company&#148;), and Lloyd Klickstein (the &#147;Executive&#148;) and is contingent upon the closing (the &#147;Closing&#148;)
of the transaction (the &#147;Merger&#148;) contemplated by that certain Agreement and Plan of Merger (the &#147;Merger Agreement&#148;) by and among resTORbio, Inc. (&#147;Parent&#148;), Adicet Bio, Inc. (&#147;Adicet Bio&#148;) and the other
parties thereto. Subject to Section&nbsp;11, except with respect to the Employee Confidentiality, Assignment and <FONT STYLE="white-space:nowrap">Non-Solicitation</FONT> Agreement between the Executive and Parent, dated May&nbsp;13, 2019 (the
&#147;Prior Restrictive Covenants Agreement&#148;) and the Equity Documents (as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and Parent regarding the subject matter herein, including without
limitation (i)&nbsp;the employment agreement between the Executive and Parent dated May&nbsp;13, 2019, (the &#147;Prior Agreement&#148;), and (ii)&nbsp;any offer letter, employment agreement or severance agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Adicet Bio, Inc. will change its name to Adicet Therapeutics, Inc. post-Closing and Parent will change its name to Adicet Bio, Inc.
post-Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company beginning on
the effective date of the Closing of the Merger (the &#147;Effective Date&#148;) on the terms contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in
consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows: </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Employment</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Term</U>. The term of this Agreement shall commence on the Effective Date and continue until terminated in
accordance with the provisions hereof (the &#147;Term&#148;). The Executive&#146;s employment with the Company shall be &#147;at will,&#148; meaning that the Executive&#146;s employment may be terminated by the Company or the Executive at any time
and for any reason subject to the terms of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Position and Duties</U>. The Executive shall
serve as the Chief Innovation Officer of the Company and shall have such powers and duties as may from time to time be prescribed by the Chief Executive Officer of the Company (the &#147;CEO&#148;). The Executive shall devote his full working time
and efforts to the business and affairs of the Company. Notwithstanding the foregoing, the Executive may serve on other boards of directors, with the approval of the Governance Committee of the Board of Directors of the Parent (the &#147;Governance
Committee&#148; of the &#147;Board&#148;), or engage in religious, charitable or other community activities as long as such services and activities do not interfere with the Executive&#146;s performance of his duties to the Parent and the Company as
provided in this Agreement; provided that the Executive may continue to serve as a director on the boards of Blade Therapeutics, Inc. and the Lupus Foundation of New England, and as a member of the scientific advisory boards of Third Harmonic Bio
and Aditum Bio, subject to the Governance Committee&#146;s continued discretionary approval. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Compensation and Related Matters</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Base Salary</U>. The Executive&#146;s initial base salary shall be paid at the rate of $403,700 per year. The
Executive&#146;s base salary shall be subject to periodic review by the Compensation Committee of the Board (the &#147;Compensation Committee&#148;). The base salary in effect at any given time is referred to herein as &#147;Base Salary.&#148; The
Base Salary shall be payable in a manner that is consistent with the Company&#146;s usual payroll practices for executive officers. The Executive&#146;s salary and any other cash compensation may be provided through TriNet, Inc. or another
professional employer organization (a &#147;<U>PEO</U>&#148;). As a result of the Company&#146;s arrangement with the PEO, the PEO will be considered the Executive&#146;s employer of record for these purposes for so long as that arrangement exists.
While the PEO will have responsibility for the functions above, the Company retains responsibility for overseeing the Executive&#146;s work and reviewing the Executive&#146;s performance, among other functions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Incentive Compensation</U>. The Executive shall be eligible to receive cash incentive compensation as determined
by the Board or the Compensation Committee from time to time. Commencing in calendar year 2021, the Executive&#146;s initial target annual incentive compensation shall be forty (40)&nbsp;percent of the Executive&#146;s Base Salary; provided that any
incentive compensation for calendar year 2020 will be prorated based on the Effective Date. The target annual incentive compensation in effect at any given time is referred to herein as &#147;Target Bonus.&#148; The actual amount of the
Executive&#146;s annual incentive compensation, if any, shall be determined in the sole discretion of the Board or the Compensation Committee, subject to the terms of any applicable incentive compensation plan that may be in effect from time to
time. Except as otherwise provided herein, as may be provided by the Board or the Compensation Committee or as may otherwise be set forth in the applicable incentive compensation plan the Executive must be employed by the Company on the day such
incentive compensation is paid in order to earn or receive any incentive compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Expenses</U>. The
Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by the Executive during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the
Company for its executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Other Benefits</U>. The Executive shall be eligible to participate in
or receive benefits under the Company&#146;s employee benefit plans in effect from time to time, subject to the terms of such plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Paid Time Off</U>. The Company&#146;s current paid time off policy for executives is flexible and paid time off
may be taken at such times and intervals as the Executive may determine, subject to the business needs of the Company and the terms and conditions of any policies as may be in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Equity</U>. The equity awards held by the Executive shall be treated as described in the Merger Agreement and,
subject to the terms and conditions of the Merger Agreement, shall continue to be governed by the terms and conditions of the applicable equity incentive plan(s) and the applicable award agreement(s) governing the terms of such equity awards
(collectively, the &#147;Equity Documents&#148;); provided, however, and notwithstanding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
anything to the contrary in the Equity Documents, Section&nbsp;6(a)(ii) of this Agreement shall apply in the event of a termination by the Company without Cause or by the Executive for Good
Reason in either event within the Change in Control Period (as such terms are defined below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification</U>. The Company shall indemnify the Executive to the extent that its officers, directors and
employees are entitled to indemnification pursuant to the Company&#146;s Certificate of Incorporation and Bylaws for any acts or omissions by reason of being an officer or employee of the Company as of the Effective Date. At all times during the
Employment Term, the Company shall maintain in effect a director and officers liability insurance policy with the Executive as a covered officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>. The Executive&#146;s employment hereunder may be terminated without any breach of this Agreement
under the following circumstances: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Death</U>. The Executive&#146;s employment hereunder shall terminate
upon death. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Disability</U>. The Company may terminate the Executive&#146;s employment if the Executive is
disabled and unable to perform or expected to be unable to perform the essential functions of the Executive&#146;s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180 days (which need
not be consecutive) in any <FONT STYLE="white-space:nowrap">12-month</FONT> period. If any question shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executive&#146;s
then existing position or positions with or without reasonable accommodation, the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the
Executive or the Executive&#146;s guardian has no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and such certification shall for the purposes of this Agreement be conclusive of
the issue. The Executive shall cooperate with any reasonable request of the physician in connection with such certification. If such question shall arise and the Executive shall fail to submit such certification, the Company&#146;s determination of
such issue shall be binding on the Executive. Nothing in this Section&nbsp;3(b) shall be construed to waive the Executive&#146;s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C.
&#167;2601 <I>et seq</I>. and the Americans with Disabilities Act, 42 U.S.C. &#167;12101 <I>et seq.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination by the Company for Cause</U>. The Company may terminate the Executive&#146;s employment hereunder
for Cause. For purposes of this Agreement, &#147;Cause&#148; shall mean: (i)&nbsp;conduct by the Executive constituting a material act of misconduct in connection with the performance of his duties, including, without limitation, misappropriation of
funds or property of the Company, Parent or any of its or their subsidiaries or affiliates other than the occasional, customary and de minimis use of Company or Parent property for personal purposes; (ii) the commission by the Executive of acts
satisfying the elements of (A)&nbsp;any felony or (B)&nbsp;a misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii)&nbsp;any misconduct by the Executive, regardless of whether or not in the course of the Executive&#146;s
employment, that would reasonably be expected to result in material injury or reputational harm to the Company, Parent or any of its or their subsidiaries or affiliates if the Executive were to continue to be employed in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the same position; (iv)&nbsp;continued willful nonperformance by the Executive of his material duties hereunder (other than by reason of the Executive&#146;s physical or mental illness,
incapacity or disability) which, to the extent it is curable by the Executive, is not cured within thirty (30)&nbsp;after written notice thereof is given to the Executive by the CEO; (v)&nbsp;a breach by the Executive of the Restrictive Covenants
Agreement or any of the provisions contained in Section&nbsp;8 of this Agreement; (vi)&nbsp;a material violation by the Executive of the Company&#146;s or Parent&#146;s written employment policies; or (vii)&nbsp;failure to cooperate with a bona fide
internal investigation or an investigation by regulatory or law enforcement authorities, after being instructed by the Company or Parent to cooperate, or the willful destruction or failure to preserve documents or other materials known to be
relevant to such investigation or the inducement of others to fail to cooperate or to produce documents or other materials in connection with such investigation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination by the Company without Cause</U>. The Company may terminate the Executive&#146;s employment
hereunder at any time without Cause. Any termination by the Company of the Executive&#146;s employment under this Agreement which does not constitute a termination for Cause under Section&nbsp;3(c) and does not result from the death or disability of
the Executive under Section&nbsp;3(a) or (b)&nbsp;shall be deemed a termination without Cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination
by the Executive</U>. The Executive may terminate his employment hereunder at any time for any reason, including for Good Reason. For purposes of this Agreement, &#147;Good Reason&#148; shall mean that the Executive has complied with the &#147;Good
Reason Process&#148; (hereinafter defined) following the occurrence of any of the following events: (i) a material diminution in the Executive&#146;s responsibilities, authority or duties <I>provided </I>changes to the Executive&#146;s
responsibilities, authority or duties prior to a Change in Control that are made in the good faith discretion of the Company&#146;s CEO as part of the Company&#146;s evolving business needs and strategy shall not be a Good Reason occurrence;
(ii)&nbsp;a material diminution in the Executive&#146;s Base Salary except for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">across-the-board</FONT></FONT> salary reductions based on the Company&#146;s or Parent&#146;s financial
performance similarly affecting all or substantially all senior management employees of the Company or Parent; (iii)&nbsp;a material change in the geographic location at which the Executive provides services to the Company such that there is an
increase of at least thirty (30) miles of driving distance to such location from the Executive&#146;s principal residence as of such change; or (iv)&nbsp;the material breach of this Agreement by the Company. &#147;Good Reason Process&#148; shall
mean that (i)&nbsp;the Executive reasonably determines in good faith that a &#147;Good Reason&#148; condition has occurred; (ii)&nbsp;the Executive notifies the Company in writing of the first occurrence of the Good Reason condition within 60 days
of the first occurrence of such condition; (iii)&nbsp;the Executive cooperates in good faith with the Company&#146;s efforts, for a period not less than 30 days following such notice (the &#147;Cure Period&#148;), to remedy the condition;
(iv)&nbsp;notwithstanding such efforts, the Good Reason condition continues to exist; and (v)&nbsp;the Executive terminates his employment within 180 days after the end of the Cure Period. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Matters Related to</U><U> </U><U>Termination</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice of Termination</U>. Except for termination as specified in Section&nbsp;3(a), any termination of the
Executive&#146;s employment by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto. For purposes of this Agreement, a &#147;Notice of Termination&#148; shall mean a
notice which shall indicate the specific termination provision in this Agreement relied upon. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Date of Termination</U>. &#147;Date of Termination&#148; shall
mean: (i)&nbsp;if the Executive&#146;s employment is terminated by death, the date of death; (ii)&nbsp;if the Executive&#146;s employment is terminated on account of disability under Section&nbsp;3(b) or by the Company for Cause under
Section&nbsp;3(c), the date on which Notice of Termination is given; (iii)&nbsp;if the Executive&#146;s employment is terminated by the Company without Cause under Section&nbsp;3(d), the date on which a Notice of Termination is given or the date
otherwise specified by the Company in the Notice of Termination; (iv)&nbsp;if the Executive&#146;s employment is terminated by the Executive under Section&nbsp;3(e) other than for Good Reason, 30 days after the date on which a Notice of Termination
is given, and (v)&nbsp;if the Executive&#146;s employment is terminated by the Executive under Section&nbsp;3(e) for Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period. Notwithstanding the foregoing, in
the event that the Executive gives a Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Accrued Obligations</U>. If the Executive&#146;s employment with the Company is terminated for any reason, the
Company shall pay or provide to the Executive (or to the Executive&#146;s authorized representative or estate)&nbsp;(i) any Base Salary earned through the Date of Termination; (ii)&nbsp;unpaid expense reimbursements (subject to, and in accordance
with, Section&nbsp;2(c) of this Agreement); and (iii)&nbsp;any vested benefits the Executive may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance
with the terms of such employee benefit plans (collectively, the &#147;Accrued Obligations&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Resignation of All Other Positions</U>. To the extent applicable, the Executive shall be deemed to have resigned
from all officer and board member positions that the Executive holds with the Company or any of its respective subsidiaries and affiliates upon the termination of the Executive&#146;s employment for any reason. The Executive shall execute any
documents in reasonable form as may be requested to confirm or effectuate any such resignations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Severance
Pay and Benefits Upon Termination by the Company without Cause or by the Executive for Good Reason Outside the Change in Control Period</U>. If the Executive&#146;s employment is terminated by the Company without Cause as provided in
Section&nbsp;3(d) or the Executive terminates employment for Good Reason as provided in Section&nbsp;3(e), in each case outside of the Change in Control Period (as defined below), then, in addition to the Accrued Obligations, subject to the
Executive signing a separation agreement containing, among other provisions, a general release of claims in favor of the Company and related persons and entities, including the PEO, a reaffirmation of the Executive&#146;s Continuing Obligations (as
defined below), confidentiality, return of property and <FONT STYLE="white-space:nowrap">non-disparagement,</FONT> in a form and manner satisfactory to the Company (the &#147;Separation Agreement and Release&#148;) and the Separation Agreement and
Release becoming irrevocable and fully effective, all within 60 days after the Date of Termination (or such shorter time period provided in the Separation Agreement and Release): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall pay the Executive an amount equal to nine (9)&nbsp;months of the Executive&#146;s Base Salary
(the &#147;Severance Amount&#148;); and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall pay any unpaid bonus earned for the year
preceding the date of Executive&#146;s employment termination, payable at the time it otherwise would have been paid had the Executive&#146;s employment with the Company not terminated; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;subject to the Executive&#146;s copayment of premium amounts at the applicable active employees&#146; rate and the
Executive&#146;s proper election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#147;<U>COBRA</U>&#148;), the Company shall pay to the Executive a monthly cash payment (including a gross up payment
to account for applicable taxes and withholdings) equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive and covered dependents if the Executive had remained employed by the Company
until the earliest of (A)&nbsp;the nine (9)&nbsp;month anniversary of the Date of Termination; (B)&nbsp;the date that the Executive becomes eligible for group medical plan benefits under any other employer&#146;s group medical plan; or (C) the
cessation of the Executive&#146;s health continuation rights under COBRA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts payable under Section&nbsp;5(a) and (c), to the extent taxable,
shall be paid out in substantially equal installments in accordance with the Company&#146;s payroll practice over nine (9)&nbsp;months commencing within 60 days after the Date of Termination; provided, however, that if the <FONT
STYLE="white-space:nowrap">60-day</FONT> period begins in one calendar year and ends in a second calendar year, such payments, to the extent they qualify as <FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148;
within the meaning of Section&nbsp;409A of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), shall begin to be paid in the second calendar year by the last day of such <FONT STYLE="white-space:nowrap">60-day</FONT> period;
provided, further, that the initial payment shall include a <FONT STYLE="white-space:nowrap">catch-up</FONT> payment to cover amounts retroactive to the day immediately following the Date of Termination. Each payment pursuant to this Agreement is
intended to constitute a separate payment for purposes of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Severance Pay and Benefits Upon Termination by the Company without Cause or by the Executive for Good Reason
within the Change in Control Period</U>. The provisions of this Section&nbsp;6 shall apply in lieu of, and expressly supersede, the provisions of Section&nbsp;5 if (i)&nbsp;the Executive&#146;s employment is terminated either (a)&nbsp;by the Company
without Cause as provided in Section&nbsp;3(d), or (b)&nbsp;by the Executive for Good Reason as provided in Section&nbsp;3(e), and (ii)&nbsp;the Date of Termination occurs on or within 12 months after the occurrence of the first event constituting a
Change in Control (such period, the &#147;Change in Control Period&#148;) following the Effective Date. These provisions shall terminate and be of no further force or effect after the Change in Control Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;If the Executive&#146;s employment is terminated by the Company without Cause as provided in Section&nbsp;3(d) or
the Executive terminates employment for Good Reason as provided in Section&nbsp;3(e) and in each case the Date of Termination occurs during the Change in Control Period, then, in addition to the Accrued Obligations, and subject to the signing of the
Separation Agreement and Release by the Executive and the Separation Agreement and Release becoming fully effective, all within the time frame set forth in the Separation Agreement and Release but in no event more than 60 days after the Date of
Termination: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall pay the Executive a lump sum in cash in an amount equal to one
(1)&nbsp;times the sum of (A)&nbsp;the Executive&#146;s then-current Base Salary (or the Executive&#146;s Base Salary in effect immediately prior to the Change in Control, if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
higher) plus (B)&nbsp;the Executive&#146;s Target Bonus for the then-current year (or the Executive&#146;s Target Bonus in effect immediately prior to the Change in Control, if higher) and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall pay any unpaid bonus earned for the year preceding the date of Executive&#146;s
employment termination, payable at the time it otherwise would have been paid had the Executive&#146;s employment with the Company not terminated, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;notwithstanding anything to the contrary in any applicable option agreement or other stock-based
award agreement, all stock options and other stock-based awards held by the Executive that are subject solely to time-based vesting (the &#147;Time- Based Equity Awards&#148;) shall immediately accelerate and become fully vested and exercisable or
nonforfeitable as of the later of (i)&nbsp;the Date of Termination or (ii)&nbsp;the effective date of the Separation Agreement and Release (the &#147;Accelerated Vesting Date&#148;), provided in order to effectuate the accelerated vesting
contemplated by this subsection, the unvested portion of the Executive&#146;s options that would otherwise be forfeited on the Date of Termination will be delayed until the earlier of (A)&nbsp;the effective date of the Separation Agreement Release
(at which time acceleration will occur), or (B)&nbsp;the date that the Separation Agreement and Release can no longer become fully effective (at which time the unvested Time-Based Equity Awards will be terminated or forfeited). Notwithstanding the
foregoing, no additional time-based vesting of the Time-Based Equity Awards shall occur during the period between the Date of Termination and the Accelerated Vesting Date; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;subject to the Executive&#146;s copayment of premium amounts at the applicable active
employees&#146; rate and the Executive&#146;s proper election to receive benefits under COBRA, the Company shall pay to the Executive a monthly cash payment (including a gross up payment to account for applicable taxes and withholdings) equal to the
monthly employer contribution that the Company would have made to provide health insurance to the Executive and covered dependents if the Executive had remained employed by the Company until the earliest of (A)&nbsp;the eighteen (18)&nbsp;month
anniversary of the Date of Termination; (B)&nbsp;the date that the Executive becomes eligible for group medical plan benefits under any other employer&#146;s group medical plan; or (C)&nbsp;the cessation of the Executive&#146;s health continuation
rights under COBRA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts payable under this Section&nbsp;6(a), to the extent taxable, shall be paid or commence to be paid within 60 days after
the Date of Termination; provided, however, that if the <FONT STYLE="white-space:nowrap">60-day</FONT> period begins in one calendar year and ends in a second calendar year, such payments to the extent they qualify as
<FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; within the meaning of Section&nbsp;409A of the Code, shall be paid or commence to be paid in the second calendar year by the last day of such <FONT
STYLE="white-space:nowrap">60-day</FONT> period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Additional</U><U> </U><U>Limitation</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any
compensation, payment or distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with
Section&nbsp;280G of the Code, and the applicable regulations thereunder (the &#147;Aggregate Payments&#148;), would be subject to the excise tax imposed by Section&nbsp;4999 of the Code, then the Aggregate Payments shall be reduced (but not below
zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which the Executive becomes subject to the excise tax imposed by Section&nbsp;4999 of the Code; provided that such reduction shall only occur if it would
result in the Executive receiving a higher After Tax Amount (as defined below) than the Executive would receive if the Aggregate Payments were not subject to such reduction. In such event, the Aggregate Payments shall be reduced in the following
order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section&nbsp;280G of the Code: (1)&nbsp;cash payments not
subject to Section&nbsp;409A of the Code; (2)&nbsp;cash payments subject to Section&nbsp;409A of the Code; (3)&nbsp;equity-based payments and acceleration; and <FONT STYLE="white-space:nowrap">(4)&nbsp;non-cash</FONT> forms of benefits; provided
that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. <FONT STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT STYLE="white-space:nowrap">Q&amp;A-24(b)</FONT> or
(c) shall be reduced before any amounts that are subject to calculation under Treas. Reg. <FONT STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT STYLE="white-space:nowrap">Q&amp;A-24(b)</FONT> or (c). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;For purposes of this Section&nbsp;6(b), the &#147;After Tax Amount&#148; means the amount of the
Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on the Executive as a result of the Executive&#146;s receipt of the Aggregate Payments. For purposes of determining the After Tax Amount, the Executive
shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal
rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to
Section&nbsp;6(b)(i) shall be made by a nationally recognized accounting firm selected by the Company (the &#147;Accounting Firm&#148;), which shall provide detailed supporting calculations both to the Company and the Executive within 15 business
days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Executive. Any determination by the Accounting Firm shall be binding upon the Company and the Executive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>. For purposes of this Section&nbsp;6, the following terms shall have the following meanings:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Change in Control&#148; shall mean any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;any &#147;person,&#148; as such term is used in Sections 13(d) and 14(d) of the Securities Exchange
Act of 1934, as amended (the &#147;Act&#148;), any of its subsidiaries, or any trustee, fiduciary or other person or entity holding securities under any employee benefit plan or trust of Parent or any of its subsidiaries), together with all
&#147;affiliates&#148; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
&#147;associates&#148; (as such terms are defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Act) of such person, shall become the &#147;beneficial owner&#148; (as such term
is defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Act), directly or indirectly, of securities of Parent representing 50&nbsp;percent or more of the combined voting power of Parent&#146;s then outstanding securities having
the right to vote in an election of the Board (&#147;Voting Securities&#148;) (in such case other than as a result of an acquisition of securities directly from Parent); or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the date a majority of the members of the Board is replaced during any <FONT
STYLE="white-space:nowrap">12-month</FONT> period by directors whose appointment or election is not endorsed by a majority of the members of the Board before the date of the appointment or election; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;the consummation of (A)&nbsp;any consolidation or merger of Parent where the stockholders of
Parent, immediately prior to the consolidation or merger, would not, immediately after the consolidation or merger, beneficially own (as such term is defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Act), directly or
indirectly, shares representing in the aggregate more than 50&nbsp;percent of the voting shares of Parent issuing cash or securities in the consolidation or merger (or of its ultimate parent corporation, if any), or (B)&nbsp;any sale or other
transfer (in one transaction or a series of transactions contemplated or arranged by any party as a single plan) of all or substantially all of the assets of Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, a &#147;Change in Control&#148; shall not be deemed to have occurred for purposes of the foregoing clause
(i)&nbsp;solely as the result of an acquisition of securities by Parent which, by reducing the number of shares of Voting Securities outstanding, increases the proportionate number of Voting Securities beneficially owned by any person to
50&nbsp;percent or more of the combined voting power of all of the then outstanding Voting Securities; provided, however, that if any person referred to in this sentence shall thereafter become the beneficial owner of any additional shares of Voting
Securities (other than pursuant to a stock split, stock dividend, or similar transaction or as a result of an acquisition of securities directly from Parent) and immediately thereafter beneficially owns 50&nbsp;percent or more of the combined voting
power of all of the then outstanding Voting Securities, then a &#147;Change in Control&#148; shall be deemed to have occurred for purposes of the foregoing clause (i). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Section</U><U></U><U>&nbsp;409A</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive&#146;s separation from
service within the meaning of Section&nbsp;409A of the Code, the Company determines that the Executive is a &#147;specified employee&#148; within the meaning of Section&nbsp;409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit
that the Executive becomes entitled to under this Agreement or otherwise on account of the Executive&#146;s separation from service would be considered deferred compensation otherwise subject to the 20&nbsp;percent additional tax imposed pursuant to
Section&nbsp;409A(a) of the Code as a result of the application of Section&nbsp;409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A)&nbsp;six months and one
day after the Executive&#146;s separation from service, or (B)&nbsp;the Executive&#146;s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a
<FONT STYLE="white-space:nowrap">catch-up</FONT> payment covering amounts that would otherwise have been paid during the <FONT STYLE="white-space:nowrap">six-month</FONT> period but for the application of this provision, and the balance of the
installments shall be payable in accordance with their original schedule. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;All <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits
provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively
practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits provided or
reimbursable expenses incurred in one taxable year shall not affect the <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other
aggregate limitation applicable to medical expenses). Such right to reimbursement or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits is not subject to liquidation or exchange for another benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;To the extent that any payment or benefit described in this Agreement constitutes
<FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; under Section&nbsp;409A of the Code, and to the extent that such payment or benefit is payable upon the Executive&#146;s termination of employment, then such
payments or benefits shall be payable only upon the Executive&#146;s &#147;separation from service.&#148; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in
Treasury Regulation Section <FONT STYLE="white-space:nowrap">1.409A-1(h).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;The parties intend that this
Agreement will be administered in accordance with Section&nbsp;409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section&nbsp;409A of the Code, the provision shall be read in such a manner so
that all payments hereunder comply with Section&nbsp;409A of the Code. Each payment pursuant to this Agreement or the Restrictive Covenants Agreement is intended to constitute a separate payment for purposes of Treasury Regulation <FONT
STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2).</FONT> The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section&nbsp;409A of the Code and all related
rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;The Company makes no representation or warranty and shall have no liability to the Executive or any other person if
any provisions of this Agreement are determined to constitute deferred compensation subject to Section&nbsp;409A of the Code but do not satisfy an exemption from, or the conditions of, such Section. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Continuing</U><U> </U><U>Obligations</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Restrictive Covenants Agreement</U>. As a condition of employment, the Executive is required to enter into the
Employee Confidentiality, Assignment and Nonsolicitation Agreement, attached hereto as <U>Exhibit A</U> (the &#147;Restrictive Covenants Agreement&#148;). For the avoidance of doubt, the Restrictive Covenants Agreement is supplemental to the Prior
Restrictive Covenants Agreement, which remains in full force and effect. For purposes of this Agreement, the obligations in this Section&nbsp;8 and those that arise in the Restrictive Covenants Agreement, the Prior Restrictive Covenants Agreement
and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the &#147;Continuing Obligations.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Third-Party Agreements and Rights</U>. The Executive hereby
confirms that the Executive is not bound by the terms of any agreement with any previous employer or other party which restricts in any way the Executive&#146;s use or disclosure of information, other than confidentiality restrictions (if any), or
the Executive&#146;s engagement in any business. The Executive represents to the Company that the Executive&#146;s execution of this Agreement, the Executive&#146;s employment with the Company and the performance of the Executive&#146;s proposed
duties for the Company will not violate any obligations the Executive may have to any such previous employer or other party. In the Executive&#146;s work for the Company, the Executive will not disclose or make use of any information in violation of
any agreements with or rights of any such previous employer or other party, and the Executive will not bring to the premises of the Company any copies or other tangible embodiments of <FONT STYLE="white-space:nowrap">non-public</FONT> information
belonging to or obtained from any such previous employment or other party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Litigation and Regulatory
Cooperation</U>. During and after the Executive&#146;s employment, the Executive shall cooperate fully with the Company in (i)&nbsp;the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or
on behalf of the Company which relate to events or occurrences that transpired while the Executive was employed by the Company, and (ii)&nbsp;the investigation, whether internal or external, of any matters about which the Company believes the
Executive may have knowledge or information. The Executive&#146;s full cooperation in connection with such claims, actions or investigations shall include, but not be limited to, being available to meet with counsel to answer questions or to prepare
for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During and after the Executive&#146;s employment, the Executive also shall cooperate fully with the Company in connection with any investigation or
review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Executive was employed by the Company. The Company shall reimburse the Executive for any
reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with the Executive&#146;s performance of obligations pursuant to this Section&nbsp;8(c). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Relief</U>. The Executive agrees that it would be difficult to measure any damages caused to the Company which
might result from any breach by the Executive of the Continuing Obligations, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly<B>, </B>the Executive agrees that if the Executive breaches, or proposes
to breach, any portion of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other appropriate equitable relief to restrain any such breach without showing or proving
any actual damage to the Company. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Arbitration of</U><U> </U><U>Disputes</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Arbitration Generally</U>. Any controversy or claim arising out of or relating to this Agreement or the breach
thereof or otherwise arising out of the Executive&#146;s employment or the termination of that employment (including, without limitation, any claims of unlawful employment discrimination or retaliation, whether based on race, religion, national
origin, sex, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
gender, age, disability, sexual orientation, or any other protected class under applicable law) shall, to the fullest extent permitted by law, be settled by arbitration in any forum and form
agreed upon by the parties or, in the absence of such an agreement, under the auspices of JAMS in Boston, Massachusetts in accordance with the JAMS Employment Arbitration Rules, including, but not limited to, the rules and procedures applicable to
the selection of arbitrators. The Executive understands that the Executive may only bring such claims in the Executive&#146;s individual capacity, and not as a plaintiff or class member in any purported class proceeding or any purported
representative proceeding.&nbsp;&nbsp;&nbsp;&nbsp;The Executive further understands that, by signing this Agreement, the Company and the Executive are giving up any right they may have to a jury trial on all claims they may have against each other.
Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. This Section&nbsp;9 shall be specifically enforceable. Notwithstanding the foregoing, this Section&nbsp;9 shall not preclude either party
from pursuing a court action for the sole purpose of obtaining a temporary restraining order or a preliminary injunction in circumstances in which such relief is appropriate, including without limitation relief sought under the Restrictive Covenants
Agreement; provided that any other relief shall be pursued through an arbitration proceeding pursuant to this Section&nbsp;9. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Arbitration Fees and Costs</U>. The Executive shall be required to pay an arbitration fee to initiate any
arbitration equal to what the Executive would be charged as a first appearance fee in court. The Company shall advance the remaining fees and costs of the arbitrator. However, to the extent permissible under the law, and following the
arbitrator&#146;s ruling on the matter, the arbitrator may rule that the arbitrator&#146;s fees and costs be distributed in an alternative manner. Each party shall pay its own costs and attorneys&#146; fees, if any. If, however, any party prevails
on a statutory or contractual claim that affords the prevailing party attorneys&#146; fees (including pursuant to this Agreement), the arbitrator may award attorneys&#146; fees to the prevailing party to the extent permitted by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Consent to Jurisdiction</U>. The parties hereby consent to the jurisdiction of the state and federal courts of
the Commonwealth of Massachusetts. Accordingly, with respect to any such court action, the Executive (a)&nbsp;submits to the exclusive personal jurisdiction of such courts; (b) consents to service of process; and (c)&nbsp;waives any other
requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&nbsp;&nbsp;&nbsp;&nbsp;<U>Integration</U>. This Agreement constitutes the entire agreement between the parties with respect to the subject
matter hereof and supersedes all prior agreements between the parties concerning such subject matter including the Prior Agreement, provided that the Prior Restrictive Covenants Agreement, the Restrictive Covenants Agreement and the Equity Documents
remain in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&nbsp;&nbsp;&nbsp;&nbsp;<U>Withholding; Tax Effect</U>. All payments made by the Company to the
Executive under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law. Nothing in this Agreement shall be construed to require the Company to make any payments to compensate the Executive
for any adverse tax effect associated with any payments or benefits or for any deduction or withholding from any payment or benefit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors and Assigns</U>. Neither the Executive nor the
Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement
(including the Restrictive Covenants Agreement) without the Executive&#146;s consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization or consolidation, into which the Company merges or to whom
it transfers all or substantially all of its properties or assets; provided further that if the Executive remains employed or becomes employed by the Company, the purchaser or any of their affiliates in connection with any such transaction, then the
Executive shall not be entitled to any payments, benefits or vesting pursuant to Section&nbsp;5 or pursuant to Section&nbsp;6 of this Agreement solely as a result of such transaction. This Agreement shall inure to the benefit of and be binding upon
the Executive and the Company, and each of the Executive&#146;s and the Company&#146;s respective successors, executors, administrators, heirs and permitted assigns. In the event of the Executive&#146;s death after the Executive&#146;s termination
of employment but prior to the completion by the Company of all payments due to the Executive under this Agreement, the Company shall continue such payments to the Executive&#146;s beneficiary designated in writing to the Company prior to the
Executive&#146;s death (or to the Executive&#146;s estate, if the Executive fails to make such designation). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.&nbsp;&nbsp;&nbsp;&nbsp;<U>Enforceability</U>. If any portion or provision of this Agreement (including, without limitation, any portion or
provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other
than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U>. The provisions of this Agreement shall survive the termination of this Agreement and/or the
termination of the Executive&#146;s employment to the extent necessary to effectuate the terms contained herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver</U>. No waiver of any provision hereof shall be effective unless made in writing and signed by the
waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be
deemed a waiver of any subsequent breach. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>. Any notices, requests, demands and other
communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to
the Executive at the last address the Executive has filed in writing with the Company or, in the case of the Company, at its main offices, attention of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18.&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment</U>. This Agreement may be amended or modified only by a written instrument signed by the Executive
and by a duly authorized representative of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.&nbsp;&nbsp;&nbsp;&nbsp;<U>Effect on Other Plans and Agreements</U>. An election by the
Executive to resign for Good Reason under the provisions of this Agreement shall not be deemed a voluntary termination of employment by the Executive for the purpose of interpreting the provisions of any of the Company&#146;s benefit plans, programs
or policies. Nothing in this Agreement shall be construed to limit the rights of the Executive under the Company&#146;s benefit plans, programs or policies except as otherwise provided in Section&nbsp;8 hereof, and except that the Executive shall
have no rights to any severance benefits under any Company severance pay plan, offer letter or otherwise. In the event that the Executive is party to an agreement with the Company providing for payments or benefits under such plan or agreement and
under this Agreement, the terms of this Agreement shall govern and the Executive may receive payment under this Agreement only and not both. Further, Section&nbsp;5 and Section&nbsp;6 of this Agreement are mutually exclusive and in no event shall
the Executive be entitled to payments or benefits pursuant to both Section&nbsp;5 and Section&nbsp;6 of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20.&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing Law</U>. This is a Massachusetts contract and shall be construed under and be governed in all respects
by the laws of the Commonwealth of Massachusetts, without giving effect to the conflict of laws principles thereof. With respect to any disputes concerning federal law, such disputes shall be determined in accordance with the law as it would be
interpreted and applied by the United States Court of Appeals for the 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> Circuit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>. This Agreement may be executed in any number of counterparts, each of which when so executed
and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS
WHEREOF, the parties have executed this Agreement effective on the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ADICET THERAPEUTICS,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>INC./RESTORBIO, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Chen Schor</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chen Schor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LLOYD KLICKSTEIN</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Lloyd Klickstein</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Lloyd Klickstein</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>[Exhibit A</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Restrictive Covenants Agreement] </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>6
<FILENAME>d91031dex105.htm
<DESCRIPTION>EX-10.5
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Employment Agreement (&#147;Agreement&#148;) is made between Adicet Therapeutics, Inc., a Delaware corporation (the &#147;Company&#148;),
and Nick Harvey (the &#147;Executive&#148;) and is contingent upon the closing (the &#147;Closing&#148;) of the transaction (the &#147;Merger&#148;) contemplated by that certain Agreement and Plan of Merger (the &#147;Merger Agreement&#148;) by and
among resTORbio, Inc. (&#147;Parent&#148;), Adicet Bio, Inc. (&#147;Adicet Bio&#148;) and the other parties thereto. Subject to Section&nbsp;11, this Agreement supersedes in all respects all prior agreements between the Executive and Adicet Bio
regarding the subject matter herein, including without limitation the Independent Contractor Services Agreement between the Executive and Adicet Bio dated August&nbsp;17, 2020 (the &#147;Prior Agreement&#148;) except as specifically preserved
herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Adicet Bio, Inc. will change its name to Adicet Therapeutics, Inc. post- Closing and Parent will change its name to
Adicet Bio, Inc. post-Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the
Company beginning on the effective date of the Closing of the Merger (the &#147;Effective Date&#148;) on the terms contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW,
THEREFORE, in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Employment</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Term</U>. The term of this Agreement shall commence on the Effective Date and continue until terminated in
accordance with the provisions hereof (the &#147;Term&#148;). The Executive&#146;s employment with the Company shall be &#147;at will,&#148; meaning that the Executive&#146;s employment may be terminated by the Company or the Executive at any time
and for any reason subject to the terms of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Position and Duties</U>. The Executive shall
serve as the Chief Financial Officer of the Company and shall have such powers and duties as may from time to time be prescribed by the Chief Executive Officer of the Company (the &#147;CEO&#148;). The Executive shall devote his full working time
and efforts to the business and affairs of the Company. Notwithstanding the foregoing, the Executive may serve on other boards of directors, with the approval of the Governance Committee of the Board of Directors of the Parent (the &#147;Governance
Committee&#148; of the &#147;Board&#148;), or engage in religious, charitable or other community activities as long as such services and activities do not interfere with the Executive&#146;s performance of his duties to the Parent and the Company as
provided in this Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Compensation and Related Matters</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Base Salary</U>. The Executive&#146;s initial base salary shall be paid at the rate of $385,000 per year. The
Executive&#146;s base salary shall be subject to periodic review by the Compensation Committee of the Board (the &#147;Compensation Committee&#148;). The base salary in effect at any given time is referred to herein as &#147;Base Salary.&#148; The
Base Salary shall be payable </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in a manner that is consistent with the Company&#146;s usual payroll practices for executive officers. The
Executive&#146;s salary and any other cash compensation may be provided through TriNet, Inc. or another professional employer organization (a &#147;<U>PEO</U>&#148;). As a result of the Company&#146;s arrangement with the PEO, the PEO will be
considered the Executive&#146;s employer of record for these purposes for so long as that arrangement exists. While the PEO will have responsibility for the functions above, the Company retains responsibility for overseeing the Executive&#146;s work
and reviewing the Executive&#146;s performance, among other functions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Incentive Compensation</U>. The
Executive shall be eligible to receive cash incentive compensation as determined by the Board or the Compensation Committee from time to time. The Executive&#146;s initial target annual incentive compensation shall be forty (40)&nbsp;percent of the
Executive&#146;s Base Salary; provided that any incentive compensation for calendar year 2020 will be prorated based on the Effective Date. The target annual incentive compensation in effect at any given time is referred to herein as &#147;Target
Bonus.&#148; The actual amount of the Executive&#146;s annual incentive compensation, if any, shall be determined in the sole discretion of the Board or the Compensation Committee, subject to the terms of any applicable incentive compensation plan
that may be in effect from time to time. Except as otherwise provided herein, as may be provided by the Board or the Compensation Committee or as may otherwise be set forth in the applicable incentive compensation plan the Executive must be employed
by the Company on the day such incentive compensation is paid in order to earn or receive any incentive compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Expenses</U>. The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses
incurred by the Executive during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Other Benefits</U>. The Executive shall be eligible to participate in or receive benefits under the
Company&#146;s employee benefit plans in effect from time to time, subject to the terms of such plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Paid
Time Off</U>. The Company&#146;s current paid time off policy for executives is flexible and paid time off may be taken at such times and intervals as the Executive may determine, subject to the business needs of the Company and the terms and
conditions of any policies as may be in effect from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Equity</U>. As a material inducement to
the Executive&#146;s acceptance of this offer, subject to approval of the Board or the Compensation Committee and contingent upon consummation of the Merger, the Executive shall be granted an option to purchase approximately one (1)&nbsp;percent of
issued and outstanding shares of Parent Common Stock at the Closing of the Merger at a per share exercise price determined on the grant date in accordance with the Company&#146;s equity grant policies, with 25&nbsp;percent of the shares underlying
the option vesting on the first anniversary of the Effective Date and the remainder of the shares underlying the option vesting thereafter in 36 equal monthly installments until the fourth anniversary of the Effective Date, subject to the
Executive&#146;s continued service with the Company through each such vesting date. This grant will be subject to the terms of a <FONT STYLE="white-space:nowrap">non-shareholder</FONT> approved equity incentive plan to be approved by the Board
pursuant to the &#147;inducement exception&#148; provided under NASDAQ Listing Rule 5635(c)(4). We anticipate that the terms of this plan and the applicable stock option agreement will be similar to the terms of the Company&#146;s other equity
incentive plan and standard form of stock option agreement thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification</U>. The Company shall indemnify the Executive
to the extent that its officers, directors and employees are entitled to indemnification pursuant to the Company&#146;s Certificate of Incorporation and Bylaws for any acts or omissions by reason of being an officer or employee of the Company as of
the Effective Date. At all times during the Employment Term, the Company shall maintain in effect a director and officers liability insurance policy with the Executive as a covered officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>. The Executive&#146;s employment hereunder may be terminated without any breach of this Agreement
under the following circumstances: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Death</U>. The Executive&#146;s employment hereunder shall terminate
upon death. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Disability</U>. The Company may terminate the Executive&#146;s employment if the Executive is
disabled and unable to perform or expected to be unable to perform the essential functions of the Executive&#146;s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180 days (which need
not be consecutive) in any <FONT STYLE="white-space:nowrap">12-month</FONT> period. If any question shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executive&#146;s
then existing position or positions with or without reasonable accommodation, the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the
Executive or the Executive&#146;s guardian has no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and such certification shall for the purposes of this Agreement be conclusive of
the issue. The Executive shall cooperate with any reasonable request of the physician in connection with such certification. If such question shall arise and the Executive shall fail to submit such certification, the Company&#146;s determination of
such issue shall be binding on the Executive. Nothing in this Section&nbsp;3(b) shall be construed to waive the Executive&#146;s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C.
&#167;2601 <I>et seq</I>. and the Americans with Disabilities Act, 42 U.S.C. &#167;12101 <I>et seq.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination by the Company for Cause</U>. The Company may terminate the Executive&#146;s employment hereunder
for Cause. For purposes of this Agreement, &#147;Cause&#148; shall mean: (i)&nbsp;conduct by the Executive constituting a material act of misconduct in connection with the performance of his duties, including, without limitation, misappropriation of
funds or property of the Company, Parent or any of its or their subsidiaries or affiliates other than the occasional, customary and de minimis use of Company or Parent property for personal purposes; (ii) the commission by the Executive of acts
satisfying the elements of (A)&nbsp;any felony or (B)&nbsp;a misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii)&nbsp;any misconduct by the Executive, regardless of whether or not in the course of the Executive&#146;s
employment, that would reasonably be expected to result in material injury or reputational harm to the Company, Parent or any of its or their subsidiaries or affiliates if the Executive were to continue to be employed in the same position;
(iv)&nbsp;continued willful nonperformance by the Executive of his material duties </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">hereunder (other than by reason of the Executive&#146;s physical or mental illness, incapacity or
disability) which, to the extent it is curable by the Executive, is not cured within thirty (30)&nbsp;after written notice thereof is given to the Executive by the CEO; (v)&nbsp;a breach by the Executive of the Restrictive Covenants Agreement or any
of the provisions contained in Section&nbsp;8 of this Agreement; (vi)&nbsp;a material violation by the Executive of the Company&#146;s or Parent&#146;s written employment policies; or (vii)&nbsp;failure to cooperate with a bona fide internal
investigation or an investigation by regulatory or law enforcement authorities, after being instructed by the Company or Parent to cooperate, or the willful destruction or failure to preserve documents or other materials known to be relevant to such
investigation or the inducement of others to fail to cooperate or to produce documents or other materials in connection with such investigation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination by the Company without Cause</U>. The Company may terminate the Executive&#146;s employment
hereunder at any time without Cause. Any termination by the Company of the Executive&#146;s employment under this Agreement which does not constitute a termination for Cause under Section&nbsp;3(c) and does not result from the death or disability of
the Executive under Section&nbsp;3(a) or (b)&nbsp;shall be deemed a termination without Cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination
by the Executive</U>. The Executive may terminate his employment hereunder at any time for any reason, including for Good Reason. For purposes of this Agreement, &#147;Good Reason&#148; shall mean that the Executive has complied with the &#147;Good
Reason Process&#148; (hereinafter defined) following the occurrence of any of the following events: (i) a material diminution in the Executive&#146;s responsibilities, authority or duties <I>provided </I>changes to the Executive&#146;s
responsibilities, authority or duties prior to a Change in Control that are made in the good faith discretion of the Company&#146;s CEO as part of the Company&#146;s evolving business needs and strategy shall not be a Good Reason occurrence;
(ii)&nbsp;a material diminution in the Executive&#146;s Base Salary except for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">across-the-board</FONT></FONT> salary reductions based on the Company&#146;s or Parent&#146;s financial
performance similarly affecting all or substantially all senior management employees of the Company or Parent; (iii)&nbsp;a material change in the geographic location at which the Executive provides services to the Company such that there is an
increase of at least thirty (30) miles of driving distance to such location from the Executive&#146;s principal residence as of such change; or (iv)&nbsp;the material breach of this Agreement by the Company. &#147;Good Reason Process&#148; shall
mean that (i)&nbsp;the Executive reasonably determines in good faith that a &#147;Good Reason&#148; condition has occurred; (ii)&nbsp;the Executive notifies the Company in writing of the first occurrence of the Good Reason condition within 60 days
of the first occurrence of such condition; (iii)&nbsp;the Executive cooperates in good faith with the Company&#146;s efforts, for a period not less than 30 days following such notice (the &#147;Cure Period&#148;), to remedy the condition;
(iv)&nbsp;notwithstanding such efforts, the Good Reason condition continues to exist; and (v)&nbsp;the Executive terminates his employment within 180 days after the end of the Cure Period. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Matters Related to</U><U> </U><U>Termination</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice of Termination</U>. Except for termination as specified in Section&nbsp;3(a), any termination of the
Executive&#146;s employment by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto. For purposes of this Agreement, a &#147;Notice of Termination&#148; shall mean a
notice which shall indicate the specific termination provision in this Agreement relied upon. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Date of Termination</U>. &#147;Date of Termination&#148; shall
mean: (i)&nbsp;if the Executive&#146;s employment is terminated by death, the date of death; (ii)&nbsp;if the Executive&#146;s employment is terminated on account of disability under Section&nbsp;3(b) or by the Company for Cause under
Section&nbsp;3(c), the date on which Notice of Termination is given; (iii)&nbsp;if the Executive&#146;s employment is terminated by the Company without Cause under Section&nbsp;3(d), the date on which a Notice of Termination is given or the date
otherwise specified by the Company in the Notice of Termination; (iv)&nbsp;if the Executive&#146;s employment is terminated by the Executive under Section&nbsp;3(e) other than for Good Reason, 30 days after the date on which a Notice of Termination
is given, and (v)&nbsp;if the Executive&#146;s employment is terminated by the Executive under Section&nbsp;3(e) for Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period. Notwithstanding the foregoing, in
the event that the Executive gives a Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Accrued Obligations</U>. If the Executive&#146;s employment with the Company is terminated for any reason, the
Company shall pay or provide to the Executive (or to the Executive&#146;s authorized representative or estate)&nbsp;(i) any Base Salary earned through the Date of Termination; (ii)&nbsp;unpaid expense reimbursements (subject to, and in accordance
with, Section&nbsp;2(c) of this Agreement); and (iii)&nbsp;any vested benefits the Executive may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance
with the terms of such employee benefit plans (collectively, the &#147;Accrued Obligations&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Resignation of All Other Positions</U>. To the extent applicable, the Executive shall be deemed to have resigned
from all officer and board member positions that the Executive holds with the Company or any of its respective subsidiaries and affiliates upon the termination of the Executive&#146;s employment for any reason. The Executive shall execute any
documents in reasonable form as may be requested to confirm or effectuate any such resignations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Severance
Pay and Benefits Upon Termination by the Company without Cause or by the Executive for Good Reason Outside the Change in Control Period</U>. If the Executive&#146;s employment is terminated by the Company without Cause as provided in
Section&nbsp;3(d) or the Executive terminates employment for Good Reason as provided in Section&nbsp;3(e), in each case outside of the Change in Control Period (as defined below), then, in addition to the Accrued Obligations, subject to the
Executive signing a separation agreement containing, among other provisions, a general release of claims in favor of the Company and related persons and entities, including the PEO, a reaffirmation of the Executive&#146;s Continuing Obligations (as
defined below), confidentiality, return of property and <FONT STYLE="white-space:nowrap">non-disparagement,</FONT> in a form and manner satisfactory to the Company (the &#147;Separation Agreement and Release&#148;) and the Separation Agreement and
Release becoming irrevocable and fully effective, all within 60 days after the Date of Termination (or such shorter time period provided in the Separation Agreement and Release): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall pay the Executive an amount equal to nine (9)&nbsp;months of the Executive&#146;s Base Salary
(the &#147;Severance Amount&#148;); and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall pay any unpaid bonus earned for the year
preceding the date of Executive&#146;s employment termination, payable at the time it otherwise would have been paid had the Executive&#146;s employment with the Company not terminated; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;subject to the Executive&#146;s copayment of premium amounts at the applicable active employees&#146; rate and the
Executive&#146;s proper election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#147;<U>COBRA</U>&#148;), the Company shall pay to the Executive a monthly cash payment (including a gross up payment
to account for applicable taxes and withholdings) equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive and covered dependents if the Executive had remained employed by the Company
until the earliest of (A)&nbsp;the nine (9)&nbsp;month anniversary of the Date of Termination; (B)&nbsp;the date that the Executive becomes eligible for group medical plan benefits under any other employer&#146;s group medical plan; or (C) the
cessation of the Executive&#146;s health continuation rights under COBRA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts payable under Section&nbsp;5(a) and (c), to the extent taxable,
shall be paid out in substantially equal installments in accordance with the Company&#146;s payroll practice over nine (9)&nbsp;months commencing within 60 days after the Date of Termination; provided, however, that if the <FONT
STYLE="white-space:nowrap">60-day</FONT> period begins in one calendar year and ends in a second calendar year, such payments, to the extent they qualify as <FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148;
within the meaning of Section&nbsp;409A of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), shall begin to be paid in the second calendar year by the last day of such <FONT STYLE="white-space:nowrap">60-day</FONT> period;
provided, further, that the initial payment shall include a <FONT STYLE="white-space:nowrap">catch-up</FONT> payment to cover amounts retroactive to the day immediately following the Date of Termination. Each payment pursuant to this Agreement is
intended to constitute a separate payment for purposes of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Severance Pay and Benefits Upon Termination by the Company without Cause or by the Executive for Good Reason
within the Change in Control Period</U>. The provisions of this Section&nbsp;6 shall apply in lieu of, and expressly supersede, the provisions of Section&nbsp;5 if (i)&nbsp;the Executive&#146;s employment is terminated either (a)&nbsp;by the Company
without Cause as provided in Section&nbsp;3(d), or (b)&nbsp;by the Executive for Good Reason as provided in Section&nbsp;3(e), and (ii)&nbsp;the Date of Termination occurs on or within 12 months after the occurrence of the first event constituting a
Change in Control (such period, the &#147;Change in Control Period&#148;) following the Effective Date. These provisions shall terminate and be of no further force or effect after the Change in Control Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;If the Executive&#146;s employment is terminated by the Company without Cause as provided in Section&nbsp;3(d) or
the Executive terminates employment for Good Reason as provided in Section&nbsp;3(e) and in each case the Date of Termination occurs during the Change in Control Period, then, in addition to the Accrued Obligations, and subject to the signing of the
Separation Agreement and Release by the Executive and the Separation Agreement and Release becoming fully effective, all within the time frame set forth in the Separation Agreement and Release but in no event more than 60 days after the Date of
Termination: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall pay the Executive a lump sum in cash in an amount equal to one
(1)&nbsp;times the sum of (A)&nbsp;the Executive&#146;s then-current Base Salary (or the Executive&#146;s Base Salary in effect immediately prior to the Change in Control, if higher) plus (B)&nbsp;the Executive&#146;s Target Bonus for the
then-current year (or the Executive&#146;s Target Bonus in effect immediately prior to the Change in Control, if higher) and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall pay any unpaid bonus earned
for the year preceding the date of Executive&#146;s employment termination, payable at the time it otherwise would have been paid had the Executive&#146;s employment with the Company not terminated, and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;notwithstanding anything to the contrary in any applicable option agreement or other stock-based
award agreement, all stock options and other stock-based awards held by the Executive that are subject solely to time-based vesting (the &#147;Time- Based Equity Awards&#148;) shall immediately accelerate and become fully vested and exercisable or
nonforfeitable as of the later of (i)&nbsp;the Date of Termination or (ii)&nbsp;the effective date of the Separation Agreement and Release (the &#147;Accelerated Vesting Date&#148;), provided in order to effectuate the accelerated vesting
contemplated by this subsection, the unvested portion of the Executive&#146;s options that would otherwise be forfeited on the Date of Termination will be delayed until the earlier of (A)&nbsp;the effective date of the Separation Agreement Release
(at which time acceleration will occur), or (B)&nbsp;the date that the Separation Agreement and Release can no longer become fully effective (at which time the unvested Time-Based Equity Awards will be terminated or forfeited). Notwithstanding the
foregoing, no additional time-based vesting of the Time-Based Equity Awards shall occur during the period between the Date of Termination and the Accelerated Vesting Date; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;subject to the Executive&#146;s copayment of premium amounts at the applicable active
employees&#146; rate and the Executive&#146;s proper election to receive benefits under COBRA, the Company shall pay to the Executive a monthly cash payment (including a gross up payment to account for applicable taxes and withholdings) equal to the
monthly employer contribution that the Company would have made to provide health insurance to the Executive and covered dependents if the Executive had remained employed by the Company until the earliest of (A)&nbsp;the twelve (12)&nbsp;month
anniversary of the Date of Termination; (B)&nbsp;the date that the Executive becomes eligible for group medical plan benefits under any other employer&#146;s group medical plan; or (C)&nbsp;the cessation of the Executive&#146;s health continuation
rights under COBRA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts payable under this Section&nbsp;6(a), to the extent taxable, shall be paid or commence to be paid within 60 days after
the Date of Termination; provided, however, that if the <FONT STYLE="white-space:nowrap">60-day</FONT> period begins in one calendar year and ends in a second calendar year, such payments to the extent they qualify as
<FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; within the meaning of Section&nbsp;409A of the Code, shall be paid or commence to be paid in the second calendar year by the last day of such <FONT
STYLE="white-space:nowrap">60-day</FONT> period. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Additional</U><U> </U><U>Limitation</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any
compensation, payment or distribution by the Company to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">or for the benefit of the Executive, whether paid or payable or distributed or distributable
pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section&nbsp;280G of the Code, and the applicable regulations thereunder (the &#147;Aggregate Payments&#148;), would be subject to the excise tax imposed by
Section&nbsp;4999 of the Code, then the Aggregate Payments shall be reduced (but not below zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which the Executive becomes subject to the excise tax imposed by
Section&nbsp;4999 of the Code; provided that such reduction shall only occur if it would result in the Executive receiving a higher After Tax Amount (as defined below) than the Executive would receive if the Aggregate Payments were not subject to
such reduction. In such event, the Aggregate Payments shall be reduced in the following order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the
transaction that is subject to Section&nbsp;280G of the Code: (1)&nbsp;cash payments not subject to Section&nbsp;409A of the Code; (2)&nbsp;cash payments subject to Section&nbsp;409A of the Code; (3)&nbsp;equity-based payments and acceleration; and <FONT
STYLE="white-space:nowrap">(4)&nbsp;non-cash</FONT> forms of benefits; provided that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg.
<FONT STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT STYLE="white-space:nowrap">Q&amp;A-24(b)</FONT> or (c) shall be reduced before any amounts that are subject to calculation under Treas. Reg.
<FONT STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT STYLE="white-space:nowrap">Q&amp;A-24(b)</FONT> or (c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;For purposes of this Section&nbsp;6(b), the &#147;After Tax Amount&#148; means the amount of the
Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on the Executive as a result of the Executive&#146;s receipt of the Aggregate Payments. For purposes of determining the After Tax Amount, the Executive
shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal
rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to
Section&nbsp;6(b)(i) shall be made by a nationally recognized accounting firm selected by the Company (the &#147;Accounting Firm&#148;), which shall provide detailed supporting calculations both to the Company and the Executive within 15 business
days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Executive. Any determination by the Accounting Firm shall be binding upon the Company and the Executive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>. For purposes of this Section&nbsp;6, the following terms shall have the following meanings:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Change in Control&#148; shall mean any of the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;any &#147;person,&#148; as such term is used in Sections 13(d) and 14(d) of the Securities Exchange
Act of 1934, as amended (the &#147;Act&#148;), any of its subsidiaries, or any trustee, fiduciary or other person or entity holding securities under any employee benefit plan or trust of Parent or any of its subsidiaries), together with all
&#147;affiliates&#148; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;associates&#148; (as such terms are defined in Rule <FONT
STYLE="white-space:nowrap">12b-2</FONT> under the Act) of such person, shall become the &#147;beneficial owner&#148; (as such term is defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Act), directly or indirectly, of securities
of Parent representing 50&nbsp;percent or more of the combined voting power of Parent&#146;s then outstanding securities having the right to vote in an election of the Board (&#147;Voting Securities&#148;) (in such case other than as a result of an
acquisition of securities directly from Parent); or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the date a majority of the members of the
Board is replaced during any <FONT STYLE="white-space:nowrap">12-month</FONT> period by directors whose appointment or election is not endorsed by a majority of the members of the Board before the date of the appointment or election; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;the consummation of (A)&nbsp;any consolidation or merger of Parent where the stockholders of
Parent, immediately prior to the consolidation or merger, would not, immediately after the consolidation or merger, beneficially own (as such term is defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Act), directly or
indirectly, shares representing in the aggregate more than 50&nbsp;percent of the voting shares of Parent issuing cash or securities in the consolidation or merger (or of its ultimate parent corporation, if any), or (B)&nbsp;any sale or other
transfer (in one transaction or a series of transactions contemplated or arranged by any party as a single plan) of all or substantially all of the assets of Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, a &#147;Change in Control&#148; shall not be deemed to have occurred for purposes of the foregoing clause
(i)&nbsp;solely as the result of an acquisition of securities by Parent which, by reducing the number of shares of Voting Securities outstanding, increases the proportionate number of Voting Securities beneficially owned by any person to
50&nbsp;percent or more of the combined voting power of all of the then outstanding Voting Securities; provided, however, that if any person referred to in this sentence shall thereafter become the beneficial owner of any additional shares of Voting
Securities (other than pursuant to a stock split, stock dividend, or similar transaction or as a result of an acquisition of securities directly from Parent) and immediately thereafter beneficially owns 50&nbsp;percent or more of the combined voting
power of all of the then outstanding Voting Securities, then a &#147;Change in Control&#148; shall be deemed to have occurred for purposes of the foregoing clause (i). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Section</U><U></U><U>&nbsp;409A</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive&#146;s separation from
service within the meaning of Section&nbsp;409A of the Code, the Company determines that the Executive is a &#147;specified employee&#148; within the meaning of Section&nbsp;409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit
that the Executive becomes entitled to under this Agreement or otherwise on account of the Executive&#146;s separation from service would be considered deferred compensation otherwise subject to the 20&nbsp;percent additional tax imposed pursuant to
Section&nbsp;409A(a) of the Code as a result of the application of Section&nbsp;409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A)&nbsp;six months and one
day after the Executive&#146;s separation from service, or (B)&nbsp;the Executive&#146;s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a
<FONT STYLE="white-space:nowrap">catch-up</FONT> payment covering amounts that would otherwise have been paid during the <FONT STYLE="white-space:nowrap">six-month</FONT> period but for the application of this provision, and the balance of the
installments shall be payable in accordance with their original schedule. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;All <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits
provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively
practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits provided or
reimbursable expenses incurred in one taxable year shall not affect the <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other
aggregate limitation applicable to medical expenses). Such right to reimbursement or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits is not subject to liquidation or exchange for another benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;To the extent that any payment or benefit described in this Agreement constitutes
<FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; under Section&nbsp;409A of the Code, and to the extent that such payment or benefit is payable upon the Executive&#146;s termination of employment, then such
payments or benefits shall be payable only upon the Executive&#146;s &#147;separation from service.&#148; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in
Treasury Regulation Section <FONT STYLE="white-space:nowrap">1.409A-1(h).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;The parties
intend that this Agreement will be administered in accordance with Section&nbsp;409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section&nbsp;409A of the Code, the provision shall be read in
such a manner so that all payments hereunder comply with Section&nbsp;409A of the Code. Each payment pursuant to this Agreement or the Restrictive Covenants Agreement is intended to constitute a separate payment for purposes of Treasury Regulation <FONT
STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2).</FONT> The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section&nbsp;409A of the Code and all related
rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;The Company makes no representation or warranty and shall have no liability to the Executive or any
other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section&nbsp;409A of the Code but do not satisfy an exemption from, or the conditions of, such Section. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Continuing</U><U> </U><U>Obligations</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Restrictive Covenants Agreement</U>. As a condition of employment, the Executive is required to enter into the
Employee Confidentiality, Assignment and Nonsolicitation Agreement, attached hereto as <U>Exhibit A</U> (the &#147;Restrictive Covenants Agreement&#148;). For the avoidance of doubt, the Restrictive Covenants Agreement is supplemental to
Section&nbsp;3 (&#147;Disclosure and Assignment of Work Product&#148;), Section&nbsp;4 (&#147;Confidentiality&#148;) and Section&nbsp;10 <FONT STYLE="white-space:nowrap">(&#147;Non-Solicitation&#148;)</FONT> of the Prior Agreement (collectively, the
&#147;Preserved Provisions&#148;), which remain in full force and effect. For purposes of this Agreement, the obligations in this Section&nbsp;8 and those that arise in the Restrictive Covenants Agreement, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Preserved Provisions and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the &#147;Continuing
Obligations.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Third-Party Agreements and Rights</U>. The Executive hereby confirms that the Executive
is not bound by the terms of any agreement with any previous employer or other party which restricts in any way the Executive&#146;s use or disclosure of information, other than confidentiality restrictions (if any), or the Executive&#146;s
engagement in any business. The Executive represents to the Company that the Executive&#146;s execution of this Agreement, the Executive&#146;s employment with the Company and the performance of the Executive&#146;s proposed duties for the Company
will not violate any obligations the Executive may have to any such previous employer or other party. In the Executive&#146;s work for the Company, the Executive will not disclose or make use of any information in violation of any agreements with or
rights of any such previous employer or other party, and the Executive will not bring to the premises of the Company any copies or other tangible embodiments of <FONT STYLE="white-space:nowrap">non-public</FONT> information belonging to or obtained
from any such previous employment or other party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Litigation and Regulatory Cooperation</U>. During and
after the Executive&#146;s employment, the Executive shall cooperate fully with the Company in (i)&nbsp;the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company
which relate to events or occurrences that transpired while the Executive was employed by the Company, and (ii)&nbsp;the investigation, whether internal or external, of any matters about which the Company believes the Executive may have knowledge or
information. The Executive&#146;s full cooperation in connection with such claims, actions or investigations shall include, but not be limited to, being available to meet with counsel to answer questions or to prepare for discovery or trial and to
act as a witness on behalf of the Company at mutually convenient times. During and after the Executive&#146;s employment, the Executive also shall cooperate fully with the Company in connection with any investigation or review of any federal, state
or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Executive was employed by the Company. The Company shall reimburse the Executive for any reasonable <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with the Executive&#146;s performance of obligations pursuant to this Section&nbsp;8(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Relief</U>. The Executive agrees that it would be difficult to measure any damages caused to the Company which
might result from any breach by the Executive of the Continuing Obligations, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly<B>, </B>the Executive agrees that if the Executive breaches, or proposes
to breach, any portion of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other appropriate equitable relief to restrain any such breach without showing or proving
any actual damage to the Company. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Arbitration of</U><U> </U><U>Disputes</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Arbitration Generally</U>. Any controversy or claim arising out of or relating to this Agreement or the breach
thereof or otherwise arising out of the Executive&#146;s employment or the termination of that employment (including, without limitation, any claims of unlawful </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employment discrimination or retaliation, whether based on race, religion, national origin, sex, gender, age, disability, sexual orientation, or any other protected class under applicable law)
shall, to the fullest extent permitted by law, be settled by arbitration in any forum and form agreed upon by the parties or, in the absence of such an agreement, under the auspices of JAMS in Boston, Massachusetts in accordance with the JAMS
Employment Arbitration Rules, including, but not limited to, the rules and procedures applicable to the selection of arbitrators. The Executive understands that the Executive may only bring such claims in the Executive&#146;s individual capacity,
and not as a plaintiff or class member in any purported class proceeding or any purported representative proceeding. The Executive further understands that, by signing this Agreement, the Company and the Executive are giving up any right they may
have to a jury trial on all claims they may have against each other. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. This Section&nbsp;9 shall be specifically enforceable. Notwithstanding
the foregoing, this Section&nbsp;9 shall not preclude either party from pursuing a court action for the sole purpose of obtaining a temporary restraining order or a preliminary injunction in circumstances in which such relief is appropriate,
including without limitation relief sought under the Restrictive Covenants Agreement; provided that any other relief shall be pursued through an arbitration proceeding pursuant to this Section&nbsp;9. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Arbitration Fees and Costs</U>. The Executive shall be required to pay an arbitration fee to initiate any
arbitration equal to what the Executive would be charged as a first appearance fee in court. The Company shall advance the remaining fees and costs of the arbitrator. However, to the extent permissible under the law, and following the
arbitrator&#146;s ruling on the matter, the arbitrator may rule that the arbitrator&#146;s fees and costs be distributed in an alternative manner. Each party shall pay its own costs and attorneys&#146; fees, if any. If, however, any party prevails
on a statutory or contractual claim that affords the prevailing party attorneys&#146; fees (including pursuant to this Agreement), the arbitrator may award attorneys&#146; fees to the prevailing party to the extent permitted by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Consent to Jurisdiction</U>. The parties hereby consent to the jurisdiction of the state and federal courts of
the Commonwealth of Massachusetts. Accordingly, with respect to any such court action, the Executive (a)&nbsp;submits to the exclusive personal jurisdiction of such courts; (b) consents to service of process; and (c)&nbsp;waives any other
requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&nbsp;&nbsp;&nbsp;&nbsp;<U>Integration</U>. This Agreement constitutes the entire agreement between the parties with respect to the subject
matter hereof and supersedes all prior agreements between the parties concerning such subject matter, including the Prior Agreement, provided that the Preserved Provisions and the Restrictive Covenants Agreement remain in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&nbsp;&nbsp;&nbsp;&nbsp;<U>Withholding; Tax Effect</U>. All payments made by the Company to the Executive under this Agreement shall be net
of any tax or other amounts required to be withheld by the Company under applicable law. Nothing in this Agreement shall be construed to require the Company to make any payments to compensate the Executive for any adverse tax effect associated with
any payments or benefits or for any deduction or withholding from any payment or benefit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors and Assigns</U>. Neither the Executive nor the
Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement
(including the Restrictive Covenants Agreement) without the Executive&#146;s consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization or consolidation, into which the Company merges or to whom
it transfers all or substantially all of its properties or assets; provided further that if the Executive remains employed or becomes employed by the Company, the purchaser or any of their affiliates in connection with any such transaction, then the
Executive shall not be entitled to any payments, benefits or vesting pursuant to Section&nbsp;5 or pursuant to Section&nbsp;6 of this Agreement solely as a result of such transaction. This Agreement shall inure to the benefit of and be binding upon
the Executive and the Company, and each of the Executive&#146;s and the Company&#146;s respective successors, executors, administrators, heirs and permitted assigns. In the event of the Executive&#146;s death after the Executive&#146;s termination
of employment but prior to the completion by the Company of all payments due to the Executive under this Agreement, the Company shall continue such payments to the Executive&#146;s beneficiary designated in writing to the Company prior to the
Executive&#146;s death (or to the Executive&#146;s estate, if the Executive fails to make such designation). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.&nbsp;&nbsp;&nbsp;&nbsp;<U>Enforceability</U>. If any portion or provision of this Agreement (including, without limitation, any portion or
provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other
than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U>. The provisions of this Agreement shall survive the termination of this Agreement and/or the
termination of the Executive&#146;s employment to the extent necessary to effectuate the terms contained herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver</U>. No waiver of any provision hereof shall be effective unless made in writing and signed by the
waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be
deemed a waiver of any subsequent breach. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>. Any notices, requests, demands and other
communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to
the Executive at the last address the Executive has filed in writing with the Company or, in the case of the Company, at its main offices, attention of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18.&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment</U>. This Agreement may be amended or modified only by a written instrument signed by the Executive
and by a duly authorized representative of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.&nbsp;&nbsp;&nbsp;&nbsp;<U>Effect on Other Plans and Agreements</U>. An election by the
Executive to resign for Good Reason under the provisions of this Agreement shall not be deemed a voluntary termination of employment by the Executive for the purpose of interpreting the provisions of any of the Company&#146;s benefit plans, programs
or policies. Nothing in this Agreement shall be construed to limit the rights of the Executive under the Company&#146;s benefit plans, programs or policies except as otherwise provided in Section&nbsp;8 hereof, and except that the Executive shall
have no rights to any severance benefits under any Company severance pay plan, offer letter or otherwise. In the event that the Executive is party to an agreement with the Company providing for payments or benefits under such plan or agreement and
under this Agreement, the terms of this Agreement shall govern and the Executive may receive payment under this Agreement only and not both. Further, Section&nbsp;5 and Section&nbsp;6 of this Agreement are mutually exclusive and in no event shall
the Executive be entitled to payments or benefits pursuant to both Section&nbsp;5 and Section&nbsp;6 of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20.&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing Law</U>. This is a Massachusetts contract and shall be construed under and be governed in all respects
by the laws of the Commonwealth of Massachusetts, without giving effect to the conflict of laws principles thereof. With respect to any disputes concerning federal law, such disputes shall be determined in accordance with the law as it would be
interpreted and applied by the United States Court of Appeals for the 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> Circuit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.&nbsp;&nbsp;&nbsp;&nbsp;<U>Conditions</U>. Notwithstanding anything to the contrary herein, the effectiveness of this Agreement shall be
conditioned on (i)&nbsp;the Executive&#146;s satisfactory completion of reference and background checks, if so requested by the Company, and (ii)&nbsp;the Executive&#146;s submission of satisfactory proof of the Executive&#146;s legal authorization
to work in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22.&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>. This Agreement may be executed in any number of
counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement effective on
the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ADICET THERAPEUTICS, INC./RESTORBIO, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Chen Schor</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chen Schor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">NICK HARVEY</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Nick Harvey</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Nick Harvey</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>[Exhibit A</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Restrictive Covenants Agreement] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>7
<FILENAME>d91031dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MANAGEMENT FOLLOWING THE MERGER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors of the Combined Company Following the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the merger, the resTORbio Board is expected to consist of seven directors. Pursuant to the merger agreement, all of the current directors of
resTORbio, other than Chen Schor, who is expected to act as the Chief Executive Officer of the combined company, and Jeffrey Chodakewitz, the designee selected by resTORbio to remain on the resTORbio Board, will resign from the resTORbio Board
effective and contingent upon the closing of the merger. Such remaining directors will then elect, effective as of the effective time of the merger, up to five designees selected by Adicet, each to serve as members of the resTORbio Board until each
of their respective successors are duly elected or appointed and qualified or their earlier death, resignation or removal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than pursuant to the
merger agreement, there are no arrangements or understanding between any of the expected directors or executive officers of the combined company and any other person pursuant to which he or she was or is to be selected as a director or executive
officer. There are no family relationships between any of the expected directors or executive officers of the combined company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table
provides information regarding the expected directors and executive officers of the combined company following the closing of the merger </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="66%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Executive Officers</I></B><B></B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chen Schor</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer, President, Secretary and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stewart Abbot</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Senior Vice President, Chief Scientific Officer and Chief Operating Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Francesco Galimi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Senior Vice President and Chief Medical Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lloyd Klickstein</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Innovation Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carrie Krehlik</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Senior Vice President and Chief Human Resource Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Directors</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey Chodakewitz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Erez Chimovits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steve Dubin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carl Gordon</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aya Jakobovits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yair Schindel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc923175_103b"></A>ADICET EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adicet&#146;s Senior Vice President, Chief Scientific Officer and Chief Operating Officer, Stewart Abbot, Senior Vice President and Chief Medical Officer,
Francesco Galimi, and Senior Vice President and Chief Human Resource Officer, Carrie Krehlik will each become an executive officer of the combined company, referred to in this section as Adicet&#146;s &#147;named executive officers&#148; or
&#147;NEOs.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
following table shows information regarding compensation of Adicet&#146;s NEOs for the fiscal years ended December&nbsp;31, 2019 and 2018. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Awards<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Non-Equity</B><br><B>Incentive Plan</B><br><B>Compensation<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other</B><br><B>Compensation<SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="font-size:5pt">(5)</FONT></SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Stewart Abbot</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">397,083</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">187,500</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">95,365</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">127,067</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">39,159</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">846,174</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Senior Vice President, Chief Scientific Officer and Chief Operating Officer<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">192,299</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">137,500</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">31,271</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">62,198</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">12,492</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">435,760</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Francesco Galimi</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">105,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">162,500</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">18,882</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">29,400</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">15,550</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">331,332</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Senior Vice President and Chief Medical Officer<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Carrie Krehlik</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">297,917</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">30,486</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">83,417</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">720</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">412,540</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Senior Vice President and Chief Human Resources Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">272,301</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">29,140</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">90,382</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">1,520</TD>
<TD NOWRAP VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">393,344</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Abbot commenced employment with Adicet in June 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Galimi commenced employment with Adicet in September 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Initial grants of options issued to NEOs vest 25% on the <FONT STYLE="white-space:nowrap">one-year</FONT>
anniversary of grant, and in 36 equal monthly installments upon completion of each additional month of service thereafter. Grants made to Dr.&nbsp;Abbot and Ms.&nbsp;Krehlik in 2019 vest in 48 equal monthly installments. Represents the aggregate
grant date fair value of the option awards granted during the relevant fiscal year computed in accordance with FASB Topic ASC 718. The assumptions used in the valuation of these awards are consistent with the valuation methodologies specified in
Note 15 to Adicet&#146;s financial statements included in this proxy statement/prospectus/information statement. These amounts do not correspond to the actual value that will be recognized by the NEO with respect to such awards.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts in this column represent amounts awarded as bonuses paid under Adicet&#146;s annual cash incentive
plan, as discussed under &#147;<I>&#151;Narrative Disclosure to Summary Compensation Table&#151;Annual Cash Incentive</I>&#148; below. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents commuter and cell phone stipends. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes a gift card received by Ms. Krehlik. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative Disclosure to Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Offer Letters </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adicet has entered into offer
letters with its NEOs (referred to in this section as the &#147;offer letters&#148;). The offer letters set forth the NEOs&#146; base salaries, performance bonus opportunities, <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus if applicable,
equity incentive and other employee benefits that are described in this <I>Adicet Executive Compensation</I> section. The offer letters provide for <FONT STYLE="white-space:nowrap">&#147;at-will&#148;</FONT> employment, meaning that either party can
terminate the employment relationship at any time, although these offer letters provide that the NEOs would be eligible for severance benefits in certain circumstances following a termination of employment without cause (other than for death or
disability) or resignation for good reason (as defined in the offer letters). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Termination Without &#147;Cause&#148; or For &#147;Good Reason&#148; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the NEO&#146;s termination by Adicet without cause (other than for death or disability) or resignation by the NEO for good reason and subject to
execution and nonrevocation of a release of claims, the offer letters provide for: (i)&nbsp;six months&#146; base salary payable in a lump sum, (ii)&nbsp;monthly premium payments to continue the NEO&#146;s health insurance coverage for up to six
months following his or her termination, and (iii)&nbsp;if such termination occurs with 12 months following a &#147;Liquidation,&#148; acceleration of all outstanding and unvested equity awards, however resTORbio notes that the merger will not
constitute a Liquidation (as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Cause&#148; is generally defined as the NEO&#146;s: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(A) performance of any act or failure to perform any act in bad faith and to the detriment of Adicet or its affiliates, including, but not
limited to, misappropriation of trade secrets, fraud or embezzlement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(B) material breach of any agreement with Adicet or its affiliates;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(C) commission of a crime involving dishonesty, breach of trust, or physical or emotional harm to any person, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(D) willful refusal to implement or follow a lawful policy or directive of Adicet or its affiliates; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(E) engagement in misfeasance or malfeasance demonstrated by a pattern of failure to perform job duties diligently and professionally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Good Reason&#148; is general defined as the following actions taken without the consent of the NEO, subject to notice and cure periods: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(1) a change in the NEO&#146;s position with Adicet which materially and substantially reduces the level of responsibility or duties; provided,
however, that if Adicet is being acquired and made part of a larger entity, a change in the NEO&#146;s position shall not constitute Good Reason if such change does not result in a material and substantial reduction in the NEOs level of
responsibility or duties with respect to Adicet&#146;s business operations (whether as a subsidiary, business unit, division or otherwise of the acquirer) following such acquisition; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(2) a material reduction in the NEO&#146;s base salary, except for reductions that are comparable to reductions generally applicable to
similarly situated executives of Adicet; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(3) a relocation of the NEO&#146;s principal place of employment by more than seventy-five
(75)&nbsp;miles from Adicet&#146;s current headquarters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Liquidation&#148; has the meaning as set forth in Adicet&#146;s certificate of
incorporation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Compensation Elements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following describes the material terms of the elements of Adicet&#146;s executive compensation program during 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Base Salaries </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adicet&#146;s Board and compensation
committee recognize the importance of base salary as an element of compensation that helps to attract and retain the NEOs. Adicet provides base salary as a fixed source of income for its NEOs for the services they provide to Adicet during the year,
and allows Adicet to maintain a stable executive team. The current base salaries for Adicet&#146;s NEOs are as follows: $400,000 for Dr.&nbsp;Abbot (increased in 2019 in connection with Dr.&nbsp;Abbot&#146;s promotion to his current role), $385,000
for Dr.&nbsp;Galimi, and $300,000 for Ms.&nbsp;Krehlik (increased in 2019 to reflect a market adjustment). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Annual Cash Incentive </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adicet also provides its NEOs with annual performance-based cash bonus opportunities, which are specifically designed to reward NEOs for the overall
performance of Adicet in a given year. The target annual cash bonus amounts relative to base salary vary depending on each NEOs&#146; accountability, scope of responsibilities, potential impact on Adicet&#146;s performance and in alignment with the
external market. The NEOs&#146; current target performance-based cash bonuses opportunities are: 40% of base salary for Dr.&nbsp;Abbot and 35% of base salary for Dr.&nbsp;Galimi and Ms.&nbsp;Krehlik. Such bonuses are
<FONT STYLE="white-space:nowrap">pro-rated</FONT> for any partial year of employment and are paid, if applicable, during the first quarter of 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Adicet Board considers Adicet&#146;s overall performance for the preceding fiscal year and achievement of certain performance targets developed by the Adicet Board in deciding whether to award a bonus and, if one is to be awarded, the amount of the
bonus. The Adicet Board retains the ability to apply discretion in making adjustments to the final bonus payouts.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Equity Compensation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Adicet Board considers equity
incentives to be important in aligning the interests of the NEOs with those of its stockholders. As part of Adicet&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">pay-for-performance</FONT></FONT> philosophy, its
compensation program tends to emphasize the long-term equity award component of total compensation packages paid to its NEOs. In determining the size of the equity incentives to be awarded to Adicet&#146;s NEOs, it takes into account a number of
internal factors, such as the relative job scope, the value of existing long-term incentive awards, individual performance history, prior contributions and anticipated future contributions to Adicet and the size of prior grants. Adicet uses stock
options to compensate its NEOs both in the form of initial grants in connection with the commencement of employment and periodic refresher grants. Because employees are able to profit from stock options only if Adicet&#146;s stock price increases
relative to the stock option&#146;s exercise price, Adicet believes stock options in particular provide meaningful incentives to employees to achieve increases in the value of Adicet stock over time. While Adicet intends that the majority of equity
awards to its employees be made pursuant to initial grants or its periodic refresh grants, the Adicet Board retains discretion to grant equity awards to employees at other times, including in connection with the promotion of an employee, to reward
an employee, for retention purposes or for other circumstances recommended by management or the Adicet Board. The exercise price of each stock option grant is the fair market value of Adicet&#146;s common stock on the grant date. Adicet does not
have any stock ownership requirements for its named executive officers. Each of the outstanding equity incentive awards held by Dr. Abbot, Dr. Galimi and Ms. Krehlik were issued pursuant to the Adicet 2015 plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Adicet Bio Inc.&#146;s 2015 Stock Incentive Plan</I>. The Adicet 2015 plan was originally adopted by the Board/approved by the stockholders of Adicet on
August&nbsp;13, 2015 and most recently amended in October 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Adicet 2015 plan allows Adicet to provide incentive stock options, within the meaning
of Section&nbsp;422 of the Code, nonstatutory stock options, stock appreciation rights, restricted stock awards and restricted stock units (each, an &#147;award&#148; and the recipient of such award, a &#147;participant&#148;) to eligible employees,
directors, officers and consultants of Adicet. Following the completion of the merger, certain outstanding Adicet awards will be converted into options to purchase common stock of resTORbio as described in more detail in the section entitled
&#147;<I>The Merger Agreement&#151;Merger Consideration and Exchange Ratio</I>&#148; beginning on page 207 of this proxy statement/prospectus/information statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Share Reserve.</I> In connection with the most recent amendment of the Adicet 2015 plan, Adicet authorized an aggregate of 21,594,044 shares of Adicet
common stock for issuance under the Adicet 2015 plan. As of August&nbsp;4, 2020, 13,462,799 shares of Adicet&#146;s common stock were issuable upon the exercise of outstanding stock options granted under the Adicet 2015 plan, and there were no other
awards outstanding under the Adicet 2015 plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Eligibility.</I> Awards other than incentive stock options may be granted to employees, directors and
consultants of Adicet. Incentive stock options may be granted only to employees of the Adicet or a subsidiary. Awards may also be granted to such employees, directors or consultants who are residing in
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions as the administrator may determine from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Administration. </I>The Adicet
2015 plan is administered by the Adicet Board or a committee thereof. The administrator has all authority and discretion necessary or appropriate to administer the Adicet 2015 plan and to control its operation, including the authority to construe
and interpret the terms of Adicet 2015 Plan and the awards granted thereunder. The administrator&#146;s decisions are final and binding on all participants and any other persons holding awards </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Corporate Transaction.</I> In the event of a corporate transaction, as defined in the Adicet 2015 plan, unless otherwise provided in an applicable award
agreement, outstanding awards that are not assumed will terminate (with vested option holders having the ability to exercise prior to closing). The Adicet 2015 plan administrator also has the option to accelerate all or a portion of any unvested
awards in connection with a corporate transaction </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Employee Benefits Program </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adicet&#146;s NEOs are eligible to participate in regular health insurance, vacation, and other employee benefit plans established by Adicet for its employees
on the same terms as are made available to employees of Adicet generally. These benefit programs are designed to enable Adicet to attract and retain its workforce in a competitive marketplace. Health, welfare and vacation benefits ensure that Adicet
has a productive and focused workforce through reliable and competitive health and other benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Galimi and Dr.&nbsp;Abbot are each entitled
to fully taxable reimbursements for reasonable travel and lodging expenses of up to $6,000 per month (for two years from start of employment with respect to Dr. Galimi, and for three years from start of employment, with respect to Dr. Abbot) for
travel to the San Francisco Bay Area in order to provide services to Adicet under their offer letters, and, in the alternative, a <FONT STYLE="white-space:nowrap">one-time</FONT> taxable lump sum payment of up to $60,000 for reasonable moving
expenses if the NEO permanently relocates to the San Francisco Bay Area in order to provide services to Adicet. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adicet currently maintains a 401(k)
retirement savings plan that allows eligible participants to defer a portion of their compensation, within limits prescribed by the Internal Revenue Code, on a <FONT STYLE="white-space:nowrap">pre-tax</FONT> or
<FONT STYLE="white-space:nowrap">after-tax</FONT> basis through contributions to the plan. Adicet&#146;s NEOs are eligible to participate in the 401(k) plan on the same terms as other full-time employees generally. No matching contributions were
provided in 2019. Adicet believes that providing a vehicle for retirement savings through Adicet&#146;s 401(k) plan adds to the overall desirability of Adicet&#146;s executive compensation package and further incentivizes Adicet employees, including
Adicet&#146;s NEOs, in accordance with Adicet&#146;s compensation policies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at August&nbsp;4, 2020 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth specified information concerning outstanding equity incentive plan awards for each of the NEOs outstanding as of August&nbsp;4,
2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>Exercisable<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR><FONT STYLE="white-space:nowrap">Non-Exercisable</FONT><BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Stewart Abbot</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/15/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86,418 </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">374,482</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/15/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Senior Vice President, Chief Scientific Officer and Chief Operating Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">8/14/2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR></TD>
<TD VALIGN="top" ALIGN="right">356,145<BR></TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">327,655</TD>
<TD NOWRAP VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">0.280</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">8/14/2028</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Francesco Galimi</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/15/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,035,685</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/15/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Senior Vice President and Chief Medical Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Carrie Krehlik</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/15/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,362 </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,238</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/15/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Senior Vice President and Chief Human Resources Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">12/13/2017<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">100,000<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">50,000<BR></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$<BR></TD>
<TD VALIGN="bottom" ALIGN="right">0.280<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">12/13/2027<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">25% of the options vest 12 months after the vesting commencement date and 1/36th of the remaining options vest
on each of the next 36 monthly anniversaries thereafter, provided that the NEO remains in continuous service as of the applicable vesting date. The vesting commencement dates are as follows: 6/27/2018 for Dr.&nbsp;Abbot, 11/27/2017 for
Ms.&nbsp;Krehlik, and 9/23/2019 for Dr.&nbsp;Galimi. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">1/48th of these options vest on each of the 48 monthly anniversaries of the grant date, provided that the NEO
remains in continuous service as of the applicable vesting date. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Securities Authorized for Issuance under Equity Compensation Plans
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides information as of August&nbsp;4, 2020 about Adicet common stock which may be issued under the Adicet plans: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Plan Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;securities&nbsp;to<BR>be&nbsp;issued&nbsp;upon&nbsp;exercise<BR>of outstanding options,<BR>warrants and rights</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-average</FONT><BR>exercise price of<BR>outstanding&nbsp;options,<BR>warrants and rights</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of securities<BR>remaining&nbsp;available&nbsp;for<BR>future issuance under<BR>equity compensation<BR>plans (excluding<BR>securities reflected
in<BR>column (a))</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(a)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(b)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(c)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans approved by security holders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,839,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,247,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by security holders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,839,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,247,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>acet-20200915.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-5 Build:20200707.2 -->
<!-- Creation date: 9/18/2020 11:21:29 PM Eastern Time -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2019-01-31"
  xmlns:acet="http://www.adicetbio.com/20200915"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.adicetbio.com/20200915"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acet-20200915_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acet-20200915_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.adicetbio.com//20200915/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>acet-20200915_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-5 Build:20200707.2 -->
<!-- Creation date: 9/18/2020 11:21:30 PM Eastern Time -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>acet-20200915_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-5 Build:20200707.2 -->
<!-- Creation date: 9/18/2020 11:21:30 PM Eastern Time -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.adicetbio.com//20200915/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="acet-20200915.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adicetbio.com//20200915/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>d91031d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="acet-20200915.xsd" xlink:type="simple"/>
    <context id="duration_2020-09-15_to_2020-09-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <startDate>2020-09-15</startDate>
            <endDate>2020-09-15</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2020-09-15_to_2020-09-15">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2020-09-15_to_2020-09-15"
      id="Hidden_dei_EntityCentralIndexKey">0001720580</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2020-09-15_to_2020-09-15">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2020-09-15_to_2020-09-15">2020-09-15</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2020-09-15_to_2020-09-15">Adicet Bio, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2020-09-15_to_2020-09-15">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2020-09-15_to_2020-09-15">001-38359</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2020-09-15_to_2020-09-15">81-3305277</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2020-09-15_to_2020-09-15">500 Boylston Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2020-09-15_to_2020-09-15">13th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2020-09-15_to_2020-09-15">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2020-09-15_to_2020-09-15">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2020-09-15_to_2020-09-15">02116</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2020-09-15_to_2020-09-15">(857)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2020-09-15_to_2020-09-15">315-5528</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2020-09-15_to_2020-09-15">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2020-09-15_to_2020-09-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2020-09-15_to_2020-09-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2020-09-15_to_2020-09-15">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2020-09-15_to_2020-09-15">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2020-09-15_to_2020-09-15">ACET</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2020-09-15_to_2020-09-15">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2020-09-15_to_2020-09-15">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2020-09-15_to_2020-09-15">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140556211210328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 15, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001720580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 15,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Adicet Bio, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-3305277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">500 Boylston Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">13th Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(857)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">315-5528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ACET<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M%     @ VX,R48.II0/4 0  ,@8   T   !X;"]S='EL97,N>&ULU57;BM1
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ VX,R41PX9>H_ 0  / (
M  \   !X;"]W;W)K8F]O:RYX;6R-4<MNPD ,_)75?D 34(M41+B4/I"J%I6*
M^Y)UB,4^(J\#+5]?)U%4I%YZ\GILC6=F%^=(QWV,1_7E74B%KIF;>9:EL@9O
MTDUL(,BDBN0-2TN'+#4$QJ8:@+W+IGD^R[S!H)>+D6M#V743&4K&& 3L@!W"
M.?W.NU:=,.$>'?)WH?NW ZT\!O1X 5OH7*M4Q_-+)+S$P,9M2XK.%7HR#'9
MC.4?>-N)_#3[U"-L]A]&A!1ZE@MAA92XW^CYC6@\@2P/7<OQ"1T#K0S#,\6V
MP7#H:,1%=F6CSV&L0XAS^D^,L:JPA%4L6P^!AQP)7"<PI!J;I%4P'@H]KB@3
MK'H,+"&I=1BH9+=S*J?7=G#-(O<J0YJC#&AM!^&C6@L5!K!O<B )+LF5&U)=
MZ7FFMW>3>TFH=>Y!L/?P&HT=S8\?M_P!4$L#!!0    ( -N#,E$D'INBK0
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ VX,R4>WT3K'O    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
MVX,R49E<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " #;@S)1M[ /7& $  !W$0  &
M    @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
MVX,R48.II0/4 0  ,@8   T              ( !I P  'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    " #;@S)1EXJ[',     3 @  "P              @ &C
M#@  7W)E;',O+G)E;'-02P$"% ,4    " #;@S)1'#AEZC\!   \ @  #P
M            @ &,#P  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ VX,R
M420>FZ*M    ^ $  !H              ( !^!   'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ VX,R4660>9(9 0  SP,  !,
M         ( !W1$  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^
) @  )Q,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d91031d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com//20200915/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d91031d8k.htm">d91031d8k.htm</File>
    <File>acet-20200915.xsd</File>
    <File>acet-20200915_lab.xml</File>
    <File>acet-20200915_pre.xml</File>
    <File>d91031dex101.htm</File>
    <File>d91031dex102.htm</File>
    <File>d91031dex103.htm</File>
    <File>d91031dex104.htm</File>
    <File>d91031dex105.htm</File>
    <File>d91031dex991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d91031d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d91031d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "acet-20200915_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "acet-20200915_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "acet-20200915.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "acet",
   "nsuri": "http://www.adicetbio.com/20200915",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d91031d8k.htm",
      "contextRef": "duration_2020-09-15_to_2020-09-15",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.adicetbio.com//20200915/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d91031d8k.htm",
      "contextRef": "duration_2020-09-15_to_2020-09-15",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20200915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20200915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20200915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20200915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20200915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20200915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20200915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20200915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20200915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20200915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20200915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20200915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20200915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20200915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20200915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20200915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20200915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20200915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20200915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20200915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20200915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20200915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20200915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20200915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001193125-20-249151-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-20-249151-xbrl.zip
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M:?TAC*CPTJ^@W#+Z0"-V/*,M>7/V;$:KMZ!L\B1M-FVGD>-.RLT9]QI9#6R
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M?$RH==QL.<Z;;Q46/\"_'<LA3"Z%$D2&A]0G[(ZY<<1O,><$[I"IW9<=).W
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M,N$A):%040WH95(QVU,5^CPBU/LSUCWN4\55]2%",')("2GISQO3G[JFQPY
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MN<V#JB7;JI8R8P5PU:X>K BN\NU\1P"KP, 7#+*6%HXLT+K_I4>!K0S'_BZ
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MJ]CFB/M)Y&,*&4>R@)V+$KU+*EE-1 $/B.W'$A#OS=9][<:.9Y@,=%FA'['
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MD/8@KQ-KG&<>E:R5;D_!#M;UE1V H0XW=DC%QQQ:I*BM@]Y1KC&"D.36?1F
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MRE5(['$]5#BRKYE(1L5?Y:ALY:I,]TXBYP7_>Z*W!JBWP;CO>(J C75[Z<4
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MWS)M+=IJTL&T4 $<CZ1(:!SLKS.>CLK[XK#-S^NHXVW98 2&C?HI^!<3754
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MAD#(_^?.J^?<X:_O7OX#?OGZ_+<WA_\?4$L#!!0    ( -N#,E&JJ2AK'#P
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M+#P_3]=Z_+QV&;<94E]>GO54#Q8SCYOP@-%"Q04+-OA#LV;L18R\P%U/P"A
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M"QLMX<6B3"WT%HMG!*>Q_V0/08TZVN*X%+0"R*,HV+=,<)ML:MC7%S^?O;T
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MDE 0R-DT%W!8<I!.UQ-?IQ:.3XTA;-:X"5J\K\OX1GSP: YW?3!;#-7T3D3
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MF6[C@5"4!#LT&KISCV7UE$$Z4ZP'YI::Z=@):^'E3#SX"F6$%<J<S2+^F"U
MK['* 2:X]6TBKRS1^EDYE:*[)+12\[HV@\/5T2!?Q7T=OK 7G6/S.W[$_C:M
MTS4(=72T\T"9QLN/&?;^\]3>I)!:Z?D-]5V_+"A;7\!3BE+!;-RAUB>^<TB_
M\C.\8M5LIYZ1!D6YOPIVG6F7Y,S!GDZ6Y=<1',J\T[*ET\9#1Z[]: HUCD=N
M3;;>?'ELDN'D<9>5Z0*J_3KLB:FYJ;4I6F>SE+M%J+QI<<U:_W#EE6"/['GH
M=B$F-7MPT5]==8I7J(.[.?,;R**)KQ&+'<F[02BZ_V>!VNIG"!'<I=77K>WI
M@7#%GOI=/5595R9AWC>.A1/FU7$*\436Y#9&C+CKA1O(5T?[%!Z(=+G_B (%
MM9L3K#ON['+RD<M/@M*@<YL>/AJ*H(='#*MP2AFX]0LFNLQ!4[4UM62?@3!*
MLI@+D$M2-:V"XCLQ#?HF$M<.(JIZ8FM+;U3\"9Q$;Y<(=U8$R5\RM^:*ZE@#
MBQ=EBRWH7?V&PYZ>? ?H_DR 3BBDKLO$I9 5'4GA]IVW^09^E_V#Z<Z!-EML
M,B)<L6VC+,EM-Z*'U2YS'?D^4/G>\KI@]ULX.RJ&=?O)/4QW'O9/3G<?S>D^
MHRCDGR8T:WM_[;4TU83PAO^XQ]<"EI;(G:5H5^%,L,(I3?6JE&YTUQR\X=<M
M)@0/JTJ8<J;VPR"3"+C!X<A;B+H)#*<DIM0XO>63+ZFNBV1P_LZ?M0Q21PMM
M90(H,2S0F*IE@>&#OTG^TV:ZB9ZW)V;G2#GF)6V3:_3^A<_JB#YR'2,:_&^I
M_RUF E7#J?VM)%4,>#1""$Y7PT_NHDBU!DW'V^MY61.N7&9%HP%L<Z;2P 0D
M5UD)(KKAK 7L,(LM3>_PO@]]+8>V^M1"S-#K2968M&>)0%MPYW5[<:^I4C9!
MW!BNAT*:MTV7$9\,1Q8/C*Z1?#@D_V4;X#[XIF5WR'NN"Y_119^3SV'2FF5T
MP([APOM\3>R^V-A]-H:_P_*8LH3#R6!VU[$[(=M8-76C</B'Z='5?W);7'Z&
M(C1R,(PXE:[B]!_3R%FW'@SBU"BR)V:_$K$WX* (+\]P8 D$</%FJF5=JTIX
MO?,G;KUC(@3QP:I"'9.O(S8XI>J\Q#G!%+Q$9Q6H=-O&B])79U[?Q[I6C;-=
M=S>Q;JT6K"G#& _E37F&B/0B"$J0Z3+I/54/70 ZR3$O:#PR)H,$Q<:,!FXH
MC> PS$6G7E%3Z22@%U6T5.L,WS)$VA&0KAB>F(+Z/!$,,^/P3R1%.UQWD/!N
M.[3"M@+"))^J.SCDTU$<.E-9&5'C3*C2D2<$ ;+AC,R 8D4DR0WYI^ZJ9'2W
M4&N38 (WK#+<;D*(]%:YW<-<'V\LP=;U,L=V@?P#88$@#>FN2U^'SC6^JP;#
M:6(.,_<6[A]L?4L-$'L0?\HQBI=WL\MXQXN(\=WW4*[^)RI7+[:^!.?(?ZRO
M[:NK4'^GF)R9E]LQY&=P"KPAF8Y'TA7DTR+"7(3/:8;1$T>)/46$WFS%98U>
MW"XH#39PZV ;A#,BP3W!"WZI2Q*I)O9(8!+Q9O;'$A#NDC/!]_;<<J-"@J+<
MF^QY9+9<.P8H@B25P-F>H#WG<T&@PT' ,-SX<R?X81A1EPUU]['/7R5(L^9Z
MMS@3-]S1E^\F)4D70]88EO^4CLJP$<$V5C=C6=J7R%!G'TT>.*;68'8DQAQ:
M97K3<^KF+'3>I-KNIJ,]-R^7= LOV#NKG:,TP4H%M]LQE5FP45$FG4<X3WV@
MU,4&\:%#M2XH4)O,3]=['>:8!.E@3D["V@_#_O<;K&UC7($!5=$U,^GP-E!J
M&N>Q3=U'>\,I8N,$I?)V]E>UR;"9;\8^S#J9@RJ7JV^WF<33[U#F%ZF;A_64
MUU(ZS.4#?%O3N8Z=L45L='T/K.4=9!)XE;W[I8TE<#U<UV\''(%5LDZ.H'-E
MG4*<=9B([]>-QV4'-<>#.MSPBY)]O7&*(0C438X*:>.RJ5 4NR7#]'TI@4+5
ME]VEFY$->W:CQ&GZG"G 80-^80WO3UY$@:Z@?HUN4-DDKM9BPT(^]8#M@2 (
MHI=#$S&';0Y&HP3N3*V<XUYRFS'6H=E(I)R=D[L!*\E.TEK%=G)GN.4T[,-'
M\FRF6+TT0(A%=7(3_!Y$@>AD%ST7, C>4TBB1J#]Z6S2''!H$P3C=+2D/ -[
MS<)!2GQZLB1>L[S^=;FD+X+,D'A(F<5^PDF5376(IL<];!&ISYA-TE.XKFLK
MD#3OKLG3#YU%94X^D0XFZ):M\ N_VY LL05P<&!(.LS$#M^C-U!L[_"GQ';I
M5Q%W92.ZT3 P*Q,*@[EZ;'@/601N.\ @R&6@6!_"K.U"\H1=ICX>]54$DS/:
M /WE8F#[6W._$M@7[<8[W/H -QJ14D9^L6::-CHSKP.Z3NK54DI58=<(WLJ5
MM!NV3[!WT30MZZ8.H,&[F&:7;=G6$A.%9,>M=3?\<%  S(U"C=-(>]U,(D)=
MBETK.:A,]#:=@+Y]L]&"-ZU9)U*FMQ.]OQF?H[+=2H?9)K7M7#*BZ@R6BIS9
M2WL'"?J@ )"A>"JIJD8@/K,\VQZB4)37R:7>.65]XQ/AH4@M(\\!Z!MM+OF_
M;O*(6Z_ -),G(G)CQKL:C"4275[+01*2LJ:S=Q=W'[)RN#GWA:,.+^(/U,3<
MZ]0C%>+(V2+%_)TH+2PHD.EF:IV\YM)-YQ6$.YMAGO%-7\T_IVY!9:5!A_#[
M@9Y-4P-(KTY+5G:HB\ -^>\_*I8%)%8F^GJ:EJ4UE1LDKB'#WP,V^X2P6=N?
M(<BA['2'^HH 6NZXLXK5\92/$$&SC6*[JHF/C"(+R<1?0F8R<DO=I4-'>!V'
M32J.:BSV9BIDO&7/9Z)U<+>'9]/$B'E(TT^J5OO;X<G'>38%38MP<#>4;<T2
M32^DGS6,<U5FJ49HTK*=RAHWD H8-YO33[;P]COTE6.OBI5OZX!<KB3 349:
MC.&G\HAD<9-1M;[#*7ZS=%J$:"7:NX!/!(TJ:U-W!P$R@:O7SM6L:]VCR%92
MA]_8RD+$^:4J4:=A26QI@>+<T=;F&H$FL+!R/IR8#S,7=#MAL7YA'7CB.-5U
M@ONZJFCU]UN%T_;WON-I&X?BW)K?KV[6>C'/JG3G'44]F%O :LHYU;,P!7;=
MCD7(R*8WNLG6D,>)7 AE6QA<S.3YDE/9L1*H_#V*<W65H<)NZJ78N%R:H>8Y
M?)5J#9U<AV4;M=4HE8;3K$[RLF[9E9MA3:R%!)PX'NO@5E-:*5]9ZESDAJ;T
M?DP5E])V2,]+IQ.$/<Z,:E2'R0G=C32C\R_ZC)W)P!LKBL1I;!_T*=H,%]_O
M+<E#?JRT)55=^P]L25C!T>#P<MUFS67I/F68%H;(W;2_9MW14]IL[S*OR^I#
M.*50R)L9"B405:"FRA0B)1,<PL 3Y-7(CGL4*QWT$,GCFB_E;/.56,=*S_RF
ME5/XCDHL.<Y]>WAX]984X5(9W+!@?%$MIF6:"> RVP!T0KAIV<)I);99EMT'
M3(F&D7E2^#4OB6IHT7XMOCM8+'\N)UR9@/(&E,5+6\I+K%UL#79<8DDJIZ[(
M*QTZFJ[R9P8ZI]?Q3<0^CZLKJ'6;K!9^?3XT6@HF7KB3M<,0B"2XW1O:2\*S
MX(@IP>XCU4?@LM7,0L4FGE)34)-7/&L;Y)'Q):IT?(!( 3#964B#FA/3?6_$
MO<#T:(I]LUR08+TE:=CP6JY"XH_KH3I4?87(,RHE)T=E:U!DNN\"H<S\[XG>
M&B#F!N-#XRG:UM8_H5<SQ1;W5VJ04WV G<Q5>JG8VV.N1\#8]<GC<6(%%D,V
M5#NX+ J!_^B@.62;SFQB3HR&=]97^SYG=NB(:YX ?U(2,0"5"/(JSG(+^RMA
M_!@>4:N<^6V-(4L$F>@/,E:!T9C$1I%%HG>:,](J# 83[#C&<N=H6L&H*-8Z
MU&%[_H(46P QQ8RRH#Z<$72'5_(3[X^;T9O7Y2WN4+CS_&MGEXF3 P,#5B$$
MXZ<BX]\Y)[2R7$&:$C=<*<IPPJ&!^:K4J^]*].E7A4G1+X1G'#O!,'X'5B*8
MM6)B \@/[M9..=M9ELD'U8@PT3*EUR47'DPO&00JBJM7=)!1WV9<EV[_A:3.
MF@["P'EFMHN%0^2H;0A9Z%(G% Z88>=?# ZB2QZ36DL18/$"],\Z2F)*MM,(
MAL^Q%^3TD^@B(\/16,((H-!];9A^G]FI%9G8Z+NZ1'RA[&S,O"G()DZQ0&*#
M*O!"I3>&$CD B6:Q2^FM%8;5Y3<O7AY.X A?'C;#>Q.$?8U'/(XD_(GRR@Y:
M^@,G" ;%7X>6V'0N%2Q%AZAU6@50'*B8^^AV=<Y/RY()LV%X\]]M80)=!6U8
MXFPK#%6-J.2(5"="$F%'+3KZ9;.=+=.H,=888+=\*>UA)<$EQL*YN9Q)8'/<
MN8S;K6_$4T(@CZIIUE1:P0Y0R%=9O42GZ=<(0;H3_X6[[@*A,O#(R2M-A0*T
M)@E*$I[@*CJ7EA B$@L63^KWZO#94K98I?@E&QH6#+C. )0A.YVZ@3:=IVPQ
MU(EQ1-BP@HFG9<ZBMLCC:Y"Z[@BH/%296SRZ4DTL/0JMLL:%=#!4/<8 OXJB
M(_ !748 BQMAN!@(8/5Q\NTB6_O?D:U/+VXZ'EVBRZ\"PKM4F/14BY.(J*(E
M73_3#B:3W6V:8S=<:@((MC8YVS8P!FA7"EF8FJBH06+I$O$S+_&R-.)9A,<G
M5.1--12<C"D@#A\0G@Q'TG*+:519,#H'[G3*80TB7+6_LZQ,(<=X6NO>2.Q1
M+MQ:]3;W"^3Z,DL8#_C'T:_O*9\>'OX9*P*CUCZ)CC%LI*R*+!Z*6* 73^R-
M=;D99J:Y;;^MN>':&CB*=7_"1B<J;3$IQ.XN=?_$YVHWI55O6%EU$#%:)$73
M]X*)*#PI0(3Q$<=TZA1]T\S/*3:3Q*"F9AIYH8 OM&*6,  (\ME,V#10":=?
MZM,DKT5E:8B6RDT@A-;,$P@66G?GE7*>'6RGYN^ [B\5[@3E/NFV0GVXWW!=
M$[3H+KG^7;MDA9]#OK#,K8?"1?]&!S\;>XA_H&'%V^L_JY$!4CKHHNV.1_]H
MTTN.G]31.]QOH:++:PT5>_P:?B!.(Q$A)#EA#R1)&F>4U6FF*\B1"$2J";7\
MIU8MD\R&A!MN%N2*0FKL+1WOYL5U;8>G3G0@MOZ@@&_7 3\>D?),%@@7&.39
M2^Z2QB,Q^TU[O]AZ0?B,7\ \Q)*R2;1>QY25,F08XX=SDJ74^\*HBV@X9572
M+G Y">=>2G4<KC1(ZF)6N^JD<ZE[)+M^IV8TR'*<7F^9$^ 35FVT_%>/:,*\
M<*/H,8*<B,<YG,>Y6JN-NJ?W$?FPTH/B,M"?E7#%X[)V7"=1B/R1C\\ZG;D-
MC;<A,R45O+#9)D/J($Z<!TRA^>LNN[29+7/LNI0RO^-<!B *%7,)>?P&6>%
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MM/\7.?/J.7?XZ]FK?\$O7U_\^N;P_P-02P,$%     @ VX,R40,_]W=A/
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M'UKKZ?E/OQ^NE!^/-IC%D]O.8BL6N=?]7YC=!3 ?S^M"6)%WV5=G<]1:2;F
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M2S0Q.HP,:>95V5[.HXLJ>ZL:<>C(JA#@IBIGH$W@59BBN#35>%16EV#I_$<
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MR85=:CSULT8O;'OS[[FNS)AW1$'=MD\"Y$Z#%MM6D"3'];Q<](2-;*<2+7%
MJ)7595QD_S%@N==P:<))Q=WD!.K"I"/U^+GQ*)-(\8R2&E:T-I(B IBZH)#2
MZ,CQY#42U1]=T^F[)NI<ZJ8S*Y(VB$/:"MS16L -TQHUJRQMZZ'@/#??LMUD
M[.4:;G*&U^I .8TG7&$^\42YOMS/=8<\O.%AQ,G(_7]]U'.<;(LDM^]#N(*.
MQ:?3.MK*!.B<RUKD-GFW)W!X-;JV<KQ,&0;J!N)#P1NV?SI9D$11(X<FDEY(
M_W1JB.EGW$5!@XV7QX>X-EEY'!L>F@KU?%B5^^%$KL!%=M/S":,.6L+!'Q5Q
M4%A[S<U]C&)/VYZK\/J$2U\@6.YO4_V7@G568!H456@Y(''T]3<H-9VD/OT5
M=TT.F_LDV[++[L;_I/=^YPS/$&DP]I-TV. 9 =$^0Y+$[=7A@U7J\$1CN13]
M834H[4%,&+]:6=RW2633#C4>>6/1EKN]/#VX1/?@8C$C: <U>DKRF-#M/%>7
MG(?6%@XLS3TCV8\GGQ>L5GK9]6>=:X18\J;<FB5DS_YN$,R9?23J@,BZ%1_?
MET.M+Z7[/*H?KN^MR_6KFOABF"OER>4CV,012WI>$D4:W#OC$5R!N2;=&1PJ
M;A:\NPN>?KC:Q*NNLBN^[TSPI56E:4R$FEY2_;%\OY2M2'_2)F'GR=6Y CYN
MYQ5!!K<H<[8^RD'.^,4MSM94J'T94C]:Z3<C(%6)]0P<33_J@VTY3Z 1F^5C
MKB1N"[K71)=U:WE-( I(36/PC$<XMD% >5M1V$I=@85[ Y<VR&DC[Q9;C5(Z
M=6YR!P>/O2S)ZWHIXTB&4,^[7H3K2DE_+[KO^M\M_BBG3+L-M@-J,"TT ,<C
M:6P7!_1UQM/Y75\=5?EY%7>\+1L,JML$GH)_,=&%PO"O%$0O!F3-/>\$,BS:
M0F2M4YB+X("^.[Q'AM4M9N]1[BM>>^8S4ZKR[$I'1*UW07[(BILY,-FHH,@N
M*A/LW640T(I[;5[J2GKT,=#TIXYQH$[R"8AA4 &7BE-^LQ27W;158:[1,>72
M$P)7 J.SD2!.307(%=\WYU\87$<SNMC#66PG*=?)AM 78OFV;$.>"\%U)5(0
M]P<QQ\*5:M1@^2[$S^-5#':$9>BVU/1B5:TZ-ZE,>7\XXP'W7?O5&4%BS%&N
MX'&O)HH+Z4:=MKG)248V"3(4?!)_Q[C4_1^XU&=DY2<K#7&&+N#$G1%$\"['
MJ\$(HC)Q RU(;:]TK1RM4.!<5@1Y4%R^+DLLK\',<R<PO($YY/<VCJ.K,F^!
MO:N;X3XSW1QGG:KA9&D0% :'I=%0DC\7YUZ7P'5V;XRH*=YQ6<4+;F2SI%IO
MK':X+?A-C@J[ *:8K-]EW71"D3.?2%I&Q5X[1:W.["4ONJR:S22QX_G5GHPM
M6LEXI+LUR,1U !/!/S)V>FY>-TZV>0C#[+@ K-[!+N'@VS=.T1Q..( 9^JM-
MC>GE)MAU=1&OG7#\LNH/ O!LV;N2RT%BU_0>CX9!A*$+<GGO+TF9]R1S46*#
MW%FJPPK]#551:^A$-[PT:S=ZQ8C>)(2V\*FU>!9FD9G2'1M!IE;,8:>XT#P(
M<+A>6KK@&MWQ]1&3O .=?[ RF> UVV3 0V_B:T?O4^=>)TE3IW8X#4Z\TZ^/
M!:%_S!N2HD+5/ 34U2;2!WZN$0X]J046^I"L0$&B;3OD&8B$1L!^M&FS(LF6
MN9*;E#$![\^>?(14DO7=Z+!.>*#T'D:8]%-.*VS3:F4@615C#M@*T"E_,;*9
M&S6"O8.0A[6$?B\H49667\.9%G3E"-.>G*L3GSQ__[MA%L>*>0A\<(46<A+G
M.Z2&GP(/W3O$'ISPQF%TC*A)=B<<MS*CX!BCLD 9D''U*D.385R;=&F;Y2?.
M"!.#'#/^0VW0ZM*\S6:F]5?,GC;Q7]PVFBM^=+_09X32ZN02\QF#G<E=24Z[
M'>R^J*5@#=9QE$K8_NO[CZ=OP:J[>'OR_OUX].>O)^<G9Z\F7E8$:3E#V$!^
M6AA!=ZHSO\#+"#O+<:9V8*WN02/<-;K)GA2;DS3N/32+GU\<O7AS$AV?O'GS
M_MW1\>G;U[_<V[M'/[\[>OE2_RR&ZP.T6U^<G;\\.:=?RZSX-SM@[+XY>O?^
MY*G^QTK2A71&6Y8-\HOS0_G'2_WAG__['ECN%R_M'_Z0I?!BK6FM'_3??W*@
M?P__<^Y\22_!,>PS:A'^E/K@1+=<PL#D@"! W;?H&7Q!Y^?P^8O#HY>GQR<7
MT05PXM&[D]\O3H_?3[!$;H5 ZOGT_L=\^O3M\>Y/YR?O+\[.7YR>32+\67_:
MDMXGN_,-AWR_GIR^_O4"-O.1OYG.[RU)#^X-COY%-]6;6?@W?>R&G]B8#6@O
MII3Y;7_U(:)0</2W/?J_6V[63_5/T3$*[?<)^/^K]N?+4O#%S=-/(Z*[B+M8
MP&E3?_(*,!/>&L5GA%\-+F?M>?%$S9T0Q9_!B\-7YT=OCT_>'Y]%K^'!WTY9
M)/S_L;R[/L14W*7JI(Q>QP@$W-E1]JC2G975N_ ?-#@.&8S[+B'%!S\@Q<]&
M3) /X)[\7].\D$N\5]LK@W;\)TYD34K8_XN<>?7L._SU[.4_X9>_7OSVYO!_
M %!+ P04    " #;@S)1L]>HS1$]  !0&P$ $    &0Y,3 S,61E>#$P-"YH
M=&WM?5ESW$B2YGN:Y7^ ::;'2+,D)5(JE:ZB&:\J<5HE:BE6U_:N[0,2B,Q$
M"PEDXR#%_O7C5YP ,DG=ZM786)=( H$(#P\/]\^O%R\O?W]U\.+EZ>')P7CT
MXO+L\M7IP>G_WME[L/OHQ7W^$7Y_7QZ(7AR=G_P].OKM^/S5^<4O]_Y\>79Y
M>@__$(U'\-RQ*AI5';PX.?M;]/;R[Z].?[EWG:7-XMF3W9^RXEX4Y]F\^.5>
MKF8-O?7BC7YL&5?SK-AIRM6S!ZOF>20_3\NF*9?\JUE9-#MU]B_U;,_^/(N7
M67[S[#);JCIZK:ZCBW(9PY<.7YW]]OJ7>U4V7\"G7AP=G+Y?9-.LB7!ET8O[
M1P<O[K_!I?7-8/_1)YQ"0C3A.?S^YM7YWW\_?7T9'?YV<7I*_])SZ2?&XX&9
M-.I]LY,5*0S^[-%?[C:S@\M%5H]'I\M57MXL883H<%XI1?_:^J__V'OT\W/S
M"_SQR?/M**MA%JF*IJJY5JJ(#M,L44UTN5!5O%)MDR7U)#HKDMU)%$<G*H^O
MXTI%25FMRBINLK*(MIJ%BGCTXW*YBHL;&1O>*-+H%<PEC?Z:9\F[NE&9]_SI
M>Y7 )ZZ4G@V^ #-*8)%9,<=YMROX!+Z1Y&4-O_,^Q[^2E\>C<D9/-E5<U'$2
M3NYW5<U5I;^$GU! J+A1:32]@1?C)DI4U<0P14LVG-";/"XB&)L'Z X9=8@*
MX^&+\;*$"5>JOCR_F&8ETU'OQ!N@HWECHNE^%#YF?^_2"*=0PO]4X]$JKIH,
MV !_4DVY&[UMI_]021,U9?16$17^JYC6J^=[>Y-(O4_4JHFNLV:!\UK)<S@<
M<XU2T7%9S#+DOPQ.=7,#4ZMK.-V&'"]^/0?NUE)@D35JIU[%B7I6E-? ,_<.
M7I?%SML2-CQKB$->W,<W#ARJ:F:C[VH>8%H352912OOR>WPC<W\XB?8?[#TE
MXH]'0L$J*ZOH0M5-E24TPG%YI8JX:.KNEFBJG?ZSA45%)V72XI_K:"NNHU3-
ML@+Y0.7E-6Q& ^?(F6[=KE15JQ2H#,P1Y[FF74T_K&@>L7Z\WK@\>'T>5RER
M,SY2RX8MXP8$2H3[F!43^%22M_00;E?9-N-1GBV%IM%6MLVDP1&4/?'QK8D\
M1..)R^%,XY":?+*W,CT'./-P0&8P^5SA&B;],X*1:G4%@J5(E/WU;K1&8N_M
M?PXY^>?+TXO3P[<]I^XZ@PU-%C$(GRB#K2SBI<(3,B@6HU59-SLBB5SJ;AC)
M?!).L#,"$Z/_ROC,M,!-%P$.!Z+.*A0JI>QD#Q?YOW'>F&J&U)+5CCM5,/<"
M*546XQ&Q+K -'UYDQTA$N*:G_-B5O*?FM1-X31]RN2J  Y=\B<1TK/E$?7G2
MOC[_<Q)=(GU_/;\XQ1,]'L&L:I"N<G?*^I9MT\; +49\T>UA!0HOP%D1_IWD
M?S0O2_[Q*L[;>)KCW>Q\@;>U4HG*5BR^ZW8V ]&LB@3/; 0"/%G@G8O?P'LK
M>0=R/%?I7*7\LKY@:#X12,M9F8.8K)]USJU#G"= G$#UZU#WW@%+#]H65%(/
MCUZ=ZK&.SB].3B]V0!]]=?CF[>DS_8^U) _WYU[$P_QR[\&]Z/CTU:LWAR<G
M9Z]_,S^_?7-XK'_^\^SD\N4O]_8>//C+/9[/150W-T#17Z)[JWBN=J:5BM\!
M-R!YG\5799;*@R?ZY4=_L8NZ/ G^^--?[D5_$^41B&(42=::]W;=5]P_>2^Y
M#!SY%(X^5K5]'@5S>O''@54F7]S_XX#/$$T4_N<"_P<W;4AZWT;)?7K74[45
MRZW3_5^8[R6<?9[II4@"/F3^A;[ >SLIE_ 37$4B-GR90H>%%=%612W\-Z?A
MLH*N33S+<0)Z<$JW&6E4=%JJ\BJKX>3QB8)O.U(+)R>RBN?G*<"/G]?NO6F&
MU,*39SW5@\5\QTQXP&BIXH(U"OA#LV'L98RRV%U/(*CAJ@XD/DH/> 9V Q8.
MI)FAS@._@3-1 P%KJW5:$=RA_$?+X+MSRW0=M[R!:X8$,:[HI$4Y9YG'+IXH
M/Q[5JKHB"4B46F1J!C=X45ZQ+#]'N0H265]A0DF2N;1SBQB':D'<KLIK4"CI
M3VG+PK6F/9E5Y9)H3'3$_TZ1I52=5-G4V27ZMIW?P*==4^GTO)_Q9&ZINBJ!
MYW&S9BW\?%U6[XB;S'[#15U63:TW>-K"!:UJN:IFLSBKZN#[N]'KLD$NKAMX
M2&N[,(J:E_#3). P7#]3&"]&NMRF):C)-&P*RD72E!5H7>9<Q"L\;'!ORF=_
M@^NS*N@XP@Q 4VZ442B.<"3\X40/I/\BZII#*SO.>&0&DE,F+_&#-*A1B>$\
MJ&(>H[I7P*G(LWE6MC!?T $KT-KQ:H9'>&$H>MH"#1&T4Z\RS0,Y&HSP7^(2
M) 9LJY#8/I>645$V\!4X9*!S.\*G<^3!;@%Z+XDF,'7<7F$XV499O=;G#-/6
MH):B)$M)U 6G^'ED_M:5-K2/1F["9\RIB<TN:HEK]_<H1Q"B1[W6,WO5KMHZ
M^K5LB]2H3GC,3XLYF.<I6R3TD:5:3NU9J%'5:3(X'U&<@F0NJQOGLY>+#-CB
M95R!I0Y/@%+.S Y*>M,N64D/)%L?EVERZV7#L<[@R"J<: P?U)QJ3)W[)V=_
M@\M38+7Q**+_?[%BA<,7BVK9D8KX*T<CF2H\5,_B_#J^J1%_>_'R(GI[]G]
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MH,J@L,XU= $72#4'C?I? K?%0C14&D_/D?_,EASBK0,Z6ILW@0:D)QY7%>)
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MV]V*PU\SA<ES6AFETA<2B(%QT1:X#6**;8&3 ^KE4QF6<E&&,VX<Q7$\\IA
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MAN%'8\;VE:\*8B/"VIU4U+%?FTEL#<&[:(N]95BX! -O(FO<8)T-Z]R/'^S
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M+?.XV-R@DQ3F[/9Q@ B/+$Y/M_LRJSUNKIX'L4]]1G\#TD?VSP.X3Z :! 2
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M=,S&Y;];U"8M2!U7:";$%'IP>6Y(IQ$V2*8H3[1[.)$]F[J4ES_'_A.+7GL
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M@!H.8B2HX=S$.14/TT3G_@*I% NG-]O.* -A\G@MN,Z'25UP?*CG8EJPUNF
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M4QWX!"/AG G75*BOU*2PD$)%:"+=BY:@'9+"#@@:]OORU:("NI7AEUPX:6?
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M%M9V\NJ?\,O79[^_>?'_ 5!+ P04    " #;@S)15.OVHB C  !0\0  $
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ME?G"4VGN6(VMK86!9[=AU<9>S,X9/578KNV=A8&GMFM5&HM#S<WZME79J4\
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M7I#*,D*[$CDC>CQ2YFI.B/SMFID=-Y<"J):7&"R#I:'L@%<(U?FNL-<'8-)
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M'=CF1-*I!"R%43_DDS5V$=-R[1::R17\N"U?W9::+M59NG.+/5"U5U"A4Y]
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M['(PVE(YH=,H3I&[45!9,;^"3>7RWJG'UK#<U)+,$%HP*N<4%&ZNBQ@!Z%6
M _)KX]+S/F++K56Z0LR&LG)5&DUTXWOVI))6BAPIC?HA:801/>'9BY%.Z-%
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MY?I9&F]^EB?%G9\;MH>*)5%."E2#AEV-<RDH4HQ YPC@6++: 01MEAS+7<O
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MOOQR]?5T__\!4$L! A0#%     @ VX,R48,5&>UC P  *@P  !$
M     ( !     &%C970M,C R,# Y,34N>'-D4$L! A0#%     @ VX,R402#
M[/NS!@  .TH  !4              ( !D@,  &%C970M,C R,# Y,35?;&%B
M+GAM;%!+ 0(4 Q0    ( -N#,E%<Z1CGXP0  )@N   5              "
M 7@*  !A8V5T+3(P,C P.3$U7W!R92YX;6Q02P$"% ,4    " #;@S)1#,'+
MB#$:  #@LP  #0              @ &.#P  9#DQ,#,Q9#AK+FAT;5!+ 0(4
M Q0    ( -N#,E'>@#9. CT   H> 0 0              "  >HI  !D.3$P
M,S%D97@Q,#$N:'1M4$L! A0#%     @ VX,R4:JI*&L</   OQ ! !
M         ( !&F<  &0Y,3 S,61E>#$P,BYH=&U02P$"% ,4    " #;@S)1
M S_W=V$\   ?$0$ $               @ %DHP  9#DQ,#,Q9&5X,3 S+FAT
M;5!+ 0(4 Q0    ( -N#,E&SUZC-$3T  % ; 0 0              "  ?/?
M  !D.3$P,S%D97@Q,#0N:'1M4$L! A0#%     @ VX,R46X KSNN/0  TQ\!
M !               ( !,AT! &0Y,3 S,61E>#$P-2YH=&U02P$"% ,4
M" #;@S)15.OVHB C  !0\0  $               @ $.6P$ 9#DQ,#,Q9&5X
=.3DQ+FAT;5!+!08     "@ * '0"  !<?@$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
